Benzopiperazine and related analogues for inhibiting YAP / TAZ-TEAD

Abstract

This disclosure relates to novel compounds for use as pharmaceuticals, more specifically for the prevention or treatment of diseases mediated by the activity of YAP / TAZ-TEAD transcription, and even more specifically for the prevention or treatment of cancer or fibrosis. This disclosure also relates to methods for the prevention or treatment of the aforementioned diseases, including the use of novel compounds.

Description

[Technical Field]

[0001] This application claims the benefits of U.S. Provisional Patent Application No. 63 / 502,612, filed on 16 May 2023, the entire contents of which are incorporated herein by reference.

[0002] This disclosure relates to novel compounds. This disclosure also relates to compounds for use as pharmaceuticals, more specifically for the prevention or treatment of diseases mediated by the activity of YAP / TAZ-TEAD transcription, such as for the prevention or treatment of cancer or fibrosis. Methods for the prevention or treatment of diseases, including the use of novel compounds, are also disclosed herein.

[0003] Furthermore, this disclosure relates to pharmaceutical compositions or combination formulations of novel compounds, and compositions or formulations for use as pharmaceuticals for the prevention or treatment of diseases mediated by the activity of YAP / TAZ-TEAD transcription, such as cancer or fibrosis. Processes for the preparation of the compounds are also disclosed herein. [Background technology]

[0004] Hippo signaling is essential for limiting organ size through inactivation of the YAP / TAZ-TEAD transcription complex. In some advanced solid tumors, Hippo signaling is inactivated via loss-of-function mutations or deletions in genes encoding upstream regulators (e.g., NF2, MST1 / 2, or LATS1 / 2), thereby unleashing constitutive YAP / TAZ-TEAD transcriptional activity, leading to uncontrolled tumor growth and metastasis. Knockout, knockdown, or pharmacological inactivation of YAP / TAZ-TEAD is sufficient to reduce YAP / TAZ-TEAD-dependent tumorigenesis. The YAP / TAZ-TEAD complex can be pharmacologically inactivated via targeted disruption of the YAP / TAZ-TEAD protein-protein interaction interface or via allosteric autopalmitoylation pockets within TEAD.

[0005] The primary physiological function of the Hippo pathway is to limit tissue growth in adult tissues and to regulate cell proliferation, differentiation, and migration in developing organs. The core of the Hippo pathway consists of a kinase cascade, transcriptional coactivators, and DNA-binding partners. In mammals, the Ste20-like kinase, MST1 / 2 (a homolog of Drosophila Hippo), phosphorylates and activates large tumor suppressor 1 / 2 (LATS1 / 2). NF2 is a scaffold for the core Hippo kinase that promotes LATS1 / 2 activation by binding MST1 / 2 to LATS1 / 2 (Lallemand et al., 2003, Genes Dev., 17, 1090-1100; Zhang et al., 2010, Dev. Cell, 19(1), 27-38). LATS kinase then phosphorylates two highly homologous transcriptional coactivators: Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ), and inactivates them by cytoplasmic sequestration via 14-3-3 and by ubiquitin-mediated degradation induced by β-TRCP E3 ligase. When the Hippo pathway is inactive, YAP and TAZ translocate into the nucleus, where they bind to the TEAD transcription factor family, inducing the expression of specific properties that promote matrix rearrangement, cell proliferation, survival, and migration. TEAD1-4 may also bind to VGLL4 in the nucleus and act as transcriptional repressors. VGLL4 is structurally unrelated to YAP / TAZ but competes with YAP / TAZ based on partially overlapping binding sites on TEAD (Johnson et al., 2014, Nat. Rev. Drug Discov., 13, 63-79).

[0006] TEAD is an evolutionarily conserved protein required for cardiac and myoblastogenesis, as well as for the development of the neural crest, notochord, and trophectoderm. In mammals, there are four genes encoding four homologous members of the TEAD family, named TEAD1-4. Each TEAD gene has a different but non-exclusive expression pattern. All TEAD family members are regulated by YAP / TAZ.

[0007] In Drosophila, loss of function of Hippo or Warts kinase (MST1 / 2 or LATS1 / 2 in mammals), or overexpression of Yorkie (Drosophila homolog of YAP and TAZ), results in dramatic cuticle overgrowth as a result of dysregulated cell proliferation and resistance to apoptosis, leading to increased organ size. In mice, overexpression of YAP, loss of MST1 / 2 or LATS1 / 2 kinase activity, or deletion of NF2 leads to upregulation of TEAD target genes and primordial cell proliferation, resulting in liver and heart overgrowth, and ultimately cancer formation in the liver, small intestine, and skin. In contrast, a serine-to-alanine mutation at position 94 of YAP, i.e., inability to bind to TEAD, prevents tumor formation (Zhao et al., 2008, Genes Dev., 22, 1962-1971). Similarly, dominant-negative TEAD mutants that cannot bind to DNA overcome YAP-driven hepatic tumorigenesis. In addition, NF2-mutated hepatocarcinoma was significantly suppressed by atypical deletion of Yap (Zhang et al., 2010, Dev Cell 19, 27-38). Finally, verteporfin, a small molecule that inhibits YAP-TEAD binding, significantly suppressed YAP's tumorigenic activity in these models (Liu-Chittenden et al., 2012, Genes Dev., 26, 1300-1305).

[0008] Gene amplification of YAP1 (encoding YAP) and WWTR1 (encoding TAZ), as well as constitutive nuclear localization of YAP / TAZ, have been reported in many human solid malignancies, including liver, lung, breast, skin, colon, and ovarian cancers, and YAP / TAZ promotes the acquisition of several significant cancer cell phenotypes, such as proliferation, resistance to apoptosis, invasion, and immunosuppression (e.g., by attracting bone marrow-derived suppressor cells) (Wang et al., 2016, Cancer Discov., 6, 80-95). In addition, gene fusion with YAP1 has been identified in several cancer types, including ependymoma, vascular carcinoma, cervical carcinoma, and porocarcinoma, which results in constitutive activation of YAP-TEAD and tumor formation in mice (Szulzewsky et al., 2020, Genes Dev., 34:1-14). In addition, several germline or somatic cell line mutations in components of the Hippo pathway associated with various cancer types have been discovered in targeted and whole-genome sequencing studies. The most well-studied example is the NF2 locus, which is frequently mutated in neurofibromatosis. Deletions of NF2 and LATS2 are also frequently observed in schwannomas. Another tumor type (approximately 70% of all cancers) commonly associated with constitutive YAP-TEAD activation via gene inactivation of NF2, LATS1 / 2, MST1 / 2, or SAV1 is malignant mesothelioma (Bueno et al., 2016, Nat Genet 48, 407-416). Current studies have revealed that several mesothelioma cell lines with NF2 loss-of-function mutations exhibit decreased YAP phosphorylation and increased YAP-TEAD reporter activity. YAP-TEAD transcription and viability of NF2 mutant mesothelioma cell lines (but not WT mesothelioma) are sensitive to YAP siRNA (potentially rescued by overexpression of siRNA-resistant YAP) and are also sensitive to treatment with the YAP antagonist verteporfin (Zhang et al., 2017, J. Cell Mol. Med., 21:2663-2676).

[0009] Nuclear YAP is also attracting attention as an important mediator of WNT-dependent colorectal tumor formation. Transcription mediated by YAP-TEAD in genes involved in proliferation and stem cell regeneration works in cooperation with WNT-driven β-catenin, and YAP is required for adenoma formation after APC (adenomatous polyposis) inactivation (Azzolin et al., 2014 Cell 158, 157-170; Gregorieff et al., 2015 Nature 526, 715-718). Recently, TIAM1 has been identified as a suppressor of progressive metastatic colorectal cancer (CRC) by counteracting YAP-TEAD transcription, and the role of YAP-TEAD in CRC has been re-emphasized (Diamantopoulou et al., 2017 Cancer Cell, 31, 621-634).

[0010] In summary, YAP / TAZ activation has been shown to promote tumorigenesis, and YAP / TAZ is overactivated in many different types of cancer in humans (often via loss-of-function mutations in upstream negative regulators). Gene deletion or pharmacological inhibition of YAP / TAZ has been shown to suppress tumorigenesis and progression in various types of cancer. Therefore, deregulation of the Hippo tumor suppressor pathway is considered a major event in the development of a wide range of cancer types and malignancies. Thus, pharmacological targeting of the Hippo cascade via inhibition of YAP, TAZ, TEAD, and / or YAP / TAZ-TEAD protein-protein interactions would be a beneficial approach for treating cancers that involve functional alterations in this pathway.

[0011] YAP / TAZ-TEAD activation has also been shown to play an important role in other diseases besides cancer, namely fibrosis and certain congenital disorders. A characteristic feature of fibrosis is the excessive deposition of the extracellular matrix (ECM), which contains cross-linked collagen fibers, leading to tissue hardening and ultimately, dysfunction of the affected organ. ECM hardening promotes nuclear activity of YAP / TAZ in cancer-associated fibroblasts, as well as in fibroblasts of the liver, kidney, lung, and skin (Mannaerts et al., 2015, J. Hepatol., 63, 679-688; Piersma et al., 2015, Am. J. Patol., 185, 3326-3337). Nuclear YAP / TAZ promotes fibrous cell phenotypes, such as increased myofibroblast differentiation and matrix rearrangement. Several genes encoding key secretory factors involved in fibrosis are direct targets of YAP / TAZ-TEAD. These genes include well-characterized pro-fibrotic factors such as connective tissue growth factor (CTGF), plasminogen activator inhibitor 1 (PAI-1), and the collagen cross-linking enzyme lysyl oxidase (LOX) family. Several pieces of evidence support the link between YAP / TAZ and fibrotic disorders in the body. These include reports of elevated YAP / TAZ levels and transcriptional activity in fibroblasts, as well as in the alveoli and respiratory epithelium of patients with idiopathic alveolar fibrosis (Gokey et al., 2018 JCI Insight 3:e98738). Increased nuclear YAP has also been observed in patients with primary sclerosing cholangitis and primary biliary cirrhosis, which are chronic fibrotic disorders of liver injury. Expression of YAP or TAZ in hepatic ductal cells promotes fibrotic progression, in parallel with fibrosis in non-alcoholic fatty liver disease (Machado et al., 2015, J. Hepatol., 63, 962-970). In summary, these studies suggest that targeting abnormal YAP / TAZ activity in fibrous diseases may preserve treatment prospects.

[0012] Neurofibromatosis type 2 is characterized by tumors of the nervous system, including schwannomas, meningiomas, and ependymoma. Neurofibromatosis type 2 is a genetic disorder caused by inactivation of NF2 (Striedinger et al., 2008, Neoplasia 10, 1204-1210). Loss of NF2 leads to constitutive activation of YAP / TAZ-TEAD. Sturge-Weber syndrome is a congenital neurocutaneous disorder characterized by a port-wine stain affecting the skin in the distribution of the ocular branch of the trigeminal nerve, abnormal capillary venous vessels in the leptomeninges and choroid of the brain, glaucoma, seizures, stroke, and intellectual disability. Sturge-Weber syndrome and port-wine stains are caused by somatic activating mutations in GNAQ that lead to activation of YAP / TAZ-TEAD transcription (Shirley et al., 2013, NEJM, 368, 1971-1979). Therefore, some congenital disorders characterized by constitutive YAP / TAZ-TEAD activation may be treatable with YAP / TAZ-TEAD inhibitors.

[0013] Several publications describe inhibitors of YAP-TEAD transcriptional activation. Inventiva highlights YAP-TEAD protein-protein interaction inhibitors in WO2020 / 070181, WO2018 / 185266, and WO2017 / 064277. General Hospital Corporation, Boston describes autopalmitoylation inhibitors in WO2017 / 053706. Vivace Therapeutics, Inc. discloses non-condensed tricyclic (WO2018 / 204532), benzosulfonyl (WO2019 / 040380), benzocarbonyl (WO2019 / 113236), oxadiazole (WO2019 / 222431), and bicyclic (WO2020 / 097389) compounds that modulate the interaction between YAP / TAZ and TEAD. A senior professor at the University of California and Vivace Therapeutics, Inc. have described tricyclic compounds that inhibit the Hippo-YAP signaling pathway in WO2013 / 188138 and WO2017 / 058716, respectively. Kyowa Hakko Kirin Co., Ltd. has identified alpha- and beta-unsaturated amide compounds exhibiting anticancer activity in WO2018 / 235926 and US2019 / 0010136. Genentech, Inc. has disclosed carboxamide and sulfonamide derivatives useful as inhibitors of YAP-TEAD protein-protein interactions in WO2019 / 232216 and WO2020 / 051099. Dana-Farber Cancer Institute, Inc. highlights inhibitors of TEAD transcription factors in WO2020 / 081572. A member of the Board of Trustees at Indiana University, in WO2020 / 087063, describes small molecules that bind within the hydrophobic palmitic acid binding pocket of TEAD. Wenchao Lu et al. have published vinyl sulfonamide as a covalent TEAD autopalmitoylation inhibitor (2019, European Journal of Medicinal Chemistry, 184, p.111767).The Korean Research Institute of Chemical Technology discloses a benzo[cd]indole-2(1H)-one derivative that inhibits YAP-TEAD binding in WO2020 / 096416. [Overview of the project] [Problems that the invention aims to solve]

[0014] However, there is still a need for novel, alternative, and / or better treatments for the prevention or treatment of YAP / TAZ-TEAD activation-mediated diseases, particularly cancer and fibrosis, among other potential indications. Treatments that are more potent, have fewer side effects, are more active, less toxic, or have better pharmacokinetic or dynamic properties, or a combination thereof, would be very welcome. [Means for solving the problem]

[0015] This disclosure provides a class of novel compounds that can be used as inhibitors of YAP / TAZ-TEAD activation-mediated diseases.

[0016] This disclosure is based on the finding that at least one of the aforementioned problems can be solved by compounds of the class described below.

[0017] This disclosure provides novel compounds that have been shown to have inhibitory activity against YAP / TAZ-TEAD transcription. Furthermore, this disclosure demonstrates that these compounds efficiently inhibit YAP / TAZ-TEAD transcriptional activity. Thus, these compounds constitute a useful class of novel potent compounds for use in the treatment and / or prevention of Hippo-mediated disorders in animals, mammals, and humans, more specifically, in particular, (i) cancer, more specifically, for example, lung cancer, breast cancer, head and neck cancer, esophageal cancer, kidney cancer, bladder cancer, colon cancer, ovarian cancer, cervical cancer, endometrial cancer, liver cancer (including but not limited to bile duct cancer), skin cancer, pancreatic cancer, gastric cancer, brain cancer, and prostate cancer, mesothelioma, and / or sarcoma, (ii) fibrosis, and (iii) YAP / TAZ-TEAD activation-related congenital disorders.

[0018] In some embodiments, the compounds described herein may be used for the treatment and / or prevention of Hippo-mediated disorders in animals, mammals, and humans, more specifically, for example, acoustic neuroma, acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, basal cell carcinoma, cholangiocarcinoma, bronchogenic carcinoma, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytes Leukemia, chronic myeloid (granulocytic) leukemia, chronic myeloid leukemia, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, abnormal proliferation (dysplasia and degeneration), fetal cancer, endometrial cancer, endometrial sarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen receptor-positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, gliablastoma, gliosarcoma, heavy chain disease, hemangioblastoma, liver cancer, liver Cellular carcinoma, hormone-insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, re-lymphatic sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovary, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myeloid leukemia, myeloma, myeloma, myxosarcoma, neuroblastoma, NU It can be used for the treatment and / or prevention of median T cell carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer, osteosarcoma, papillary adenocarcinoma, papillary carcinoma, pineal glandoma, polycythemia vera, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous carcinoma, seminomas, small cell lung cancer, solid tumors (carcinomas and sarcomas), small cell lung cancer, gastric cancer, squamous cell carcinoma, synoviomas, sweat gland carcinoma, thyroid cancer, Waldenström macroglobulinemia, testicular tumors, uterine cancer, and Wilms' tumor.

[0019] Furthermore, this disclosure relates to the use of such compounds as pharmaceuticals and, more specifically, to the use of them for the treatment and / or prevention of YAP / TAZ-TEAD activation-mediated diseases, particularly in animals or mammals, more specifically in humans, (i) cancer, more specifically lung cancer, breast cancer, head and neck cancer, esophageal cancer, kidney cancer, bladder cancer, colon cancer, ovarian cancer, cervical cancer, endometrial cancer, liver cancer (including but not limited to bile duct cancer), skin cancer, pancreatic cancer, gastric cancer, brain cancer, and prostate cancer, mesothelioma, and / or sarcoma, and (ii) fibrosis.

[0020] This disclosure also relates to methods for preparing the compounds described herein, and, for example, to pharmaceutical compositions containing them in effective amounts.

[0021] In some embodiments, the present disclosure relates to the compounds of the present invention for use as pharmaceuticals, the use of such compounds as pharmaceuticals, and for the manufacture of drugs, more specifically, for the treatment and / or prevention of YAP / TAZ-TEAD activation-mediated diseases, more specifically, for example, acoustic neuroma, acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, basal cell carcinoma, cholangiocarcinoma, Bronchogenic carcinoma, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myeloid (granulocytic) leukemia, chronic myeloid leukemia, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, abnormal proliferation (dysplasia and degeneration), fetal carcinoma, endometrial cancer, endometrial sarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen receptor-positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular carcinoma, glioma, gliablastoma Gliosarcoma, heavy chain disease, hemangioblastoma, liver cancer, hepatocellular carcinoma, hormone-insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, re-lymphatic sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovary, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myeloid leukemia, myeloma, myxosarcoma, Regarding the use of these for the treatment and / or prevention of transblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer, osteosarcoma, papillary adenocarcinoma, papillary carcinoma, pineal glandoma, polycythemia vera, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous carcinoma, seminomas, small cell lung cancer, solid tumors (carcinomas and sarcomas), small cell lung cancer, gastric cancer, squamous cell carcinoma, synoviomas, sweat gland carcinomas, thyroid cancer, Waldenström macroglobulinemia, testicular tumors, uterine cancer, and Wilms' tumor.

[0022] This disclosure also relates to a method for treating or preventing TEAD activation-mediated disorders in humans by administering one or more such compounds, optionally in combination with one or more other pharmaceutical products, to patients in need.

[0023] This disclosure also relates to a method for preparing the compounds described herein, for example, including a step for the synthesis of the compounds described herein. [Modes for carrying out the invention]

[0024] definition The term "YAP / TAZ-TEAD activation-mediated disease" refers to diseases in which hippo signaling is inactivated, thereby enabling, driving, maintaining, and facilitating YAP / TAZ-TEAD activation. This is mediated by loss-of-function mutations or deletions in genes encoding upstream regulators of YAP / TAZ-TEAD (e.g., NF2, MST1 / 2, LATS1 / 2, FAT1, or SAV1), which unleash constitutive YAP-TEAD transcriptional activity, potentially leading to uncontrolled tumor growth and metastasis in some cancers. This can also be mediated, among other things, by gene amplification, fusion, or activating mutations of YAP1 or WWTR1 (TAZ), or by YAP / TAZ overexpression or hyperactivity. Therefore, while YAP / TAZ-TEAD activation-mediated disease refers to cancer, it also includes fibrosis and certain congenital disorders. Cancers included in YAP / TAZ-TEAD-mediated diseases include, but are not limited to, lung cancer, breast cancer, head and neck cancer, esophageal cancer, kidney cancer, bladder cancer, colon cancer, ovarian cancer, cervical cancer, endometrial cancer, liver cancer (including, but not limited to, bile duct cancer), skin cancer, pancreatic cancer, stomach cancer, brain cancer, and prostate cancer, mesothelioma, and / or sarcoma. Also included are (i) squamous cell carcinomas of the lungs, cervix, ovaries, head and neck, esophagus, and / or skin, or (ii) cancers arising from neuroectoderm-derived tissues such as ependymoma, meningioma, schwannoma, peripheral nerve sheath tumors, and / or neuroblastoma, or (iii) vascular cancers such as epithelioid hemangioendothelioma. Fibrotic diseases or fibroses included in YAP / TAZ-TEAD-mediated diseases include, but are not limited to, hepatic fibrosis, pulmonary fibrosis, and cardiac fibrosis. Congenital disorders included in YAP / TAZ-TEAD-mediated disorders include, but are not limited to, Sturge-Weber syndrome and neurofibromatosis type 2.

[0025] YAP / TAZ-TEAD-mediated diseases also include cancers that have developed resistance to previous treatments such as EGFR inhibitors, MEK inhibitors, AXL inhibitors, B-RAF inhibitors, and RAS inhibitors.

[0026] As used herein, the terms “treatment” or “to treat” are intended to refer to the administration of a compound or composition to a subject for the purpose of producing a therapeutic or preventive effect through inhibition of YAP / TAZ-TEAD transcription. To treat includes reversing, mitigating, reducing, inhibiting, reducing the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such a disease, disorder, or condition mediated through YAP / TAZ-TEAD transcription. “Therapeutic effect” means eradicating, mitigating, reversing, reducing, inhibiting, or reducing the severity of the underlying disorder being treated. The therapeutic effect is also achieved by eradicating or mitigating one or more physiological symptoms associated with the underlying disorder, so that improvement is observed in the patient, even if the patient is suffering from the underlying disorder in some embodiments. With respect to preventive effects, in some embodiments, the composition is administered to patients at risk of developing a particular disease, or to patients who have reported one or more physiological symptoms of the disease, even if they have not been diagnosed with the disease.

[0027] As used herein, the term “subject” refers to an animal, such as a mammal like a human, a patient being the subject of treatment, observation, or experimentation, or a patient in need of such treatment.

[0028] As used herein, the term “therapeutic dose” means the amount of an active compound or pharmaceutical product that induces a biological or drug response in a tissue system, animal, or human, including relief or partial relief of symptoms of the disease or disorder being treated, as determined by researchers, veterinarians, physicians, or other clinicians.

[0029] As used herein, the term “composition” is intended to encompass products containing therapeutically effective amounts of specific components, as well as any products obtained directly or indirectly from specific amounts of specific combinations of components.

[0030] As used herein with respect to inhibitors of YAP / TAZ-TEAD activation, the terms “antagonist” or “inhibitor” refer to compounds that, depending on the context, can produce a functional antagonistic effect on YAP / TAZ-TEAD activation.

[0031] It should be noted that the term “comprising” as used in the claims should not be interpreted as limiting the means listed thereafter. This does not exclude any other elements or processes.

[0032] Throughout this specification, any reference to “one embodiment” or “one embodiment” means that any particular feature, structure, or characteristic described in relation to that embodiment is included in at least one embodiment of this disclosure. Furthermore, any particular feature, structure, or characteristic may be combined in any preferred manner in one or more embodiments, as will be apparent to those skilled in the art from this disclosure. When an indefinite or definite article is used when referring to a singular noun, such as “a” or “an” or “the,” this includes the plural form of that noun unless otherwise explicitly stated.

[0033] Similarly, in the description of exemplary embodiments of this disclosure, various characteristics of this disclosure may be combined in a single embodiment, figure, or description for the purpose of simplifying the disclosure and aiding in the understanding of one or more of the various aspects of the invention.

[0034] In each of the following definitions, the number of carbon atoms usually represents the maximum number of carbon atoms optimally present in a substituent or linker, and unless otherwise specified in this application, the number of carbon atoms is understood to represent the optimal maximum number of carbon atoms in that particular substituent or linker.

[0035] As used herein, the terms “leaving group” or “LG” refer to a chemical group that is readily substituted by a nucleophile, or that is cleaved or hydrolyzed under basic or acidic conditions. In certain embodiments, the leaving group is selected from halogen atoms (e.g., Cl, Br, I) or sulfonates (e.g., mesylate, tosylate, triflate).

[0036] The term "protecting group" refers to a part of a compound that masks or alters the properties of a functional group or the properties of the compound as a whole. The chemical substructures of protecting groups vary widely. One function of a protecting group is to act as an intermediate in the synthesis of the parent drug substance. Chemical protecting groups and protection / deprotection strategies are well known in the art. See, for example, “Protective Groups in Organic Chemistry”, Theodora W. Greene (John Wiley & Sons, Inc., New York, 1991). Protecting groups are often used to mask the reactivity of a particular functional group, thereby improving the efficiency of a desired chemical reaction, for example, by forming and cleaving chemical bonds in a sequential and planned manner. Protecting a functional group of a compound alters other physical properties, such as polarity, lipophilicity (hydrophobicity), and other properties measurable with common analytical tools, in addition to the reactivity of the protected functional group. Chemically protected intermediates may themselves be biologically active or inactive.

[0037] Protected compounds may also exhibit modified and, in some cases, optimized properties both in vitro and in vivo, such as resistance to cell membrane crossing and enzymatic degradation or sequestration. In this role, protected compounds with the desired therapeutic effect are sometimes called prodrugs. Another function of protecting groups is to convert parent drugs into prodrugs, thereby releasing the parent drug upon conversion of the prodrug in vivo. Because active prodrugs can be absorbed more efficiently than parent drugs, prodrugs may have higher potency than their parent drugs in vivo. Protecting groups are removed either in vitro in the case of chemical intermediates, or in vivo in the case of prodrugs. For chemical intermediates, the resulting product after deprotection, such as an alcohol, is not particularly important, but generally, it is more desirable if the product is pharmacologically harmless.

[0038] The terms "alkyl" or "C" as used herein refer to their respective uses. 1~18 The term "alkyl" refers to a C1-C molecule that does not have an unsaturated site. 18 This refers to linear, secondary or tertiary, linear, branched, or straight-chain hydrocarbons. Examples include methyl, ethyl, 1-propyl (n-propyl), 2-propyl (iPr), 1-butyl, 2-methyl-1-propyl (i-Bu), 2-butyl (s-Bu), 2-dimethyl-2-propyl (t-Bu), 1-pentyl (n-pentyl), 2-pentyl, 3-pentyl, 2-methyl-2-butyl, 3-methyl-2-butyl, 3-methyl-1-butyl, 2-methyl-1-butyl, 1-hexyl, 2-hexyl, 3-hexyl, 2-methyl- These include 2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 3-methyl-3-pentyl, 2-methyl-3-pentyl, 2,3-dimethyl-2-butyl, 3,3-dimethyl-2-butyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, n-dodecyl, n-tridecyl, n-tetradecyl, n-pentadecyl, n-hexadecyl, n-heptadecyl, n-octadecyl, n-nonadecyl, and n-icosyl. In certain embodiments, the term alkyl is used as C as further defined above herein. 1~12 Alkyl (C1~12 refers to hydrocarbons, and more specifically, C 1~9 alkyl (C 1~9 refers to hydrocarbons, and even more specifically, C 1~6 alkyl (C 1~6 refers to hydrocarbons).

[0039] The term "haloalkyl" as a group or part of a group refers to an alkyl group having the meaning as defined above, where one, two, or three hydrogen atoms are each substituted with a halogen as defined herein. Non-limiting examples of such haloalkyl groups include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl, and the like.

[0040] The term "alkoxy" or "alkyloxy" as a group or part of a group refers to a group having the formula -OR b wherein R b is C 1~6 alkyl as defined above herein. Non-limiting examples of suitable C 1~6 alkoxy include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy, and hexyloxy.

[0041] The term "haloalkoxy" as a group or part of a group refers to a group of the formula -O-R c wherein R c is haloalkyl as defined herein. Non-limiting examples of suitable haloalkoxy include fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 1,1,2,2-tetrafluoroethoxy, 2-fluoroethoxy, 2-chloroethoxy, 2,2-difluoroethoxy, 2,2,2-trichloroethoxy, trichloromethoxy, 2-bromoethoxy, pentafluoroethoxy, 3,3,3-trichloropropoxy, 4,4,4-trichlorobutoxy.

[0042] The terms "cycloalkyl" or "C" as used herein refer to the same terms used herein. 3~18 The term "cycloalkyl" means C unless otherwise specified. 3~10 Monocyclic or C 7~18 Polycyclic saturated hydrocarbons, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclopropylethylene, methylcyclopropylene, cyclohexyl, cycloheptyl, cyclooctyl, cyclooctylmethylene, norbornyl, fenquil, trimethyltricycloheptyl, dekalinyl, adamantyl, etc., mean monovalent groups of saturated hydrocarbons having 3 to 18 carbon atoms. In certain embodiments, the term cycloalkyl means C as further defined above herein. 3~12 Cycloalkyl (saturated cyclic C 3~12 This refers to hydrocarbons, and more specifically, C 3~9 Cycloalkyl (saturated cyclic C 3~9 This refers to hydrocarbons, and more specifically, C 3~6 Cycloalkyl (saturated cyclic C 3~6 This refers to hydrocarbons. To avoid misunderstanding, a condensation system of a cycloalkyl ring and a heterocycle is considered a heterocycle regardless of the ring bonded to the core structure. A condensation system of a cycloalkyl ring and an aryl ring is considered an aryl ring regardless of the ring bonded to the core structure. A condensation system of a cycloalkyl ring and a heteroaryl ring is considered a heteroaryl ring regardless of the ring bonded to the core structure.

[0043] The terms "alkenyl" or "C" used herein refer to the same term used herein. 2~18 The term "alkenyl" refers to a C2-C2 bond containing at least one (usually 1-3, preferably 1) unsaturated site, i.e., a carbon-carbon sp2 double bond. 18These are linear, secondary or tertiary, linear, branched, or straight-chain hydrocarbons. Examples include, but are not limited to, ethylene or vinyl (-CH=CH2), allyl (-CH2CH=CH2), and 5-hexenyl (-CH2CH2CH2CH2CH=CH2). The double bond may be in a cis or trans configuration. In certain embodiments, the term alkenyl means a C molecule having at least one (usually one to three, preferably one) unsaturated site, i.e., a carbon-carbon sp2 double bond, as further defined above herein. 2~12 Alkenil (C 2~12 This refers to hydrocarbons, and more specifically, C 2~9 Alkenil (C 2~9 This refers to hydrocarbons, and more specifically, C 2~6 Alkenil (C 2~6 It refers to hydrocarbons.

[0044] The term "alkenyloxy" as a group or part of a group is defined by the formula -OR d This refers to a group having R, in the formula d This is an alkenil as defined above in this specification.

[0045] As used herein, the term "cycloalkenyl" means having 5 to 18 carbon atoms, each having at least one (usually 1 to 3, preferably 1) unsaturated site, i.e., a carbon-carbon sp2 double bond, and C 5~10 Monocyclic or C 7~18 This refers to a non-aromatic hydrocarbon group consisting of or containing polycyclic hydrocarbons. Examples include, but are not limited to, cyclopentenyl (-C5H7), cyclopentenylpropylene, methylcyclohexenylene, and cyclohexenyl (-C6H9). The double bond may be in a cis or trans configuration. In certain embodiments, the term cycloalkenyl refers to a C group having at least one unsaturated site, i.e., a carbon-carbon sp2 double bond, as further defined herein above. 5~12 Cycloalkenyl (cyclic C 5~12 This refers to hydrocarbons, and more specifically, C 5~9 Cycloalkenyl (cyclic C5~9 This refers to hydrocarbons, and more specifically, C 5~6 Cycloalkenyl (cyclic C 5~6 This refers to hydrocarbons. To avoid misunderstanding, a condensation system of a cycloalkenyl ring and a heterocycle is considered a heterocycle regardless of the ring bonded to the core structure. A condensation system of a cycloalkenyl ring and an aryl ring is considered an aryl ring regardless of the ring bonded to the core structure. A condensation system of a cycloalkenyl ring and a heteroaryl ring is considered a heteroaryl ring regardless of the ring bonded to the core structure.

[0046] The terms "alkynyl" or "C" used herein refer to the same term used in this specification. 2~18 The term "alkynyl" refers to a C2-C2 group having at least one (usually 1-3, preferably 1) unsaturated site, i.e., a carbon-carbon sp triple bond. 18 This refers to linear, secondary, tertiary, linear, branched, or straight-chain hydrocarbons. Examples include, but are not limited to, ethynnyl (-C≡CH), 3-ethyl-cyclohept-1-inylene, and 1-propynyl (propargyl, -CH2C≡CH). In certain embodiments, the term alkynyl refers to a C molecule having at least one (usually one to three, preferably one) unsaturated site, i.e., a carbon-carbon sp triple bond, as further defined above herein. 2~12 Alkinyl (C 2~12 This refers to hydrocarbons, and more specifically, C 2~9 Alkinyl (C 2~9 This refers to hydrocarbons, and more specifically, C 2~6 Alkinyl (C 2~6 It refers to hydrocarbons.

[0047] The term "alkynyloxy" as a group or part of a group is defined by the formula -OR e This refers to a group having R, in the formula e This is an alkynyl as defined above in this specification.

[0048] As used herein, the term "cycloalkynyl" means having at least one (usually 1 to 3, preferably 1) unsaturated site, i.e., 5 to 18 carbon atoms having a carbon-carbon sp triple bond, and C 5~10 Monocyclic or C 7~18 This refers to a non-aromatic hydrocarbon group consisting of or containing polycyclic hydrocarbons. Examples include, but are not limited to, cyclohepto-1-yine, 3-ethyl-cyclohepto-1-inylene, 4-cyclohepto-1-yine-methylene, and ethylene-cyclohepto-1-yine. In certain embodiments, the term cycloalkynyl refers to a group having at least one (usually one to three, preferably one) unsaturated site, i.e., a carbon-carbon sp triple bond, as further defined above herein. 5~10 Cycloalkynyl (cyclic C 5~10 This refers to hydrocarbons, and more specifically, C 5~9 Cycloalkynyl (cyclic C 5~9 This refers to hydrocarbons, and more specifically, C 5~6 Cycloalkynyl (cyclic C 5~6 This refers to hydrocarbons. To avoid misunderstanding, a condensation system of a cycloalkynyl ring and a heterocycle is considered a heterocycle regardless of the ring bonded to the core structure. A condensation system of a cycloalkynyl ring and an aryl ring is considered an aryl ring regardless of the ring bonded to the core structure. A condensation system of a cycloalkynyl ring and a heteroaryl ring is considered a heteroaryl ring regardless of the ring bonded to the core structure.

[0049] As used herein, the term "alkylene" refers to a group of atoms (more specifically, C) with 1 to 18 carbon atoms. 1~12 , C 1~9 , or C 1~6A alkylene refers to a saturated branched or straight-chain hydrocarbon group of carbon atoms, having two monovalent bonds derived by the removal of two hydrogen atoms from the same or two different carbon atoms of the parent alkane. Typical alkylenes include, but are not limited to, methylene (-CH2-), diethyl (-CH2CH2-), 1,3-propyl (-CH2CH2CH2-), and 1,4-butyl (-CH2CH2CH2CH2-).

[0050] As used herein, the term "alkenylene" refers to a compound having at least one (usually 1 to 3, preferably 1) unsaturated site, i.e., a carbon-carbon sp2 double bond, comprising 2 to 18 carbon atoms (more specifically, C 2~12 , C 2~9 , or C 2~6 This refers to a branched or straight-chain hydrocarbon of carbon atoms, having two monovalent bonds induced by the removal of two hydrogen atoms from the same or two different carbon atoms of the parent alkene.

[0051] As used herein, the term "alkynylene" refers to a compound having at least one (usually 1 to 3, preferably 1) unsaturated site, i.e., a carbon-carbon sp triple bond, comprising 2 to 18 carbon atoms (more specifically, C 2~12 , C 2~9 , or C 2~6 This refers to a branched or straight-chain hydrocarbon of carbon atoms, having two monovalent bonds induced by the removal of two hydrogen atoms from the same or two different carbon atoms of the parent alkyne.

[0052] As used herein, the term "heteroalkyl" refers to an alkyl group in which one or more carbon atoms are substituted by one or more atoms selected from the group including oxygen, nitrogen, or sulfur atoms. Therefore, the term heteroalkyl is -OR b , -NR o -R b , -R a -OR b , and -SR b Includes, in the formula, R ais an alkylene as defined herein, and R b is an alkyl, and R o is hydrogen or alkyl. In certain embodiments, this term refers to C 1~12 heteroalkyl, C 1~9 heteroalkyl, or C 1~6 heteroalkyl. In some embodiments, heteroalkyl is selected from the group consisting of alkyloxy, alkyl-oxy-alkyl, (mono or di)alkylamino, (mono or di-)alkyl-amino-alkyl, alkylthio, and alkyl-thio-alkyl.

[0053] As used herein, the term "heteroalkenyl" refers to an acyclic alkenyl in which one or more carbon atoms are substituted by one or more atoms selected from oxygen, nitrogen, or sulfur atoms. Thus, the term heteroalkenyl includes -O-R d , -NH-(R d ), -N(R d ))2, -N(R b )(R d ), and -S-R d , wherein R b is an alkyl as defined herein, and R d is an alkenyl. In certain embodiments, this term refers to C 2~12 heteroalkenyl, C 2~9 heteroalkenyl, or C 2~6 heteroalkenyl. In some embodiments, heteroalkenyl is selected from the group consisting of alkenyloxy, alkenyl-oxy-alkenyl, (mono or di-)alkenylamino, (mono or di-)alkenyl-amino-alkenyl, alkenylthio, and alkenyl-thio-alkenyl.

[0054] As used herein, the term "heteroalkynyl" refers to an acyclic alkynyl in which one or more carbon atoms are substituted by oxygen, nitrogen, or sulfur atoms. Thus, the term heteroalkynyl includes -O-R d , -N(R d )2, NHRd , -N(R b )(R e ), -N(R d )(R e ), and -S-R d including but not limited to, wherein R b is alkyl as defined herein, R e is alkynyl, and R d is alkenyl. In certain embodiments, this term refers to C 2~12 heteroalkynyl, C 2~9 heteroalkynyl, or C 2~6 heteroalkynyl. In some embodiments, the term heteroalkynyl is selected from the group consisting of alkynyloxy, alkynyl-oxy-alkynyl, (mono- or di-) alkynylamino, (mono- or di-) alkynyl-amino-alkynyl, alkynylthio, alkynyl-thio-alkynyl.

[0055] As used herein, the term "heteroalkylene" refers to alkylene in which one or more carbon atoms are replaced by one or more oxygen, nitrogen, or sulfur atoms.

[0056] As used herein, the term "heteroalkenylene" refers to alkenylene in which one or more carbon atoms are replaced by one or more oxygen, nitrogen, or sulfur atoms.

[0057] As used herein, the term "heteroalkynylene" refers to alkynylene in which one or more carbon atoms are replaced by one or more oxygen, nitrogen, or sulfur atoms.

[0058] As used herein, the term “aryl” refers to an aromatic hydrocarbon comprising 6 to 20 carbon atoms derived by the removal of hydrogen from carbon atoms in a parent aromatic ring system. Typical aryl groups include, but are not limited to, a single ring or two or three rings condensed together, derived from benzene, naphthalene, anthracene, biphenyl, etc. In certain embodiments, the term aryl refers to an aromatic ring comprising 6 to 14 carbon atoms, and more specifically, an aromatic ring comprising 6 to 10 carbon atoms. A condensation system of an aryl ring with a cycloalkyl ring, or a cycloalkenyl ring, or a cycloalkynyl ring is considered aryl regardless of the ring bonded to the core structure. A condensation system of an aryl ring with a heterocycle is considered heterocycle regardless of the ring bonded to the core structure. Therefore, indoline, dihydrobenzofuran, dihydrobenzothiophene, etc., are considered heterocycles in accordance with this disclosure. A condensation system of an aryl ring with a heteroaryl ring is considered heteroaryl regardless of the ring bonded to the core structure.

[0059] The term "aryloxy" as a group or part of a group is defined by the formula -OR g This refers to a group having R, in the formula g This is an aryl as defined above in this specification.

[0060] As used herein, the terms "arylalkyl" or "arylalkyl-" refer to an alkyl group in which one of the carbon atoms, typically a hydrogen atom bonded to a terminal or sp3 carbon atom, is substituted with an aryl group. Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylethane-1-yl, 2-phenylethen-1-yl, naphthylmethyl, and 2-naphthylethyl. Arylalkyl groups contain 6 to 20 carbon atoms; for example, the alkyl portion of an arylalkyl group has 1 to 6 carbon atoms, and the aryl portion has 6 to 14 carbon atoms.

[0061] The term "arylalkyloxy" as a group or part of a group is defined by the formula -ORa -R g This refers to a group having R, in the formula g R is an aryl as defined above in this specification, a It is an alkylene.

[0062] As used herein, the terms "arylalkenyl" or "arylalkenyl-" refer to an alkenyl in which one of the hydrogen atoms bonded to a carbon atom is substituted with an aryl group. An arylalkenyl group contains 6 to 20 carbon atoms; for example, the alkenyl portion of an arylalkenyl group has 1 to 6 carbon atoms, and the aryl portion has 6 to 14 carbon atoms.

[0063] As used herein, the terms "arylalkynyl" or "arylalkynyl-" refer to an alkynyl group in which one of the hydrogen atoms bonded to a carbon atom is substituted with an aryl group. An arylalkynyl group contains 6 to 20 carbon atoms; for example, the alkynyl portion of an arylalkynyl group contains 1 to 6 carbon atoms, and the aryl portion contains 6 to 14 carbon atoms.

[0064] As used herein, the terms “arylheteroalkyl” or “arylheteroalkyl-” refer to a heteroalkyl group in which one of the carbon atoms, typically a hydrogen atom bonded to a terminal or sp3 carbon atom, is substituted with an aryl group. An arylheteroalkyl group contains 6 to 20 carbon atoms; for example, the heteroalkyl portion of an arylheteroalkyl group contains 1 to 6 carbon atoms, and the aryl portion contains 6 to 14 carbon atoms. In some embodiments, the arylheteroalkyl group is selected from the group including aryl-O-alkyl, arylalkyl-O-alkyl, aryl-NH-alkyl, aryl-N(alkyl)2, arylalkyl-NH-alkyl, arylalkyl-N-(alkyl)2, aryl-S-alkyl, and arylalkyl-S-alkyl.

[0065] As used herein, the terms “arylheteroalkenyl” or “arylheteroalkenyl-” refer to a heteroalkenyl in which one of the hydrogen atoms bonded to a carbon atom is substituted with an aryl group. An arylheteroalkenyl group contains 6 to 20 carbon atoms; for example, the heteroalkenyl portion of an arylheteroalkenyl group contains 1 to 6 carbon atoms, and the aryl portion contains 6 to 14 carbon atoms. In some embodiments, the arylheteroalkenyl is selected from the group including aryl-O-alkenyl, arylalkenyl-O-alkenyl, aryl-NH-alkenyl, aryl-N(alkenyl)2, arylalkenyl-NH-alkenyl, arylalkenyl-N-(alkenyl)2, aryl-S-alkenyl, and arylalkenyl-S-alkenyl.

[0066] As used herein, the terms “arylheteroalkynyl” or “arylheteroalkynyl-” refer to a heteroalkynyl in which one of the hydrogen atoms bonded to a carbon atom is substituted with an aryl group. An arylheteroalkynyl group contains 6 to 20 carbon atoms; for example, the heteroalkynyl portion of an arylheteroalkynyl group contains 1 to 6 carbon atoms, and the aryl portion contains 6 to 14 carbon atoms. In some embodiments, the arylheteroalkynyl is selected from the group including aryl-O-alkynyl, arylalkynyl-O-alkynyl, aryl-NH-alkynyl, aryl-N(alkynyl)2, arylalkynyl-NH-alkynyl, arylalkynyl-N-(alkynyl)2, aryl-S-alkynyl, and arylalkynyl-S-alkynyl.

[0067] As used herein, the terms “heterocycle” or “heterocyclyl” refer to a non-aromatic, fully saturated, or partially unsaturated ring system of 3 to 18 atoms, including at least one N, O, S, or P (e.g., a monocyclic ring of 3 to 7 members, a bicyclic ring of 7 to 11 members, or a total of 3 to 10 ring atoms). Each ring in a heterocycle or heterocyclyl may have 1, 2, 3, or 4 heteroatoms selected from N, O, and / or S, where the N and S heteroatoms may be optionally oxidized, the N heteroatom may be optionally quaternized, and at least one carbon atom of the heterocyclyl may be oxidized to form at least one C=O. Heterocycles may be bonded to any heteroatom or carbon atom of the ring or ring system, as far as the valence allows. The rings of a polycyclic heterocyclyl or heterocycle may be condensed, bridged, and / or linked via one or more spiroatoms. A condensation system of a heterocycle or heterocyclyl and an aryl ring is considered a heterocycle or heterocyclyl regardless of the ring bonded to the core structure. A condensation system of a heterocycle or heterocyclyl and a heteroaryl ring is considered a heteroaryl regardless of the ring bonded to the core structure.

[0068] Examples of non-limiting, exemplary heterocyclic or heterocyclic groups include piperidinyl, piperazinyl, homopiperazinyl, morpholinyl, tetrahydropyranil, tetrahydrofuranil, pyrrolidinyl, azilidinyl, oxyranil, thyranil, azetidinyl, oxetanil, thietanil, 2-imidazolinyl, pyrazolidinylimidazolidinyl, isoxazolidinyl, oxazolidinyl, isoxazolidinyl Thiazolidinil, isothiazolidinil, succinimidyl, 3H-indolyl, indolinyl, isoindolinyl, chromanil (also known as 3,4-dihydrobenzo[b]pyranyl), 2H-pyrrolyl, 1-pyrrolinil, 2-pyrrolinil, 3-pyrrolinil, 4H-quinolidinil, 2-oxopiperazinyl, 2-pyrazolinil, 3-pyrazolinil, tetrahydro-2H-pyranyl, 2H-pyranyl Examples include 4H-pyranyl, 3,4-dihydro-2H-pyranyl, 3-dioxolanyl, 1,4-dioxanyl, 2,5-dioxymidazolidinyl, 2-oxopiperidinyl, 2-oxopyrrodinyl, indolinyl, tetrahydrothiophenyl, tetrahydroquinolinyl, tetrahydroisoquinoline-1-yl, tetrahydroisoquinoline-2-yl, tetrahydroisoquinoline-3-yl, tetrahydroisoquinoline-4-yl, thiomorpholine-4-yl, thiomorpholine-4-yl sulfoxide, thiomorpholine-4-yl sulfone, 1,3-dioxolanyl, 1,4-oxathianyl, 1,4-dithianyl, 1,3,5-trioxanyl, 1H-pyrrolidinyl, tetrahydro-1,1-dioxothiophenyl, N-formylpiperazinyl, and morpholine-4-yl. As used herein, the term "aziridinyl" includes aziridin-1-yl and aziridin-2-yl. As used herein, the term "oxyranil" includes oxyranyl-2-yl. As used herein, the term "thiranil" includes thiran-2-yl. As used herein, the term "azetidinyl" includes azetidine-1-yl, azetidine-2-yl and azetidine-3-yl. As used herein, the term "oxetanyl" includes oxetane-2-yl and oxetane-3-yl. As used herein, the term "thietanyl" includes thietan-2-yl and thietan-3-yl.As used herein, the term "pyrrolidinyl" includes pyrrolidine-1-yl, pyrrolidine-2-yl, and pyrrolidine-3-yl. As used herein, the term "tetrahydrofuranyl" includes tetrahydrofuran-2-yl and tetrahydrofuran-3-yl. As used herein, the term "tetrahydrothiophenyl" includes tetrahydrothiophen-2-yl and tetrahydrothiophen-3-yl. As used herein, the term "succinimidyl" includes succinimido-1-yl and succinimido-3-yl. As used herein, the term "dihydropyrrolyl" includes 2,3-dihydropyrrole-1-yl, 2,3-dihydro-1H-pyrrole-2-yl, 2,3-dihydro-1H-pyrrole-3-yl, 2,5-dihydropyrrole-1-yl, 2,5-dihydro-1H-pyrrole-3-yl, and 2,5-dihydropyrrole-5-yl. As used herein, the term “2H-pyrrolyl” includes 2H-pyrrole-2-yl, 2H-pyrrole-3-yl, 2H-pyrrole-4-yl, and 2H-pyrrole-5-yl. As used herein, the term “3H-pyrrolyl” includes 3H-pyrrole-2-yl, 3H-pyrrole-3-yl, 3H-pyrrole-4-yl, and 3H-pyrrole-5-yl. As used herein, the term “dihydrofuranyl” includes 2,3-dihydrofuran-2-yl, 2,3-dihydrofuran-3-yl, 2,3-dihydrofuran-4-yl, 2,3-dihydrofuran-5-yl, 2,5-dihydrofuran-2-yl, 2,5-dihydrofuran-3-yl, 2,5-dihydrofuran-4-yl, and 2,5-dihydrofuran-5-yl. As used herein, the term “dihydrothiophenyl” includes 2,3-dihydrothiophen-2-yl, 2,3-dihydrothiophen-3-yl, 2,3-dihydrothiophen-4-yl, 2,3-dihydrothiophen-5-yl, 2,5-dihydrothiophen-2-yl, 2,5-dihydrothiophen-3-yl, 2,5-dihydrothiophen-4-yl, and 2,5-dihydrothiophen-5-yl. As used herein, the term “imidazolidinyl” includes imidazolidin-1-yl, imidazolidin-2-yl, and imidazolidin-4-yl.As used herein, the term "pyrazolidinyl" includes pyrazolidine-1-yl, pyrazolidine-3-yl, and pyrazolidine-4-yl. As used herein, the term "imidazolinyl" includes imidazolin-1-yl, imidazolin-2-yl, imidazolin-4-yl, and imidazolin-5-yl. As used herein, the term "pyrazolinyl" includes 1-pyrazolin-3-yl, 1-pyrazolin-4-yl, 2-pyrazolin-1-yl, 2-pyrazolin-3-yl, 2-pyrazolin-4-yl, 2-pyrazolin-5-yl, 3-pyrazolin-1-yl, 3-pyrazolin-2-yl, 3-pyrazolin-3-yl, 3-pyrazolin-4-yl, and 3-pyrazolin-5-yl. As used herein, the term “dioxolanil,” also known as “1,3-dioxolanil,” includes dioxolan-2-yl, dioxolan-4-yl, and dioxolan-5-yl. As used herein, the term “dioxoryl,” also known as “1,3-dioxoryl,” includes dioxol-2-yl, dioxol-4-yl, and dioxol-5-yl. As used herein, the term “oxazolidinyl” includes oxazolidine-2-yl, oxazolidine-3-yl, oxazolidine-4-yl, and oxazolidine-5-yl. As used herein, the term “isoxazolidinyl” includes isoxazolidine-2-yl, isoxazolidine-3-yl, isoxazolidine-4-yl, and isoxazolidine-5-yl. As used herein, the term "oxazolinyl" includes 2-oxazolinyl-2-yl, 2-oxazolinyl-4-yl, 2-oxazolinyl-5-yl, 3-oxazolinyl-2-yl, 3-oxazolinyl-4-yl, 3-oxazolinyl-5-yl, 4-oxazolinyl-2-yl, 4-oxazolinyl-3-yl, 4-oxazolinyl-4-yl, and 4-oxazolinyl-5-yl.As used herein, the term "isoxazolinyl" includes 2-isoxazolinyl-3-yl, 2-isoxazolinyl-4-yl, 2-isoxazolinyl-5-yl, 3-isoxazolinyl-3-yl, 3-isoxazolinyl-4-yl, 3-isoxazolinyl-5-yl, 4-isoxazolinyl-2-yl, 4-isoxazolinyl-3-yl, 4-isoxazolinyl-4-yl, and 4-isoxazolinyl-5-yl. As used herein, the term "thiazolidinyl" includes thiazolidinyl-2-yl, thiazolidinyl-3-yl, thiazolidinyl-4-yl, and thiazolidinyl-5-yl. As used herein, the term "isothiazolidinyl" includes thiazolidinyl-2-yl, thiazolidinyl-3-yl, thiazolidinyl-4-yl, and thiazolidinyl-5-yl. As used herein, the term "thiazolinyl" includes 2-thiazolinyl-2-yl, 2-thiazolinyl-4-yl, 2-thiazolinyl-5-yl, 3-thiazolinyl-2-yl, 3-thiazolinyl-4-yl, 3-thiazolinyl-5-yl, 4-thiazolinyl-2-yl, 4-thiazolinyl-3-yl, 4-thiazolinyl-4-yl, and 4-thiazolinyl-5-yl. As used herein, the term "isothiazolinyl" includes 2-isothiazolinyl-3-yl, 2-isothiazolinyl-4-yl, 2-isothiazolinyl-5-yl, 3-isothiazolinyl-3-yl, 3-isothiazolinyl-4-yl, 3-isothiazolinyl-5-yl, 4-isothiazolinyl-2-yl, 4-isothiazolinyl-3-yl, 4-isothiazolinyl-4-yl, and 4-isothiazolinyl-5-yl. As used herein, the term "piperidyl," also known as "piperidinyl," includes piperido-1-yl, piperido-2-yl, piperido-3-yl, and piperido-4-yl.As used herein, the term “dihydropyridinyl” refers to 1,2-dihydropyridine-1-yl, 1,2-dihydropyridine-2-yl, 1,2-dihydropyridine-3-yl, 1,2-dihydropyridine-4-yl, 1,2-dihydropyridine-5-yl, 1,2-dihydropyridine-6-yl, 1,4-dihydropyridine-1-yl, 1,4-dihydropyridine-2-yl, 1,4-dihydropyridine-3-yl, 1,4-dihydropyridine-4-yl, 2,3-dihydropyridine-2-yl, 2,3-dihydropyridine-3- This includes yl, 2,3-dihydropyridine-4-yl, 2,3-dihydropyridine-5-yl, 2,3-dihydropyridine-6-yl, 2,5-dihydropyridine-2-yl, 2,5-dihydropyridine-3-yl, 2,5-dihydropyridine-4-yl, 2,5-dihydropyridine-5-yl, 2,5-dihydropyridine-6-yl, 3,4-dihydropyridine-2-yl, 3,4-dihydropyridine-3-yl, 3,4-dihydropyridine-4-yl, 3,4-dihydropyridine-5-yl, and 3,4-dihydropyridine-6-yl. As used herein, the term "tetrahydropyridinyl" refers to 1,2,3,4-tetrahydropyridine-1-yl, 1,2,3,4-tetrahydropyridine-2-yl, 1,2,3,4-tetrahydropyridine-3-yl, 1,2,3,4-tetrahydropyridine-4-yl, 1,2,3,4-tetrahydropyridine-5-yl, 1,2,3,4-tetrahydropyridine-6-yl, 1,2,3,6-tetrahydropyridine-1-yl, 1,2,3,6-tetrahydropyridine-2-yl, and 1,2,3,6-tetrahydropyridine-1-yl, 1,2,3,6-tetrahydropyridine-2-yl. This includes hydropyridine-3-yl, 1,2,3,6-tetrahydropyridine-4-yl, 1,2,3,6-tetrahydropyridine-5-yl, 1,2,3,6-tetrahydropyridine-6-yl, 2,3,4,5-tetrahydropyridine-2-yl, 2,3,4,5-tetrahydropyridine-3-yl, 2,3,4,5-tetrahydropyridine-3-yl, 2,3,4,5-tetrahydropyridine-4-yl, 2,3,4,5-tetrahydropyridine-5-yl, and 2,3,4,5-tetrahydropyridine-6-yl.As used herein, the terms “tetrahydropyranyl,” also known as “oxanyl,” or “tetrahydro-2H-pyranyl” include tetrahydropyran-2-yl, tetrahydropyran-3-yl, and tetrahydropyran-4-yl. As used herein, the term “2H-pyranyl” includes 2H-pyran-2-yl, 2H-pyran-3-yl, 2H-pyran-4-yl, 2H-pyran-5-yl, and 2H-pyran-6-yl. As used herein, the term “4H-pyranyl” includes 4H-pyran-2-yl, 4H-pyran-3-yl, and 4H-pyran-4-yl. As used herein, the term “3,4-dihydro-2H-pyran-2-yl,” 3,4-dihydro-2H-pyran-3-yl, 3,4-dihydro-2H-pyran-4-yl, 3,4-dihydro-2H-pyran-5-yl, and 3,4-dihydro-2H-pyran-6-yl. As used herein, the term “3,6-dihydro-2H-pyran-2-yl,” 3,6-dihydro-2H-pyran-3-yl, 3,6-dihydro-2H-pyran-4-yl, 3,6-dihydro-2H-pyran-5-yl, and 3,6-dihydro-2H-pyran-6-yl. The term "tetrahydrothiophenyl" as used herein includes tetrahydrothiophen-2-yl, tetrahydrothiophenyl-3-yl, and tetrahydrothiophenyl-4-yl. The term "2H-thiopyranyl" as used herein includes 2H-thiopyran-2-yl, 2H-thiopyran-3-yl, 2H-thiopyran-4-yl, 2H-thiopyran-5-yl, and 2H-thiopyran-6-yl. The term "4H-thiopyranyl" as used herein includes 4H-thiopyran-2-yl, 4H-thiopyran-3-yl, and 4H-thiopyran-4-yl. As used herein, the term “3,4-dihydro-2H-thiopyran-2-yl,” 3,4-dihydro-2H-thiopyran-3-yl, 3,4-dihydro-2H-thiopyran-4-yl, 3,4-dihydro-2H-thiopyran-5-yl, and 3,4-dihydro-2H-thiopyran-6-yl. As used herein, the term “3,6-dihydro-2H-thiopyran-2-yl,” 3,6-dihydro-2H-thiopyran-3-yl, 3,6-dihydro-2H-thiopyran-4-yl, 3,6-dihydro-2H-thiopyran-5-yl, and 3,6-dihydro-2H-thiopyran-6-yl. As used herein, the term “piperazinyl,” also known as “piperazinyl,” includes piperazine-1-yl and piperazine-2-yl. As used herein, the term “morpholinyl” includes morpholin-2-yl, morpholin-3-yl and morpholin-4-yl. As used herein, the term “thiomorpholinyl” includes thiomorpholin-2-yl, thiomorpholin-3-yl and thiomorpholin-4-yl. As used herein, the term “dioxanyl” includes 1,2-dioxan-3-yl, 1,2-dioxan-4-yl, 1,3-dioxan-2-yl, 1,3-dioxan-4-yl, 1,3-dioxan-5-yl and 1,4-dioxan-2-yl. As used herein, the term “dithianyl” includes 1,2-dithian-3-yl, 1,2-dithian-4-yl, 1,3-dithian-2-yl, 1,3-dithian-4-yl, 1,3-dithian-5-yl, and 1,4-dithian-2-yl.As used herein, the term "oxathianyl" includes oxathian-2-yl and oxathian-3-yl. As used herein, the term "trioxanyl" includes 1,2,3-trioxan-4-yl, 1,2,3-trioxan-5-yl, 1,2,4-trioxan-3-yl, 1,2,4-trioxan-5-yl, 1,2,4-trioxan-6-yl and 1,3,4-trioxan-2-yl. As used herein, the term "azepanyl" includes azepan-1-yl, azepan-2-yl, azepan-3-yl and azepan-4-yl. As used herein, the term "homopiperazinyl" includes homopiperazin-1-yl, homopiperazin-2-yl, homopiperazin-3-yl and homopiperazin-4-yl. As used herein, the term "indolinyl" includes indolin-1-yl, indolin-2-yl, indolin-3-yl, indolin-4-yl, indolin-5-yl, indolin-6-yl, and indolin-7-yl. As used herein, the term "quinolidinyl" includes quinolidin-1-yl, quinolidin-2-yl, quinolidin-3-yl, and quinolidin-4-yl. As used herein, the term "isoindolinyl" includes isoindolin-1-yl, isoindolin-2-yl, isoindolin-3-yl, isoindolin-4-yl, isoindolin-5-yl, isoindolin-6-yl, and isoindolin-7-yl. As used herein, the term “3H-indolyl” includes 3H-indole-2-yl, 3H-indole-3-yl, 3H-indole-4-yl, 3H-indole-5-yl, 3H-indole-6-yl, and 3H-indole-7-yl. As used herein, the term “quinolidinyl” includes quinolidinidine-1-yl, quinolidinidine-2-yl, quinolidinidine-3-yl, and quinolidinidine-4-yl. As used herein, the term “quinolidinyl” includes quinolidinidine-1-yl, quinolidinidine-2-yl, quinolidinidine-3-yl, and quinolidinidine-4-yl.As used herein, the term "tetrahydroquinolinyl" includes tetrahydroquinolin-1-yl, tetrahydroquinolin-2-yl, tetrahydroquinolin-3-yl, tetrahydroquinolin-4-yl, tetrahydroquinolin-5-yl, tetrahydroquinolin-6-yl, tetrahydroquinolin-7-yl, and tetrahydroquinolin-8-yl. As used herein, the term "tetrahydroisoquinolinyl" includes tetrahydroisoquinolin-1-yl, tetrahydroisoquinolin-2-yl, tetrahydroisoquinolin-3-yl, tetrahydroisoquinolin-4-yl, tetrahydroisoquinolin-5-yl, tetrahydroisoquinolin-6-yl, tetrahydroisoquinolin-7-yl, and tetrahydroisoquinolin-8-yl. As used herein, the term “chromanil” includes chroman-2-yl, chroman-3-yl, chroman-4-yl, chroman-5-yl, chroman-6-yl, chroman-7-yl, and chroman-8-yl. As used herein, the term “1H-pyrrolidine” includes 1H-pyrrolidine-1-yl, 1H-pyrrolidine-2-yl, 1H-pyrrolidine-3-yl, 1H-pyrrolidine-5-yl, 1H-pyrrolidine-6-yl, and 1H-pyrrolidine-7-yl. As used herein, the term “3H-pyrrolidine” includes 3H-pyrrolidine-1-yl, 3H-pyrrolidine-2-yl, 3H-pyrrolidine-3-yl, 3H-pyrrolidine-5-yl, 3H-pyrrolidine-6-yl, and 3H-pyrrolidine-7-yl.

[0069] The term "heteroaryl" refers to an aromatic ring system of 5 to 18 atoms containing at least one N, O, S, or P, comprising one or two rings that are condensable together or covalently bondable, each ring typically containing 5 to 6 atoms, where at least one of the rings is aromatic, and where the N and S heteroatoms may be optionally oxidized, the N heteroatom may be optionally quaternized, and at least one carbon atom of the heteroaryl may be oxidized to form at least one C=O. A condensation system of a heteroaryl ring with a cycloalkyl ring or a cycloalkenyl ring or a cycloalkynyl ring is considered a heteroaryl regardless of the ring bonded to the core structure. A condensation system of a heteroaryl ring with a heteroring is considered a heteroaryl regardless of the ring bonded to the core structure. A condensation system of a heteroaryl ring with an aryl ring is considered a heteroaryl regardless of the ring bonded to the core structure.Non-limiting examples of such heteroaryls include triazole-2-yl, pyridinyl, 1H-pyrazole-5-yl, pyrrolyl, furanil, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyrimidyl, pyrazinyl, pyridadinyl, oxazinyl, dioxynyl, thiadinyl, triazinyl, imidazo[2,1-b][1,3]thiazolyl, thieno[3,2-b]furanil, Thieno[3,2-b]thiophenyl, thieno[2,3-d][1,3]thiazolyl, thieno[2,3-d]imidazolyl, tetrazolo[1,5-a]pyridinyl, indolyl, indolidinyl, isoindolyl, benzofuranil, isobenzofuranil, benzothiophenyl, isobenzothiophenyl, indazolyl, benzimidazolyl, 1,3-benzoxazolyl, 1,2-benzisoxazolyl, 2,1-benzisoxazolyl, 1,3-benzothiazolyl, 1,2-benzoisothiazolyl, 2,1-benzoisothiazolyl, benzotriazolyl Ryl, 1,2,3-Benzoxadiazolyl, 2,1,3-Benzoxadiazolyl, 1,2,3-Benzothiasiazolyl, 2,1,3-Benzothiasiazolyl, Benzo[d]oxazole-2(3H)-one, 2,3-Dihydro-benzofuranil, Thienopyridinyl, Purinyl, Imidazo[1,2-a]pyridinyl, 6-Oxopyridazine-1(6H)-yl, 2-Oxopyridine-1(2H)-yl, 6-Oxopyridazine-1(6H)-yl, 2-Oxopyridine-1(2H)-yl, 1,3-Benzodioxolyl, Quinolinyl, Isoquinoli Examples include nyl, cinnolinyl, quinazolinyl, and quinoxalinyl. In some embodiments, the heteroaryl group is selected from the group comprising pyridyl, pyrazinyl, pyrimidinyl, pyrazolyl, pyrrolyl, isoxazolyl, thiophenyl, imidazolyl, indolyl, benzimidazolyl, s-triazinyl, oxazolyl, isothiazolyl, furyl, thienyl, triazolyl, and thiazolyl. In some embodiments, the heteroaryl group is selected from the group comprising pyridyl, pyrazinyl, pyrimidinyl, indolyl, and benzimidazolyl.

[0070] As used herein, the term "pyrrolyl" (also known as azolyl) includes pyrrole-1-yl, pyrrole-2-yl, and pyrrole-3-yl. As used herein, the term "furanyl" (also known as "furanyl") includes fran-2-yl and fran-3-yl (also known as fran-2-yl and fran-3-yl). As used herein, the term "thiophenyl" (also known as "thienyl") includes thiophene-2-yl and thiophene-3-yl (also known as thien-2-yl and thien-3-yl). As used herein, the term "pyrazolyl" (also known as 1H-pyrazolyl and 1,2-diazolyl) includes pyrazole-1-yl, pyrazole-3-yl, or 1H-pyrazolyl-5-yl, pyrazole-4-yl, and pyrazole-5-yl. As used herein, the term "imidazolyl" includes imidazole-1-yl, imidazole-2-yl, imidazole-4-yl, and imidazole-5-yl. As used herein, the term “oxazolyl” (also known as 1,3-oxazolyl) includes oxazole-2-yl, oxazole-4-yl, and oxazole-5-yl. As used herein, the term “isoxazolyl” (also known as 1,2-oxazolyl) includes isoxazole-3-yl, isoxazole-4-yl, and isoxazole-5-yl. As used herein, the term “thiazolyl” (also known as 1,3-thiazolyl) includes thiazolyl-2-yl, thiazolyl-4-yl, and thiazolyl-5-yl (also known as 2-thiazolyl, 4-thiazolyl, and 5-thiazolyl). As used herein, the term “isothiazolyl” (also known as 1,2-thiazolyl) includes isothiazole-3-yl, isothiazole-4-yl, and isothiazole-5-yl.As used herein, the term “triazolyl” includes triazol-2-yl, 1H-triazolyl, and 4H-1,2,4-triazolyl. “1H-triazolyl” includes 1H-1,2,3-triazol-1-yl, 1H-1,2,3-triazol-4-yl, 1H-1,2,3-triazol-5-yl, 1H-1,2,4-triazol-1-yl, 1H-1,2,4-triazol-3-yl, and 1H-1,2,4-triazol-5-yl. “4H-1,2,4-triazolyl” includes 4H-1,2,4-triazol-4-yl, and 4H-1,2,4-triazol-3-yl. As used herein, the term “oxadiazolyl” includes 1,2,3-oxadiazole-4-yl, 1,2,3-oxadiazole-5-yl, 1,2,4-oxadiazole-3-yl, 1,2,4-oxadiazole-5-yl, 1,2,5-oxadiazole-3-yl, and 1,3,4-oxadiazole-2-yl. As used herein, the term “thiadiazolil” includes 1,2,3-thiadiazole-4-yl, 1,2,3-thiadiazole-5-yl, 1,2,4-thiadiazole-3-yl, 1,2,4-thiadiazole-5-yl, 1,2,5-thiadiazole-3-yl (also known as furazan-3-yl), and 1,3,4-thiadiazole-2-yl. As used herein, the term "tetrazolyl" includes 1H-tetrazole-1-yl, 1H-tetrazole-5-yl, 2H-tetrazole-2-yl, and 2H-tetrazole-5-yl. As used herein, the term "oxatriazolyl" includes 1,2,3,4-oxatriazole-5-yl and 1,2,3,5-oxatriazole-4-yl. As used herein, the term "thiatriazolyl" includes 1,2,3,4-thiatriazol-5-yl and 1,2,3,5-thiatriazol-4-yl. As used herein, the term "pyridinyl" (also called "pyridyl") includes pyridine-2-yl, pyridine-3-yl, and pyridine-4-yl (also called 2-pyridyl, 3-pyridyl, and 4-pyridyl). As used herein, the term "pyrimidyl" includes pyrimido-2-yl, pyrimido-4-yl, pyrimido-5-yl, and pyrimido-6-yl.As used herein, the term "pyrazinyl" includes pyrazin-2-yl and pyrazin-3-yl. As used herein, the term "pyridazinyl" includes pyridazin-3-yl and pyridazin-4-yl. As used herein, the term "oxazinyl" (also known as "1,4-oxazinyl") includes 1,4-oxazin-4-yl and 1,4-oxazin-5-yl. As used herein, the term "dioxynyl" (also known as "1,4-dioxynyl") includes 1,4-dioxin-2-yl and 1,4-dioxin-3-yl. As used herein, the term "thiadinyl" (also known as "1,4-thiadinyl") includes 1,4-thiadin-2-yl, 1,4-thiadin-3-yl, 1,4-thiadin-4-yl, 1,4-thiadin-5-yl and 1,4-thiadin-6-yl. As used herein, the term “triazinyl” includes 1,3,5-triazin-2-yl, 1,2,4-triazin-3-yl, 1,2,4-triazin-5-yl, 1,2,4-triazin-6-yl, 1,2,3-triazin-4-yl, and 1,2,3-triazin-5-yl. As used herein, the term “imidazo[2,1-b][1,3]thiazolyl” includes imidazo[2,1-b][1,3]thiazoi-2-yl, imidazo[2,1-b][1,3]thiazole-3-yl, imidazo[2,1-b][1,3]thiazole-5-yl, and imidazo[2,1-b][1,3]thiazole-6-yl. As used herein, the term “thieno[3,2-b]furanyl” includes thieno[3,2-b]furan-2-yl, thieno[3,2-b]furan-3-yl, thieno[3,2-b]furan-4-yl, and thieno[3,2-b]furan-5-yl. As used herein, the term “thieno[3,2-b]thiophenyl” includes thieno[3,2-b]tien-2-yl, thieno[3,2-b]tien-3-yl, thieno[3,2-b]tien-5-yl, and thieno[3,2-b]tien-6-yl.As used herein, the term “thieno[2,3-d][1,3]thiazolyl” includes thieno[2,3-d][1,3]thiazole-2-yl, thieno[2,3-d][1,3]thiazole-5-yl, and thieno[2,3-d][1,3]thiazole-6-yl. As used herein, the term “thieno[2,3-d]imidazolyl” includes thieno[2,3-d]imidazole-2-yl, thieno[2,3-d]imidazole-4-yl, and thieno[2,3-d]imidazole-5-yl. As used herein, the term “tetrazolo[1,5-a]pyridinyl” includes tetrazolo[1,5-a]pyridin-5-yl, tetrazolo[1,5-a]pyridin-6-yl, tetrazolo[1,5-a]pyridin-7-yl, and tetrazolo[1,5-a]pyridin-8-yl. As used herein, the term “indolyl” includes indole-1-yl, indole-2-yl, indole-3-yl, indole-4-yl, indole-5-yl, indole-6-yl, and indole-7-yl. As used herein, the term “indolidinyl” includes indoridine-1-yl, indoridine-2-yl, indoridine-3-yl, indoridine-5-yl, indoridine-6-yl, indoridine-7-yl, and indoridine-8-yl. As used herein, the term “isoindole” includes isoindole-1-yl, isoindole-2-yl, isoindole-3-yl, isoindole-4-yl, isoindole-5-yl, isoindole-6-yl, and isoindole-7-yl. As used herein, the term “benzofuranyl” (also known as benzo[b]furanyl) includes benzofuran-2-yl, benzofuran-3-yl, benzofuran-4-yl, benzofuran-5-yl, benzofuran-6-yl, and benzofuran-7-yl. As used herein, the term “isobenzofuranyl” (also known as benzo[c]furanyl) includes isobenzofuran-1-yl, isobenzofuran-3-yl, isobenzofuran-4-yl, isobenzofuran-5-yl, isobenzofuran-6-yl, and isobenzofuran-7-yl.As used herein, the term “benzothiophenyl” (also known as benzo[b]thienyl) includes 2-benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, and -7-benzo[b]thiophenyl (also known as benzothien-2-yl, benzothien-3-yl, benzothien-4-yl, benzothien-5-yl, benzothien-6-yl, and benzothien-7-yl). As used herein, the term “isobenzothiophenyl” (also known as benzo[c]thienyl) includes isobenzothien-1-yl, isobenzothien-3-yl, isobenzothien-4-yl, isobenzothien-5-yl, isobenzothien-6-yl, and isobenzothien-7-yl. As used herein, the term "indazolyl" (also known as 1H-indazolyl or 2-azaindyl) includes 1H-indazole-1-yl, 1H-indazole-3-yl, 1H-indazole-4-yl, 1H-indazole-5-yl, 1H-indazole-6-yl, 1H-indazole-7-yl, 2H-indazole-2-yl, 2H-indazole-3-yl, 2H-indazole-4-yl, 2H-indazole-5-yl, 2H-indazole-6-yl, and 2H-indazole-7-yl. As used herein, the term "benzimidazolyl" includes benzimidazole-1-yl, benzimidazole-2-yl, benzimidazole-4-yl, benzimidazole-5-yl, benzimidazole-6-yl, and benzimidazole-7-yl. As used herein, the term "1,3-benzoxazolyl" includes 1,3-benzoxazole-2-yl, 1,3-benzoxazole-4-yl, 1,3-benzoxazole-5-yl, 1,3-benzoxazole-6-yl, and 1,3-benzoxazole-7-yl. As used herein, the term "1,2-benzisoxazolyl" includes 1,2-benzisoxazole-3-yl, 1,2-benzisoxazole-4-yl, 1,2-benzisoxazole-5-yl, 1,2-benzisoxazole-6-yl, and 1,2-benzisoxazole-7-yl.As used herein, the term “2,1-benzisoxazolyl” includes 2,1-benzisoxazole-3-yl, 2,1-benzisoxazole-4-yl, 2,1-benzisoxazole-5-yl, 2,1-benzisoxazole-6-yl, and 2,1-benzisoxazole-7-yl. As used herein, the term “1,3-benzothiazolyl” includes 1,3-benzothiazol-2-yl, 1,3-benzothiazol-4-yl, 1,3-benzothiazol-5-yl, 1,3-benzothiazol-6-yl, and 1,3-benzothiazol-7-yl. As used herein, the term "1,2-benzoisothiazolyl" includes 1,2-benzisothiazol-3-yl, 1,2-benzisothiazol-4-yl, 1,2-benzisothiazol-5-yl, 1,2-benzisothiazol-6-yl and 1,2-benzisothiazol-7-yl. As used herein, the term "2,1-benzoisothiazolyl" includes 2,1-benzisothiazol-3-yl, 2,1-benzisothiazol-4-yl and 2,1-benzisothiazol. This includes zole-5-yl, 2,1-benzisothiazol-6-yl, and 2,1-benzisothiazol-7-yl. As used herein, the term "benzotriazol" includes benzotriazol-1-yl, benzotriazol-4-yl, benzotriazol-5-yl, benzotriazol-6-yl, and benzotriazol-7-yl. As used herein, the term "1,2,3-benzoxadiazolyl" includes 1,2,3-benzoxadiazol-4-yl, 1,2,3-benzoxadiazol-5-yl, 1,2,3-benzoxadiazol-6-yl, and 1,2,3-benzoxadiazol-7-yl. As used herein, the term “2,1,3-benzoxadiazolyl” includes 2,1,3-benzoxadiazol-4-yl, 2,1,3-benzoxadiazol-5-yl, 2,1,3-benzoxadiazol-6-yl, and 2,1,3-benzoxadiazol-7-yl. As used herein, the term “1,2,3-benzothiadiazolyl” includes 1,2,3-benzothiadiazol-4-yl, 1,2,3-benzothiadiazol-5-yl, 1,2,3-benzothiadiazol-6-yl, and 1,2,3-benzothiadiazol-7-yl. As used herein, the term “2,1,3-benzothiadiazolyl” includes 2,1,3-benzothiadiazol-4-yl, 2,1,3-benzothiadiazol-5-yl, 2,1,3-benzothiadiazol-6-yl, and 2,1,3-benzothiadiazol-7-yl. As used herein, the term “thienopyridinyl” includes thieno[2,3-b]pyridinyl, thieno[2,3-c]pyridinyl, thieno[3,2-c]pyridinyl, and thieno[3,2-b]pyridinyl. As used herein, the term “prinyl” includes prin-2-yl, prin-6-yl, prin-7-yl, and prin-8-yl. As used herein, the term “imidazo[1,2-a]pyridinyl” includes imidazo[1,2-a]pyridin-2-yl, imidazo[1,2-a]pyridin-3-yl, imidazo[1,2-a]pyridin-4-yl, imidazo[1,2-a]pyridin-5-yl, imidazo[1,2-a]pyridin-6-yl, and imidazo[1,2-a]pyridin-7-yl.As used herein, the term "1,3-benzodioxolyl" includes 1,3-benzodioxol-4-yl, 1,3-benzodioxol-5-yl, 1,3-benzodioxol-6-yl, and 1,3-benzodioxol-7-yl. As used herein, the term "quinolinyl" includes quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl, and quinolin-8-yl. As used herein, the term "isoquinolinyl" includes isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl, and isoquinolin-8-yl. As used herein, the term "sinolinyl" includes sinolin-3-yl, sinolin-4-yl, sinolin-5-yl, sinolin-6-yl, sinolin-7-yl, and sinolin-8-yl. As used herein, the term "quinazolinyl" includes quinazolin-2-yl, quinazolin-4-yl, quinazolin-5-yl, quinazolin-6-yl, quinazolin-7-yl, and quinazolin-8-yl. As used herein, the term "quinoxalinyl" includes quinoxaline-2-yl, quinoxaline-5-yl, and quinoxaline-6-yl.

[0071] As used herein, heteroaryls and heterocyclics or heterocyclyls include, but are not limited to, the groups described in Paquette, Leo A. "Principles of Modern Heterocyclic Chemistry" (WABenjamin, New York, 1968), particularly chapters 1, 3, 4, 6, 7, and 9; "The Chemistry of Heterocyclic Compounds, A series of Monographs" (John Wiley & Sons, New York, 1950–present), particularly volumes 13, 14, 16, 19, and 28; Katritzky, Alan R., Rees, CW, and Scriven, E. "Comprehensive Heterocyclic Chemistry" (Pergamon Press, 1996); and J. Am. Chem. Soc. (1960) 82:5566.

[0072] The terms "heterocyclyloxy" or "heterocyclic alkoxy" as a group or part of a group are defined by the formula -OR i This refers to a group having R, in the formula i This is a heterocyclyl as defined above in this specification.

[0073] The terms "heterocyclylalkyloxy" or "heterocyclic alkoxy" as a group or part of a group are defined by the formula -OR a -R i This refers to a group having R, in the formula i R is a heterocyclyl as defined above in this specification, a It is an alkyl group.

[0074] The term "heteroaryloxy" as a group or part of a group is defined by the formula -OR k This refers to a group having R, in the formula k This is a heteroaryl compound as defined above in this specification.

[0075] The term "heteroarylalkyloxy" as a group or part of a group is defined by the formula -ORa -R i This refers to a group having R, in the formula i R is a heteroaryl as defined above in this specification, a It is an alkyl group.

[0076] The terms "heterocyclyl-alkyl" or "heterocyclic-alkyl" as a group or part of a group refer to an alkyl group in which one of the carbon atoms, typically a hydrogen atom bonded to a terminal or sp3 carbon atom, is substituted with a heterocyclyl group. A non-limiting example of a heterocyclyl-alkyl or heterocyclic-alkyl group is 2-piperidinyl methylene. A heterocyclyl-alkyl or heterocyclic-alkyl group can contain 6 to 20 atoms; for example, the alkyl group may have 1 to 6 carbon atoms and the heterocyclyl group may have 3 to 14 atoms.

[0077] The terms "heterocyclyl-alkenyl" or "heterocyclic-alkenyl," as a group or part of a group, refer to an alkenyl in which one of the hydrogen atoms bonded to a carbon atom is replaced by a heterocyclyl atom. A heterocyclyl-alkenyl or heterocyclic-alkenyl group can contain 6 to 20 atoms; for example, the alkenyl portion may have 2 to 6 carbon atoms and the heterocyclyl portion may have 3 to 14 atoms.

[0078] The terms "heterocyclyl-alkynyl" or "heterocyclic-alkynyl" as a group or part of a group refer to an alkynyl group in which one of the hydrogen atoms bonded to a carbon atom is replaced by a heterocyclyl atom. A heterocyclyl-alkynyl or heterocyclic-alkynyl group can contain 6 to 20 atoms; for example, the alkynyl portion can contain 2 to 6 carbon atoms, and the heterocyclyl portion can contain 3 to 14 atoms.

[0079] The terms "heterocyclyl-heteroalkyl" or "heterocyclic-heteroalkyl" as a group or part of a group refer to a heteroalkyl group in which one of the carbon atoms, typically a hydrogen atom bonded to a terminal or sp3 carbon atom, is substituted with a heterocyclyl. A heterocyclyl-heteroalkyl or heterocyclic-heteroalkyl group can contain 6 to 20 atoms; for example, the heteroalkyl portion can contain 1 to 6 carbon atoms, and the heterocyclyl portion can contain 3 to 14 atoms. In some embodiments, the heterocyclyl-heteroalkyl or heterocyclic-heteroalkyl group is selected from the group including heterocyclyl-O-alkyl, heterocyclylalkyl-O-alkyl, heterocyclyl-NH-alkyl, heterocyclyl-N(alkyl)2, heterocyclylalkyl-NH-alkyl, heterocyclylalkyl-N-(alkyl)2, heterocyclyl-S-alkyl, and heterocyclylalkyl-S-alkyl.

[0080] The terms "heterocyclyl-heteroalkenyl" or "heterocyclic-heteroalkenyl" as a group or part of a group refer to a heteroalkenyl in which one of the hydrogen atoms bonded to a carbon atom is substituted with a heterocyclyl. A heterocyclyl-heteroalkenyl or heterocyclic-heteroalkenyl group can contain 6 to 20 atoms; for example, the heteroalkenyl portion can contain 2 to 6 carbon atoms, and the heterocyclyl portion can contain 3 to 14 atoms. In some embodiments, the heterocyclyl-heteroalkenyl or heterocyclic-heteroalkenyl is selected from the group including heterocyclyl-O-alkenyl, heterocyclylalkyl-O-alkenyl, heterocyclyl-NH-alkenyl, heterocyclyl-N(alkenyl)2, heterocyclylalkyl-NH-alkenyl, heterocyclylalkyl-N-(alkenyl)2, heterocyclyl-S-alkenyl, and heterocyclylalkenyl-S-alkenyl.

[0081] The terms "heterocyclyl-heteroalkynyl" or "heterocyclic-heteroalkynyl" as a group or part of a group refer to a heteroalkynyl in which one of the hydrogen atoms bonded to a carbon atom is substituted with a heterocyclyl. A heterocyclyl-heteroalkynyl or heterocyclic-heteroalkynyl group can contain 6 to 20 atoms; for example, the heteroalkynyl portion can contain 2 to 6 carbon atoms, and the heterocyclyl portion can contain 3 to 14 atoms. In some embodiments, the heterocyclyl-heteroalkynyl is selected from the group including heterocyclyl-O-alkynyl, heterocyclylalkynyl-O-alkynyl, heterocyclyl-NH-alkynyl, heterocyclyl-N(alkynyl)2, heterocyclylalkynyl-NH-alkynyl, heterocyclylalkynyl-N-(alkynyl)2, heterocyclyl-S-alkynyl, and heterocyclylalkynyl-S-alkynyl.

[0082] The term "heteroarylalkyl" as a group or part of a group refers to an alkyl group in which one of the carbon atoms, typically a hydrogen atom bonded to a terminal or sp3 carbon atom, is substituted with a heteroaryl group. An example of a heteroarylalkyl group is 2-pyridylmethylene. A heteroarylalkyl group can contain 6 to 20 atoms; for example, the alkyl portion of a heteroarylalkyl group can contain 1 to 6 carbon atoms, and the heteroaryl portion can contain 5 to 14 atoms.

[0083] The term "heteroaryl-alkenyl" as a group or part of a group refers to an alkenyl in which one of the hydrogen atoms bonded to a carbon atom is substituted with a heteroaryl group. A heteroaryl-alkenyl group can contain 6 to 20 atoms; for example, the alkenyl portion of a heteroaryl-alkenyl group can contain 2 to 6 carbon atoms, and the heteroaryl portion can contain 5 to 14 atoms.

[0084] As used herein, the term "heteroaryl-alkynyl" as a group or part of a group refers to an alkynyl in which one of the hydrogen atoms bonded to a carbon atom is substituted with a heteroaryl group. A heteroaryl-alkynyl group contains 6 to 20 carbon atoms; for example, the alkynyl portion of a heteroaryl-alkynyl group contains 2 to 6 carbon atoms, and the heteroaryl portion contains 5 to 14 atoms.

[0085] As used herein, the term “heteroaryl-heteroalkyl” as a group or part of a group refers to a heteroalkyl group in which one of the carbon atoms, typically a hydrogen atom bonded to a terminal or sp3 carbon atom, is substituted with a heteroaryl group. A heteroaryl-heteroalkyl group contains 7 to 20 atoms; for example, the heteroalkyl portion of a heteroaryl-heteroalkyl group has 2 to 6 carbon atoms, and the heteroaryl portion has 5 to 14 atoms. In some embodiments, the heteroaryl-heteroalkyl group is selected from the group including heteroaryl-O-alkyl, heteroarylalkyl-O-alkyl, heteroaryl-NH-alkyl, heteroaryl-N(alkyl)2, heteroarylalkyl-NH-alkyl, heteroarylalkyl-N-(alkyl)2, heteroaryl-S-alkyl, and heteroarylalkyl-S-alkyl.

[0086] As used herein, the term “heteroaryl-heteroalkenyl” as a group or part of a group refers to a heteroalkenyl in which one of the hydrogen atoms bonded to a carbon atom is substituted with a heteroaryl group. A heteroaryl-heteroalkenyl group contains 8 to 20 atoms, for example, the heteroalkenyl portion of a heteroaryl-heteroalkenyl group contains 3 to 6 carbon atoms, and the heteroaryl portion contains 5 to 14 atoms. In some embodiments, the heteroaryl-heteroalkenyl is selected from the group including heteroaryl-O-alkenyl, heteroarylalkenyl-O-alkenyl, heteroaryl-NH-alkenyl, heteroaryl-N(alkenyl)2, heteroarylalkenyl-NH-alkenyl, heteroarylalkenyl-N-(alkenyl)2, heteroaryl-S-alkenyl, and heteroarylalkenyl-S-alkenyl.

[0087] As used herein, the term “heteroaryl-heteroalkynyl” as a group or part of a group refers to a heteroalkynyl in which one of the hydrogen atoms bonded to a carbon atom is substituted with a heteroaryl group. A heteroaryl-heteroalkynyl group contains 8 to 20 atoms, for example, the heteroalkynyl portion of a heteroaryl-heteroalkynyl group contains 2 to 6 carbon atoms, and the heteroaryl portion contains 5 to 14 atoms. In some embodiments, the heteroaryl-heteroalkynyl is selected from the group including heteroaryl-O-alkynyl, heteroarylalkynyl-O-alkynyl, heteroaryl-NH-alkynyl, heteroaryl-N(alkynyl)2, heteroarylalkynyl-NH-alkynyl, heteroarylalkynyl-N-(alkynyl)2, heteroaryl-S-alkynyl, and heteroarylalkynyl-S-alkynyl.

[0088] For example, carbon-bonded heteroaryl or heterocyclic (or heterocyclic) compounds can be attached at positions 2, 3, 4, 5, or 6 of pyridine, at positions 3, 4, 5, or 6 of pyridazine, at positions 2, 4, 5, or 6 of pyrimidine, at positions 2, 3, 5, or 6 of pyrazine, at positions 2, 3, 5, or 5 of furan, tetrahydrofuran, thiophene, pyrrole, or tetrahydropyrrole, at positions 2, 3, 4, or 5 of oxazole, imidazole, or thiazole, at positions 3, 4, or 5 of isoxazole, pyrazole, or isothiazole, at position 2 or 3 of aziridine, at positions 2, 3, or 4 of azetidine, at positions 2, 3, 4, 5, 6, 7, or 8 of quinoline, or at positions 1, 3, 4, 5, 6, 7, or 8 of isoquinoline. More typically, carbon-bonded heteroaryls and heterocyclyls include 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, 6-pyridyl, 3-pyridazinyl, 4-pyridazinyl, 5-pyridazinyl, 6-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 6-pyrimidinyl, 2-pyrazinyl, 3-pyrazinyl, 5-pyrazinyl, 6-pyrazinyl, 2-thiazolyl, 4-thiazolyl, or 5-thiazolyl. For example, nitrogen-bonded heterocycles are bonded at position 1 of aziridine, azetidine, pyrrole, pyrrolidine, 2-pyrroline, 3-pyrroline, imidazole, imidazolidine, 2-imidazoline, 3-imidazoline, pyrazole, pyrazoline, 2-pyrazoline, 3-pyrazoline, piperidine, piperazine, indole, indoline, and 1H-indazole, at position 2 of isoindole or isoindoline, at position 4 of morpholine, and at position 9 of carbazole or β-carbolin. More typically, nitrogen-bonded heteroaryl or heterocyclils include 1-aziridyl, 1-azetezyl, 1-pyrrolyl, 1-imidazolyl, 1-pyrazolyl, and 1-piperidinyl.

[0089] As used herein, and unless otherwise specified, the terms “alkoxy,” “cycloalkoxy,” “aryloxy,” “arylalkyloxy,” “heteroaryloxy,” “heterocyclyloxy,” “alkylthio,” “cycloalkylthio,” “arylthio,” “arylalkylthio,” “heteroarylthio,” and “heterocyclylthio” refer to substituents of an alkyl group, cycloalkyl, aryl, arylalkylheteroaryl, or heterocyclyl (as defined herein), that are bonded to an oxygen or sulfur atom via a single bond, such as, but not limited to, methoxy, ethoxy, propoxy, butoxy, thioethyl, thiomethyl, phenyloxy, benzyloxy, and mercaptobenzyl. The same definitions apply to alkenyls and alkynyls instead of alkyls.

[0090] The term "alkylthio" as a group or part of a group is defined by formula -SR b This refers to a group having R, in the formula b This refers to alkyl groups as defined above in this specification. Non-limiting examples of alkylthio groups include methylthio (-SCH3), ethylthio (-SCH2CH3), n-propylthio, isopropylthio, n-butylthio, isobutylthio, sec-butylthio, and tert-butylthio.

[0091] The term "alkenylthio" as a group or part of a group is defined by formula -SR d This refers to a group having R, in the formula d This is an alkenil as defined above in this specification.

[0092] The term "alkynylthio" as a group or part of a group is defined by formula -SR e This refers to a group having R, in the formula e This is an alkynyl as defined above in this specification.

[0093] The term "arylthio" as a group or part of a group is defined by formula -SR g This refers to a group having R, in the formulag This is an aryl as defined above in this specification.

[0094] The term "arylalkylthio" as a group or part of a group is defined by formula -SR a -R g This refers to a group having R, in the formula a R is an alkylene as defined above in this specification, g That is Ariel.

[0095] The term "heterocyclilthio" as a group or part of a group is defined by formula -SR i This refers to a group having R, in the formula i This is a heterocyclyl as defined above in this specification.

[0096] The term "heteroarylthio" as a group or part of a group is defined by formula -SR k This refers to a group having R, in the formula k This is a heteroaryl compound as defined above in this specification.

[0097] The term "heterocyclylalkylthio" as a group or part of a group is defined by formula -SR a -R i This refers to a group having R, in the formula a R is an alkylene as defined above in this specification, i It is a heterocycline.

[0098] The term "heteroarylalkylthio" as a group or part of a group is defined by formula -SR a -R k This refers to a group having R, in the formula a R is an alkylene as defined above in this specification, k It is a heteroaryl compound.

[0099] The term "mono- or di-alkylamino" as a group or part of a group is defined by the formula -N(R o )(R b ) refers to the base, and in the formula, R ois hydrogen or alkyl, and R b It is alkyl. Therefore, examples of alkylaminos include mono-alkylamino groups (for example, mono-alkylamino groups such as methylamino and ethylamino) and di-alkylamino groups (for example, di-alkylamino groups such as dimethylamino and diethylamino). Non-limiting examples of preferred mono- or di-alkylamino groups include n-propylamino, isopropylamino, n-butylamino, i-butylamino, sec-butylamino, t-butylamino, pentylamino, n-hexylamino, di-n-propylamino, di-i-propylamino, ethylmethylamino, methyl-n-propylamino, methyl-i-propylamino, n-butylmethylamino, i-butylmethylamino, t-butylmethylamino, ethyl-n-propylamino, ethyl-i-propylamino, n-butylethylamino, i-butylethylamino, t-butylethylamino, di-n-butylamino, di-i-butylamino, methylpentylamino, methylhexylamino, ethylpentylamino, ethylhexylamino, propylpentylamino, and propylhexylamino.

[0100] The term "mono- or di-arylamino" as a group or part of a group is defined by the formula -N(R q )(R r ) refers to the base, and in the formula, R q and R r R is independently selected from hydrogen, aryl, or alkyl, q or R r At least one of them is an arrow.

[0101] The term "mono- or di-heteroarylamino" as a group or part of a group is defined by the formula -N(R u )(R v ) refers to the base, and in the formula, R u and R v R is independently selected from hydrogen, heteroaryl, or alkyl, u or R v At least one of them is a heteroaryl as defined herein.

[0102] The term “mono- or di-heterocyclylamino” as a group or part of a group is defined by the formula -N(R w )(R x ) refers to the base, and in the formula, R w and R x R is independently selected from hydrogen, heterocyclyl, or alkyl, w or R x At least one of them is a heterocyclyl as defined herein.

[0103] As used herein, and unless otherwise specified, the term halogen means any atom selected from the group consisting of fluorine (F), chlorine (Cl), bromine (Br), and iodine (I).

[0104] As used herein, the term "optionally comprising one or more heteroatoms, wherein the heteroatoms are selected from atoms consisting of O, S, and N" refers to groups in which one or more carbon atoms are substituted with oxygen, nitrogen, or sulfur atoms, and therefore, depending on the group referred to, in particular, heteroalkyl, heteroalkenyl, heteroalkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, cycloheteroalkyl, cycloheteroalkenyl, cycloheteroalkynyl, heteroaryl, arylheteroalkyl, heteroarylalkyl, heteroarylheteroalkyl, arylheteroalkenyl, heteroarylalkenyl, heteroarylheteroalkenyl, arylheteroalkynyl, heteroarylalkynyl, and heteroarylheteroalkynyl groups. Therefore, depending on the group mentioned, this term includes, as an example, alkoxy, alkenyloxy, alkynyloxy, alkyl-O-alkylene, alkenyl-O-alkylene, arylalkoxy, benzyloxy, heteroaryl-heteroalkyl, heterocyclyl-heteroalkyl, heteroaryl-alkoxy, and heterocyclyl-alkoxy. Therefore, as an example, the term "alkyl comprising one or more heteroatoms of any choice, wherein the heteroatoms are selected from atoms consisting of O, S, and N" refers to a heteroalkyl, meaning an alkyl group that contains one or more heteroatoms in a hydrocarbon chain, where the heteroatoms may be located at the beginning, within, or at the end of the hydrocarbon chain. Examples of heteroalkyls include, among many other examples, methoxy, methylthio, ethoxy, propoxy, CH3-O-CH2-, CH3-S-CH2-, CH3-CH2-O-CH2-, CH3-NH-, (CH3)2-N-, and (CH3)2-CH2-NH-CH2-CH2-. Therefore, as an example, the term "arylalkylene optionally containing one or more heteroatoms in the alkylene chain, wherein the heteroatoms are selected from atoms consisting of O, S, and N" refers to an arylheteroalkylene, meaning an arylalkylene containing one or more heteroatoms in the hydrocarbon chain, while the heteroatoms may be located at the beginning, within, or at the end of the hydrocarbon chain.Therefore, examples of “aryl heteroalkylenes” include aryloxy, arylalkoxy, and aryl-alkyl-NH-, among many other examples, particularly phenyloxy, benzyloxy, aryl-CH2-S-CH2-, aryl-CH2-O-CH2-, and aryl-NH-CH2-. The same applies to “heteroalkenylene,” “heteroalkylynylene,” and other terms used herein when referred to as “containing one or more heteroatoms of any choice, wherein the heteroatoms are selected from atoms consisting of O, S, and N.”

[0105] As used herein, the term relating to a chemical group in which "two or more hydrogen atoms in contact with the carbon or heteroatom of the group can be used together to form =O or =S" refers to a group in which two or more hydrogen atoms in contact with the carbon or heteroatom of the group can be used together to form =O or =S. For example, the term refers to an alkyl group in which two or more hydrogen atoms in contact with the carbon or heteroatom of the alkyl can be used together to form =O or =S, among other examples, CH3-C(O)-CH2-, CH3-C(O)-, CH3-C(S)-CH2-, CH3-S(O)2-CH2-, and (CH3)2-CH2-C(O)-CH2-CH2-.

[0106] A combination of groups that "optionally comprises one or more heteroatoms, the heteroatoms being selected from atoms consisting of O, S, and N" and "optionally allows two or more hydrogen atoms in contact with the carbon or heteroatom of the group to be used together to form =O or =S" can be combined in the two embodiments described above herein, and when the group is referred to as alkyl, other examples include, among others, CH3-C(O)O-, CH3-C(O)O-CH2-, CH3-NH-C(O)-, CH3-C(O)-NH-, CH3-NH-C(O)-CH2-, CH3-NH-C(S)-CH2-, CH3-NH-C(S)-NH-CH2-, CH3-NH-S(O)2-, and CH3-NH-S(O)2-NH-CH2-.

[0107] As used herein with respect to linking groups, the term "single bond" refers to a molecule in which no linking group exists, and therefore refers to a compound in which two sites that would be linked by a linking group are directly linked via a single bond.

[0108] As used herein with respect to substituents, and unless otherwise specified, the term "substituted" in "substituted alkyl," "substituted alkenyl," "substituted alkynyl," "substituted aryl," "substituted heteroaryl," "substituted heterocyclyl," "substituted arylalkyl," "substituted heteroaryl-alkyl," and "substituted heterocyclyl-alkyl" refers to the chemical structure as defined herein, where the alkyl, alkenyl, alkynyl, group and / or the aryl, heteroaryl, or heterocyclyl may be substituted with one or more substituents (preferably 1, 2, 3, 4, 5, or 6), meaning that one or more hydrogen atoms are independently substituted with at least one substituent. Typical substituents, though not limited to, include halogens, aminos, hydroxyls, sulfhydryls, alkyls, alkoxys, alkenyls, alkenyloxys, alkynyls, alkynyloxys, cycloalkyls, cycloalkenyls, cycloalkynyls, heteroalkyls, heteroalkenyls, heteroalkynyls, aryls, heteroaryls, heterocyclyls, arylalkyls, arylalkenyls, arylalkynyls, cycloalkyl-alkyls, cycloalkylalkenyls, cycloalkylalkynyls, heteroaryl-alkyls, heterocyclyl-alkyls, heteroaryl-alkenyls, heterocyclyl-alkenyls, and heteroarylalkynyls, heterocyclylalkynyls, -X, -Z, -O - -OZ, =O, -SZ, -S - ,=S,-NZ2,-N + Z3, =NZ, =N-OZ, -CX3 (e.g., trifluoromethyl), -CN, -OCN, -SCN, -N=C=O, -N=C=S, -NO, -NO2, =N2, -N3, -NZC(O)Z, -NZC(S)Z, -NZC(O)O - , -NZC(O)OZ, -NZC(S)OZ, -NZC(O)NZZ, NZC(NZ)Z, NZC(NZ)NZZ, -C(O)NZZ, -C(NZ)Z, -S(O)2O - , -S(O)2OZ, -S(O)2Z, -OS(O)2OZ, -OS(O)2Z, -OS(O)2O -, -S(O)2NZZ, -S(O)(NZ)Z, -S(O)Z, -OP(O)(OZ)2, -P(O)(OZ)2, -P(O)(O - )2, -P(O)(OZ)(O - ), -P(O)(OH)2, -C(O)Z, -C(O)X, -C(S)Z, -C(O)OZ, -C(O)O - , -C(S)OZ, -C(O)SZ, -C(S)SZ, -C(O)NZZ, -C(S)NZZ, -C(NZ)NZZ, -OC(O)Z, -OC(S)Z, -OC(O)O - Examples include -OC(O)OZ and -OC(S)OZ, and in certain embodiments, the substituents are independently selected from the group consisting of those listed above, where each X is independently a halogen selected from F, Cl, Br, or I, and each Z is independently -H, alkyl, alkenyl, alkynyl, heteroalkyl, heteroalkenyl, heteroalkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, protecting group, or prodrug moiety, where two Zs bonded to a nitrogen atom are available together with a nitrogen atom to which they are bonded to form a heteroaryl or heterocyclyl. Alkyl (alkylene), alkenyl (alkenylene), and alkynyl (alkynylene) groups can also be substituted in a similar manner.

[0109] The notation for any substituents found at two or more sites of the compounds of this disclosure shall be independently selected.

[0110] Substituents are designed with or without bonding, at their discretion. Regardless of the indication of bonding, if the substituent is polyvalent (based on its position in the structure mentioned), any and all possible arrangements of the substituent are intended.

[0111] As used herein, and unless otherwise specified, the term “solvate” includes any combination that may be formed by a derivative of the present disclosure with a suitable inorganic solvent (e.g., hydrate) or an organic solvent (e.g., alcohols, ketones, esters, ethers, nitriles, etc.).

[0112] As used herein, the term “heteroatom” means an atom selected from quaternizable nitrogen; oxygen; and sulfur, including sulfoxides and sulfones.

[0113] As used herein, the term "hydroxy" means -OH.

[0114] As used herein, the term "carbonyl" refers to a carbon atom bonded to oxygen by a double bond, i.e., C=O.

[0115] As used herein, the term "amino" refers to the -NH2 group.

[0116] This disclosure provides novel compounds that have been shown to possess YAP / TAZ-TEAD transcription inhibitory activity. Furthermore, this disclosure demonstrates that these compounds efficiently inhibit TEAD activation, thereby inhibiting the activation of YAP / TAZ-TEAD transcription. Thus, these compounds constitute a useful class of novel potent compounds that can be used for the treatment and / or prevention of YAP / TAZ-TEAD activation-mediated diseases in subjects, more specifically for the treatment and / or prevention of other diseases, particularly cancer and fibrosis.

[0117] Furthermore, this disclosure relates to compounds for use as pharmaceuticals and their use in the manufacture of drugs for the treatment and / or prevention of cancer or fibrosis. This disclosure relates to compounds for use as pharmaceuticals for the treatment and / or prevention of YAP / TAZ-TEAD activation-mediated diseases such as cancer or fibrosis in animals, mammals, and more specifically in humans. This disclosure also relates to methods for the preparation of all such compounds and pharmaceutical compositions containing them in effective amounts. This disclosure also relates to methods for the treatment or prevention of cancer or fibrosis in humans by administering one or more such compounds, optionally combined with one or more other pharmaceuticals, to patients in need. This disclosure also relates to compounds for veterinary use as pharmaceuticals for the prevention or treatment of diseases in non-human mammals, such as cancer and fibrosis in non-human mammals, and their use.

[0118] In one embodiment, the present disclosure relates to a compound of formula I: [ka] Or provide stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, in the formula, Z is selected from -O-, -N-, -S-, -S(O)-, or -S(O)2-. However, if Z is -O-, -S-, -S(O)-, or -S(O)2-, R 3 It does not exist; X 1 and X 2 Is it independently selected from the following group: (i) Hydrogen, (ii) Halogen, (iii) Hydroxyl, (iv) Cyano, (v) C1-C6 alkyl groups, (vi) C1-C6 haloalkyl, (vii) C2-C6 alkenyls, and (viii) Carbonyl, or X 1 and X 2Together with the carbon atoms to which they are bonded, they form the following: (i) Unsubstituted or substituted C3-C6 cycloalkyls, where zero or more cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), (ii) Unsubstituted or substituted 3-6 membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), (iii) C6~C non-substituted or substituted 10 Aryl, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), or (iv) Unsubstituted or substituted 5- to 9-membered heteroaryl compounds, where zero or more heterocyclic carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), However, these are subject to the following conditions: (i) X 1 and X 2 When these come together to form an aryl or heteroaryl, [ka] represents a double bond, and (ii) X 1 and X 2 If that is not the case (i.e., X 1 and X 2 (If they do not form an aryl or heteroaryl group together), [ka] represents a single bond; R 1 The group is selected from the following: (i) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: (a) Non-substituted or substituted C6~C 10 Aryl, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) C1-C6 alkyl, (4) C3-C6 cycloalkyl, (5) C1-C6 haloalkyl, (6) -OZ 1 , (7) C2-C6 alkenyls, and (8) C2-C6 alkynyl, (b) Unsubstituted or substituted C3-C6 cycloalkyls, where zero or more cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) C1-C6 alkyl, (4) C3-C6 cycloalkyl, (5) C1-C6 haloalkyls, (6) -OZ 1 , (c) C2-C6 alkinyls, and (d) Unsubstituted or substituted 3-6 membered heterorings, where zero or more of the heterocyclic carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, cyanos, C2-C8 alkenyls, and C1-C6 alkyls. (ii) Non-substitutive or substituted C6~C 10 Aryl, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) C1-C6 alkyl groups, (d) C3-C6 cycloalkyl, (e) C1-C6 haloalkyl, (f) -OZ 1 , and (g) Unsubstituted or substituted C6~C 10 Aryl, where one or more substituents are halogens, C1-C6 alkyls, C1-C6 haloalkyls, and -OZ 1 Independently selected from the group consisting of, (iii) Unsubstituted or substituted 5- to 9-membered heteroaryl compounds, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) C1-C6 alkyl groups, (d) C3-C6 cycloalkyl, (e) C1-C6 haloalkyl, (f) -OZ 1 , and (g) Unsubstituted or substituted C6~C 10 Aryl, where one or more substituents are halogens, C1-C6 alkyls, C1-C6 haloalkyls, and -OZ 1 Independently selected from the group consisting of, (iv) Unsubstituted or substituted C3-C6 cycloalkyls, where zero or more cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) C1-C6 alkyl groups, (d) C3-C6 cycloalkyl, (e) C1-C6 haloalkyls, and (f) -OZ 1 , (v) Unsubstituted or substituted 3-6 membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) C1-C6 alkyl groups, (d) C3-C6 cycloalkyl, (e) C1-C6 haloalkyls, and (f) -OZ 1 , (vi) -S(=O)2Z 2 , and (vii) -C(=O)Z 2 ; R 2 and R 3 Is it independently selected from the following group: (i) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C1-C6 alkyl groups, c. -S(=O)2Z 5 , d. C3-C8 cycloalkyl, e. -C(=O)OH, f. -C(=O)Z 1 , g. -NZ 3 Z 4 , h. Halogen, i. Hydroxyl, j. Unsubstituted or substituted 3-8 membered heterorings, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more of the heterocyclic carbons can be oxidized to form C=O. k. Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more heteroaryl carbons can be oxidized to form C=O, and l. Non-substitutive or substituted C6~C 10 An aryl, where zero or more aryl carbons can be oxidized to form a C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 haloalkyls, and cyanos. (ii) Unsubstituted or substituted 3-6 membered heteroaryls, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. C1-C6 alkyl groups, d. C3-C6 cycloalkyl, e. C1-C6 haloalkyl, f. -OZ 1 , and g. -C(=O)Z 1 , (iii) an unsubstituted or substituted 3-6 membered heteroring, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. C1-C6 alkyl groups, d. C3-C6 cycloalkyl, e. C1-C6 haloalkyl, f. -OZ 1 , and g. -C(=O)Z 1 , (iv) Hydrogen, (v) -C(=O)Z 1 , and (vi) -S(=O)2Z 5 ,or, R 2 and R 3 They are bonded together with the carbon and nitrogen atoms, respectively, to form the following: (i) Unsubstituted or substituted 3-6 membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are independently selected from the group consisting of: (1) Cyano, (2) C3-C8 cycloalkyl, (3) -C(=O)OH, (4) -S(=O)2Z 1 , (5) -NZ 3 Z 4 , (6) Halogens, and (7) Unsubstituted or substituted C3-C6 aryls, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. Hydroxy, d. C1-C6 alkyl groups, e. C3-C6 cycloalkyl, f. C1-C6 haloalkyl, g. -OZ 1 , h. -C(=O)Z 1 , and i. S(=O)2Z 5 , (d) C3-C6 cycloalkyl, (e) C1-C6 haloalkyl, (f) -OZ 1 , (g) -C(=O)Z 1 , (h) -S(=O)2Z 1 , (i) Unsubstituted or substituted C3-C6 aryls, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) Hydroxy, (4) C1-C6 alkyl, (5) C3-C6 cycloalkyl, (6) C1-C6 haloalkyl, (7) -OZ 1 , (8) -C(=O)Z 1 , and (9) S(=O)2Z 5 , and (j) Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) C1-C6 alkyl, (4) C3-C6 cycloalkyl, (5) C1-C6 haloalkyl, (6) -OZ 1 , (7) -C(=O)Z 1 , and (8) S(=O)2Z 5 ; each Z 1 It is independently selected from the following group: (i) Hydrogen, (ii) Hydroxyl, (iii) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C1-C6 alkyl groups, c. -S(=O)2Z 5 , d. C3-C8 cycloalkyl, e. -C(=O)OH, f. -NZ 3 Z 4 , g. Halogen, h. Unsubstituted or substituted 3-8 membered heterorings, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more of the heterocyclic carbons can be oxidized to form C=O. i. Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more heteroaryl carbons can be oxidized to form C=O, and j. Non-substitutive or substituted C6~C 10 An aryl, where zero or more aryl carbons can be oxidized to form a C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 haloalkyls, and cyanos. (iv) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. -S(=O)2Z 5 , c. Halogens, and d. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: i. Cyano, ii. -S(=O)2Z 5 , iii. C3-C8 cycloalkyl, iv. -C(=O)OH, v. -NZ 3 Z 4 , vi. Halogen, vii. Unsubstituted or substituted 3-8 membered heterorings, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more of the heterocyclic carbons can be oxidized to form C=O. viii. Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more heteroaryl carbons can be oxidized to form C=O, and ix. Non-substitutive or substituted C6~C 10 Aryl, where one or more substituents are halogen, C1-C6 haloalkyl, cyano, -S(=O)2Z 5, -NZ 3 Z 4 , and an unsubstituted or substituted 3- to 8-membered heterocycle (where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls), wherein zero or more aryl carbons can be oxidized to form C=O, (v) C2-C6 alkynyl, (vi) C3-C6 cycloalkyl, (vii) C3-C6 cycloalkenyl, (viii) C1-C6 haloalkyl, (ix) -OZ 2 , (x) -C(=O)Z 2 , (xi) -NHZ 2 , (xii) Unsubstituted or substituted C3-C8 cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 5 , -NZ 3 Z 4 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiii) C6~C of non-substitutive or substituted types 10 Aryl, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 5 , -NZ 3 Z 4 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiv) Unsubstituted or substituted 3- to 8-membered heteroaryls, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and (xv) Unsubstituted or substituted 3- to 8-membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls; each Z 2 It is independently selected from the following group: (i) C1-C6 alkyl groups, (ii) -NHZ 3 , (iii) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are cyano, -S(=O)2Z 5 , halogens, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 5 , -NZ 3 Z 4 (and independently selected from the group consisting of 4- to 8-membered heterocycles), (iv) C2-C6 alkinyl, (v) C3-C6 cycloalkyl, (vi) C3-C6 cycloalkenyl, (vii) C1-C6 haloalkyls, and (viii) Hydrogen; each Z 3 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are C2-C6 alkenyl, cyano, -C(=O)OH, or -S(=O)2Z. 5 Halogen, -NZ 3 Z 4 and independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iii) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are cyano, -S(=O)2Z 5 , halogens, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 5 , -NZ 6 Z 4 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) -C(=O)Z 7 , (v) C2-C6 alkynyl, (vi) C3-C6 cycloalkyl, (vii) C3-C6 cycloalkenyls, and (viii) C1-C6 haloalkyl; each Z 4 It is independently selected from the following group: (i) Hydrogen, (ii) C1-C6 alkyl, and (iii) C3-C6 cycloalkyl; each Z 5 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are independently selected from the group consisting of halogens, cyanos, and C1-C6 alkyls. (iii) Unsubstituted or substituted C2-C6 alkenyl, where one or more substituents are halogens, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are -NZ 6 Z 4 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) Halogens, and (v) hydroxy; each Z 6 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are C2-C6 alkenyl, cyano, -C(=O)OH, -S(=O)2H, -S(=O)2 (unsubstituted or substituted C1-C6 alkyl), -S(=O)2 (unsubstituted or substituted C2-C6 alkenyl), -S(=O)2 (halogen), -S(=O)2OH, -NHZ 8 -N (unsubstituted or substituted C1-C6 alkyl)Z 8 , -N (unsubstituted or substituted C2-C6 alkenyl) Z 8 , -N(-C(=O)Z 7 )Z 8 -N(C2~C6 alkynyl)Z 8 , -N(C3~C6 cycloalkyl)Z 4 ,-N(C3~C6 cycloalkenyl)Z 8 -N(C1~C6 haloalkyl)Z 8 and independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iii) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are cyano, -S(=O)2H, -S(=O)2 (unsubstituted or substituted C1-C6 alkyl), -S(=O)2 (unsubstituted or substituted C2-C6 alkenyl), -S(=O)2 (halogen), -S(=O)2OH, halogen, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 9 , -NHZ 8 -N (unsubstituted or substituted C1-C6 alkyl)Z 8 , -N (unsubstituted or substituted C2-C6 alkenyl) Z 8 , -N(-C(=O)Z 7 )Z 8 -N(C2~C6 alkynyl)Z 8 , -N(C3~C6 cycloalkyl)Z 8 ,-N(C3~C6 cycloalkenyl)Z 8 -N(C1~C6 haloalkyl)Z 8, and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) -C(=O)Z 7 , (v) C2-C6 alkynyl, (vi) C3-C6 cycloalkyl, (vii) C3-C6 cycloalkenyls, and (viii) C1-C6 haloalkyl; and each Z 7 It is independently selected from the following group: (i) Hydrogen, (ii) Hydroxyl, (iii) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C1-C6 alkyl groups, c. -S(=O)2Z 9 , d. C3-C8 cycloalkyl, e. -C(=O)OH, f. -NHZ 8 , g. -N(unsubstituted or substituted C1-C6 alkyl)Z 8 , h. -N (unsubstituted or substituted C2-C6 alkenyl) Z 8 , i. -N(-C(=O) unsubstituted or substituted C3-C6 cycloalkyl)Z 8 , j. -N(-C(=O) unsubstituted or substituted C3~C6 cycloalkenyl)Z 8 , k. -N(-C(=O) unsubstituted or substituted C1-C6 haloalkyl)Z 8 , l. -N(C2~C6 alkynyl)Z 8 , m. -N(C3~C6 cycloalkyl)Z 8 , n. -N(C3~C6 cycloalkenyl)Z8 , o. -N(C1~C6 haloalkyl)Z 8 , p. Halogen, q. An unsubstituted or substituted 3- to 8-membered heteroring, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more of the heteroring carbons can be oxidized to form C=O. r. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more heteroaryl carbons can be oxidized to form C=O, and s. Non-substitutive or substituted C6~C 10 An aryl, where zero or more aryl carbons can be oxidized to form a C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 haloalkyls, and cyanos. (iv) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. -S(=O)2Z 9 , c. Halogens, and (v) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: i. Cyano, ii. -S(=O)2Z 9 , iii. C3-C8 cycloalkyl, iv. -C(=O)OH, (vi) -NHZ 8 , (vii) -N(unsubstituted or substituted C1-C6 alkyl)Z 8 , (viii) -N(unsubstituted or substituted C2-C6 alkenyl)Z 8 , (ix) -N(unsubstituted or substituted C2-C6 alkynyl)Z 8 , (x) -N(unsubstituted or substituted C3-C6 cycloalkyl)Z 8 , (xi) -N(unsubstituted or substituted C3-C6 cycloalkenyl)Z 8 , (xii) -N(C1~C6 Haloalkyl)Z 8 , (xiii) Halogen, (xiv) Unsubstituted or substituted 3- to 8-membered heterorings, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 acetyls and C2-C6 alkenyls, and zero or more of the heteroring carbons can be oxidized to form C=O. (xv) Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more heteroaryl carbons can be oxidized to form C=O, and (xvi) C6~C of non-substitution or substitution 10 Aryl, where one or more substituents are halogen, C1-C6 haloalkyl, cyano, -S(=O)2Z 9 , -NZ 6 Z 8 , and an unsubstituted or substituted 3- to 8-membered heterocycle (where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls), wherein zero or more aryl carbons can be oxidized to form C=O, (xxviii) C2~C6 alkinyl, (xxix) C3-C6 cycloalkyl, (xxx) C3-C6 cycloalkenyl, (xxxi) C1-C6 haloalkyl, (xxxii) -OZ 10 , (xxxiii) -C(=O)Z 10 , (xxxiv) -NHZ 10 , (xxxv) Unsubstituted or substituted C3-C8 cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 9 , -NZ 6 Z 8 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xxxvi) C6~C non-substitutive or substituted 10 Aryl, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 9 , -NZ 6 Z 8 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xxxvii) Unsubstituted or substituted 3-8 membered heteroaryls, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls. (xxxviii) Unsubstituted or substituted 3- to 8-membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls; and each Z 8 It is independently selected from the following group: (i) Hydrogen, (ii) C1-C6 alkyl, and (iii) C3-C6 cycloalkyl; each Z 9 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are independently selected from the group consisting of halogens, cyanos, and C1-C6 alkyls. (iii) Unsubstituted or substituted C2-C6 alkenyl, where one or more substituents are halogens, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are -NZ 6 Z 4 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) Halogens, and (v) hydroxy; and each Z 10 It is independently selected from the following group: (i) C1-C6 alkyl groups, (ii) -NH2, (iii) -NH(C1~C6 alkyl), (iv) -N(C1~C6 alkyl)2, (v) Unsubstituted or substituted C2-C6 alkenyl, where one or more substituents are cyano, -S(=O)2Z 5 , halogens, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 9 , -NZ 6 Z 8 (and independently selected from the group consisting of 4- to 8-membered heterocycles), (vi) C2~C6 alkinyl, (vii) C3-C6 cycloalkyl, (viii) C3-C6 cycloalkenyl, (ix) C1-C6 haloalkyls, and (x) Hydrogen.

[0119] In one embodiment, the disclosure provides a compound of formula I, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z is selected from -O- or -N-, including, if Z is -O-, R3 This is accompanied by the condition that it does not exist.

[0120] In one embodiment, the present disclosure provides a compound of formula I, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z is selected from -O, -N-, or -S(O)2-, including, if Z is -O- or -S(O)2-, R 3 This is accompanied by the condition that it does not exist.

[0121] In one embodiment, the present disclosure provides a compound of formula I, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z is selected from -S(O)2-, including, if Z is -S(O)2-, R 3 This is accompanied by the condition that it does not exist.

[0122] In another embodiment, the present disclosure relates to a compound of formula II: [ka] Or provide stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, in the formula, Z' and Z'' are selected independently of -CH= or -N=; and Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 , Z 8 , Z 9 , Z 10 , Z, R 1 , R 2 , and R 3 This is as defined in relation to formula I. In another embodiment, the disclosure provides a compound of formula II, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z' and Z'' are -CH=. In another embodiment, the disclosure provides a compound of formula II, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z' is -N= and Z'' is -CH=.

[0123] In another embodiment, the present disclosure provides a compound of formula II, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z' and Z'' are -N=.

[0124] In another embodiment, the present disclosure provides a compound of formula II, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z is -O-.

[0125] In another embodiment, the present disclosure provides a compound of formula II, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z is -N-.

[0126] In another embodiment, the present disclosure relates to a compound of formula III: [ka] Or provide stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, in the formula, R' is selected from the following group: i. Hydrogen, ii. Halogen, iii. Cyano, iv. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a) Cyano, b) C3-C8 cycloalkyl, c) -C(=O)OH, d) -S(=O)2Z 1 , e) -NZ 3 Z 4 , f) Halogens, and g) Unsubstituted or substituted C3-C6 aryls, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: 1. Halogen, 2. Cyano, 3. Hydroxyl, 4. C1-C6 alkyl groups, 5. C3-C6 cycloalkyl, 6. C1-C6 haloalkyl, 7. -OZ 1 , 8. -C(=O)Z 1 , and 9. S(=O)2Z 5 , v. C3-C6 cycloalkyl, vi. C1-C6 haloalkyl groups, vii. -OZ 1 , viii. -C(=O)Z 1 , ix. -S(=O)2Z 1 , x. Unsubstituted or substituted C3-C6 aryl atoms, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the following group: a) Halogen, b) Cyano, c) Hydroxy, d) C1-C6 alkyl groups, e) C3-C6 cycloalkyl, f) C1-C6 haloalkyl, g) -OZ 1 , h) -C(=O)Z 1 , and i) S(=O)2Z 5 , and xi. Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the following group: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 ; Furthermore, Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 , Z 8 , Z 9 , Z 10 , R 1 , X 1 , and X 2 This is as defined in relation to Equation I.

[0127] In another embodiment, the present disclosure provides a compound of formula III, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where R' is -C(=O)Z 1 In another embodiment, the present disclosure provides a compound of formula III, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where R' is -S(=O)2Z 1 That is the case.

[0128] In another embodiment, the present disclosure provides a compound of formula III, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where R' is an unsubstituted or substituted 3-6 membered heteroaryl, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 .

[0129] In another embodiment, the present disclosure relates to a compound of formula IV: [ka] Or provide stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, in the formula, Z' and Z'' are selected independently of -CH= or -N=; R' is selected from the following group: i. Hydrogen, ii. Halogen, iii. Cyano, iv. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a) Cyano, b) C3-C8 cycloalkyl, c) -C(=O)OH, d) -S(=O)2Z 1 , e) -NZ 3 Z 4 , f) Halogens, and g) Unsubstituted or substituted C3-C6 aryls, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: 1. Halogen, 2. Cyano, 3. Hydroxyl, 4. C1-C6 alkyl groups, 5. C3-C6 cycloalkyl, 6. C1-C6 haloalkyl, 7. -OZ 1 , 8. -C(=O)Z 1 , and 9. S(=O)2Z 5 , v. C3-C6 cycloalkyl, vi. C1-C6 haloalkyl groups, vii. -OZ 1 , viii. -C(=O)Z 1, ix. -S(=O)2Z 1 , x. Unsubstituted or substituted C3-C6 aryl atoms, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the following group: a) Halogen, b) Cyano, c) Hydroxy, d) C1-C6 alkyl groups, e) C3-C6 cycloalkyl, f) C1-C6 haloalkyl, g) -OZ 1 , h) -C(=O)Z 1 , and i) S(=O)2Z 5 , and xi. Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the following group: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 ; Furthermore, Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 , Z 8 , Z 9 , Z 10 , and R 1 This is as defined in relation to Equation I.

[0130] In another embodiment, the disclosure provides a compound of formula IV, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z' and Z'' are -CH=. In another embodiment, the disclosure provides a compound of formula IV, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z' is -N= and Z'' is -CH=.

[0131] In another embodiment, the present disclosure provides a compound of formula IV, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z' and Z'' are -N=.

[0132] In another embodiment, the present disclosure provides a compound of formula IV, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where R' is -C(=O)Z 1 That is the case.

[0133] In another embodiment, the disclosure provides a compound of formula IV, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where R' is -S(=O)2Z 1 That is the case.

[0134] In another embodiment, the present disclosure provides compounds of formula IV, or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, where R' is an unsubstituted or substituted 3- to 6-membered heteroaryl compound, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 .

[0135] In another embodiment, the present disclosure relates to a compound of formula V: [ka] Or provide stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, in the formula, Z' and Z'' are selected independently of -CH= or -N=; Q 1 Q 2 Q 3 , and Q 4 Each of them is independently =N- or =CH-; Furthermore, Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 , Z 8 , Z 9 , Z 10 , Z, R 2 , and R 3 This is as defined in relation to Equation I.

[0136] In another embodiment, the present disclosure provides a compound of formula V, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z' and Z'' are -CH=.

[0137] In another embodiment, the disclosure provides a compound of formula V, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z' is -N= and Z'' is -CH=.

[0138] In another embodiment, the present disclosure provides a compound of formula V, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z' and Z'' are -N=.

[0139] In another embodiment, the disclosure provides a compound of formula V, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z is -O-.

[0140] In another embodiment, the disclosure provides a compound of formula V, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z is -N-.

[0141] In another embodiment, the present disclosure provides a compound of formula V, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein Q 1 Q 2 Q 3 , and Q 4 It is =CH-.

[0142] In another embodiment, the present disclosure provides a compound of formula V, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein Q 1 Q 2 , and Q 4 is =CH- and Q 3 This is equal to N-.

[0143] In another embodiment, the present disclosure provides a compound of formula V, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein Q 1 Q 2 , and Q 3 is =CH- and Q 4 This is equal to N-.

[0144] In another embodiment, the present disclosure relates to a compound of formula VI: [ka] Or provide stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, in the formula, R' is selected from the following group: i. Hydrogen, ii. Halogen, iii. Cyano, iv. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a) Cyano, b) C3-C8 cycloalkyl, c) -C(=O)OH, d) -S(=O)2Z 1 , e) -NZ 3 Z 4 , f) Halogens, and g) Unsubstituted or substituted C3-C6 aryls, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: 1. Halogen, 2. Cyano, 3. Hydroxyl, 4. C1-C6 alkyl groups, 5. C3-C6 cycloalkyl, 6. C1-C6 haloalkyl, 7. -OZ 1 , 8. -C(=O)Z 1 , and 9. S(=O)2Z 5 , v. C3-C6 cycloalkyl, vi. C1-C6 haloalkyl groups, vii. -OZ 1 , viii. -C(=O)Z 1 , ix. -S(=O)2Z 1 , x. Unsubstituted or substituted C3-C6 aryl atoms, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the following group: a) Halogen, b) Cyano, c) Hydroxy, d) C1-C6 alkyl groups, e) C3-C6 cycloalkyl, f) C1-C6 haloalkyl, g) -OZ 1 , h) -C(=O)Z1 , and i) S(=O)2Z 5 , and xi. Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the following group: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 ; Q 1 Q 2 Q 3 , and Q 4 Each of them is independently =N- or =CH-; Furthermore, Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 , Z 8 , Z 9 , Z 10 , X 1 , and X 2 This is as defined in relation to Equation I.

[0145] In another embodiment, the present disclosure provides a compound of formula VI, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where R' is -C(=O)Z 1 That is the case.

[0146] In another embodiment, the present disclosure provides a compound of formula VI, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where R' is -S(=O)2Z 1 That is the case.

[0147] In another embodiment, the disclosure provides compounds of formula VI, or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, where R' is an unsubstituted or substituted 3- to 6-membered heteroaryl compound, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 .

[0148] In another embodiment, the present disclosure provides a compound of formula VI, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein Q 1 Q 2 Q 3 , and Q 4 It is =CH-.

[0149] In another embodiment, the present disclosure provides a compound of formula VI, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein Q 1 Q 2 , and Q 4 is =CH- and Q 3 This is equal to N-.

[0150] In another embodiment, the present disclosure provides a compound of formula VI, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein Q 1 Q 2 , and Q 3 is =CH- and Q 4 This is equal to N-.

[0151] In another embodiment, the present disclosure relates to a compound of formula VII: [ka] Or provide stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, in the formula, Z' and Z'' are selected independently of -CH= or -N=; R' is selected from the following group: i. Hydrogen, ii. Halogen, iii. Cyano, iv. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a) Cyano, b) C3-C8 cycloalkyl, c) -C(=O)OH, d) -S(=O)2Z 1 , e) -NZ 3 Z 4 , f) Halogens, and g) Unsubstituted or substituted C3-C6 aryls, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: 1. Halogen, 2. Cyano, 3. Hydroxyl, 4. C1-C6 alkyl groups, 5. C3-C6 cycloalkyl, 6. C1-C6 haloalkyl, 7. -OZ 1 , 8. -C(=O)Z 1 , and 9. S(=O)2Z 5 , v. C3-C6 cycloalkyl, vi. C1-C6 haloalkyl groups, vii. -OZ 1 , viii. -C(=O)Z 1, ix. -S(=O)2Z 1 , x. Unsubstituted or substituted C3-C6 aryl atoms, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the following group: a) Halogen, b) Cyano, c) Hydroxy, d) C1-C6 alkyl groups, e) C3-C6 cycloalkyl, f) C1-C6 haloalkyl, g) -OZ 1 , h) -C(=O)Z 1 , and i) S(=O)2Z 5 , and xi. Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the following group: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 ; Q 1 Q 2 Q 3 , and Q 4 Each of them is independently =N- or =CH-; Furthermore, Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 , Z 8 , Z 9 , Z 10This is as defined in relation to Equation I.

[0152] In another embodiment, the present disclosure provides a compound of formula VII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z' and Z'' are -CH=.

[0153] In another embodiment, the present disclosure provides a compound of formula VII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z' is -N= and Z'' is -CH=.

[0154] In another embodiment, the disclosure provides a compound of formula VII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z' and Z'' are -N=.

[0155] In another embodiment, the disclosure provides a compound of formula VII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where R' is -C(=O)Z 1 That is the case.

[0156] In another embodiment, the disclosure provides a compound of formula VII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where R' is -S(=O)2Z 1 That is the case.

[0157] In another embodiment, the disclosure provides compounds of formula VII, or stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, where R' is an unsubstituted or substituted 3- to 6-membered heteroaryl, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 .

[0158] In another embodiment, the present disclosure provides a compound of formula VII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Q 1 Q 2 Q 3 , and Q 4 It is =CH-.

[0159] In another embodiment, the present disclosure provides a compound of formula VII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Q 1 Q 2 , and Q 4 is =CH- and Q 3 This is equal to N-.

[0160] In another embodiment, the present disclosure provides a compound of formula VII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Q 1 Q 2 , and Q 3 is =CH- and Q 4 This is equal to N-.

[0161] In another embodiment, the present disclosure relates to a compound of formula VIII: [ka] Or provide stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, in the formula, Q 1 Q 2 Q 3 , and Q 4 Each of them is independently =N- or =CH-; Z is selected from -O-, -N-, -S-, -S(O)-, or -S(O)2-. However, if Z is -O-, -S-, -S(O)-, or -S(O)2-, R 3 It does not exist; X 1 and X 2 Is it independently selected from the following group: (i) Hydrogen, (ii) Halogen, (iii) Hydroxyl, (iv) Cyano, (v) C1-C6 alkyl groups, (vi) C1-C6 haloalkyl, (vii) C2-C6 alkenyls, and (viii) Carbonyl, or X 1 and X 2 Together with the carbon atoms to which they are bonded, they form the following: (i) Unsubstituted or substituted C3-C6 cycloalkyls, where zero or more cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), (ii) Unsubstituted or substituted 3-6 membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), (iii) C6~C non-substituted or substituted 10 Aryl, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), or (iv) Unsubstituted or substituted 5- to 9-membered heteroaryl compounds, where zero or more heterocyclic carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), However, these are subject to the following conditions: (i) X 1 and X 2When these come together to form an aryl or heteroaryl, [ka] represents a double bond, and (ii) X 1 and X 2 If that is not the case (i.e., X 1 and X 2 (If they do not form an aryl or heteroaryl group together), [ka] represents a single bond; R 2 and R 3 Is it independently selected from the following group: (i) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C1-C6 alkyl groups, c. -S(=O)2Z 5 , d. C3-C8 cycloalkyl, e. -C(=O)OH, f. -C(=O)Z 1 , g. -NZ 3 Z 4 , h. Halogen, i. Hydroxyl, j. Unsubstituted or substituted 3-8 membered heterorings, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more of the heterocyclic carbons can be oxidized to form C=O. k. Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more heteroaryl carbons can be oxidized to form C=O, and l. Non-substitutive or substituted C6~C 10An aryl, where zero or more aryl carbons can be oxidized to form a C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 haloalkyls, and cyanos. (ii) Unsubstituted or substituted 3-6 membered heteroaryls, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. C1-C6 alkyl groups, d. C3-C6 cycloalkyl, e. C1-C6 haloalkyl, f. -OZ 1 , and g. -C(=O)Z 1 , (iii) an unsubstituted or substituted 3-6 membered heteroring, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. C1-C6 alkyl groups, d. C3-C6 cycloalkyl, e. C1-C6 haloalkyl, f. -OZ 1 , and g. -C(=O)Z 1 , (iv) Hydrogen, (v) -C(=O)Z 1 , and (vi) -S(=O)2Z 5 ,or, R 2 and R 3 They are bonded together with the carbon and nitrogen atoms, respectively, to form the following: (i) Unsubstituted or substituted 3-6 membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are independently selected from the group consisting of: (1) Cyano, (2) C3-C8 cycloalkyl, (3) -C(=O)OH, (4) -S(=O)2Z 1 , (5) -NZ 3 Z 4 , and (6) Halogen, (d) C3-C6 cycloalkyl, (e) C1-C6 haloalkyl, (f) -OZ 1 , (g) -C(=O)Z 1 , (h) -S(=O)2Z 1 , (i) Unsubstituted or substituted C3-C6 aryls, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) Hydroxy, (4) C1-C6 alkyl, (5) C3-C6 cycloalkyl, (6) C1-C6 haloalkyl, (7) -OZ 1 , (8) -C(=O)Z 1 , and (9) S(=O)2Z 5 , and (j) Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) C1-C6 alkyl, (4) C3-C6 cycloalkyl, (5) C1-C6 haloalkyl, (6) -OZ 1 , (7) -C(=O)Z 1 , and (8) S(=O)2Z 5 ; each Z 1 It is independently selected from the following group: (i) Hydrogen, (ii) Hydroxyl, (iii) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C1-C6 alkyl groups, c. -S(=O)2Z 5 , d. C3-C8 cycloalkyl, e. -C(=O)OH, f. -NZ 3 Z 4 , g. Halogen, h. Unsubstituted or substituted 3-8 membered heterorings, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more of the heterocyclic carbons can be oxidized to form C=O. i. Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more heteroaryl carbons can be oxidized to form C=O, and j. Non-substitutive or substituted C6~C 10 An aryl, where zero or more aryl carbons can be oxidized to form a C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 haloalkyls, and cyanos. (iv) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. -S(=O)2Z 5 , c. Halogens, and d. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: i. Cyano, ii. -S(=O)2Z 5 , iii. C3-C8 cycloalkyl, iv. -C(=O)OH, v. -NZ 3 Z 4 , vi. Halogen, vii. Unsubstituted or substituted 3-8 membered heterorings, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more of the heterocyclic carbons can be oxidized to form C=O. viii. Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more heteroaryl carbons can be oxidized to form C=O, and ix. Non-substitutive or substituted C6~C 10 Aryl, where one or more substituents are halogen, C1-C6 haloalkyl, cyano, -S(=O)2Z 5 , -NZ 3 Z 4 , and an unsubstituted or substituted 3- to 8-membered heterocycle (where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls), wherein zero or more aryl carbons can be oxidized to form C=O, (v) C2-C6 alkynyl, (vi) C3-C6 cycloalkyl, (vii) C3-C6 cycloalkenyl, (viii) C1-C6 haloalkyl, (ix) -OZ 2 , (x) -C(=O)Z 2 , (xi) -NHZ 2 , (xii) Unsubstituted or substituted C3-C8 cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 5 , -NZ 3 Z 4 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiii) C6~C of non-substitutive or substituted types 10 Aryl, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 5 , -NZ 3 Z 4 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiv) Unsubstituted or substituted 3- to 8-membered heteroaryls, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and (xv) Unsubstituted or substituted 3- to 8-membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls; each Z 2 It is independently selected from the following group: (i) C1-C6 alkyl groups, (ii) -NHZ 3 , (iii) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are cyano, -S(=O)2Z 5 , halogens, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 5 , -NZ 3 Z 4 (and independently selected from the group consisting of 4- to 8-membered heterocycles), (iv) C2-C6 alkinyl, (v) C3-C6 cycloalkyl, (vi) C3-C6 cycloalkenyl, (vii) C1-C6 haloalkyls, and (viii) Hydrogen; each Z 3 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are C2-C6 alkenyl, cyano, -C(=O)OH, or -S(=O)2Z. 5 Halogen, -NZ 3 Z 4 and independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iii) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are cyano, -S(=O)2Z 5 , halogens, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 5 , -NZ 6 Z 4 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) -C(=O)Z 7 , (v) C2-C6 alkynyl, (vi) C3-C6 cycloalkyl, (vii) C3-C6 cycloalkenyls, and (viii) C1-C6 haloalkyl; each Z 4 It is independently selected from the following group: (i) Hydrogen, (ii) C1-C6 alkyl, and (iii) C3-C6 cycloalkyl; each Z 5 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are independently selected from the group consisting of halogens, cyanos, and C1-C6 alkyls. (iii) Unsubstituted or substituted C2-C6 alkenyl, where one or more substituents are halogens, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are -NZ 6 Z 4 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) Halogens, and (v) hydroxy; each Z 6 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are C2-C6 alkenyl, cyano, -C(=O)OH, -S(=O)2H, -S(=O)2 (unsubstituted or substituted C1-C6 alkyl), -S(=O)2 (unsubstituted or substituted C2-C6 alkenyl), -S(=O)2 (halogen), -S(=O)2OH, -NHZ 8 -N (unsubstituted or substituted C1-C6 alkyl)Z 8 , -N (unsubstituted or substituted C2-C6 alkenyl) Z 8 , -N(-C(=O)Z 7 )Z 8 -N(C2~C6 alkynyl)Z 8 , -N(C3~C6 cycloalkyl)Z 8 ,-N(C3~C6 cycloalkenyl)Z8 -N(C1~C6 haloalkyl)Z 8 and independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iii) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are cyano, -S(=O)2H, -S(=O)2 (unsubstituted or substituted C1-C6 alkyl), -S(=O)2 (unsubstituted or substituted C2-C6 alkenyl), -S(=O)2 (halogen), -S(=O)2OH, halogen, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 9 , -NHZ 8 -N (unsubstituted or substituted C1-C6 alkyl)Z 8 , -N (unsubstituted or substituted C2-C6 alkenyl) Z 8 , -N(-C(=O)Z 7 )Z 8 -N(C2~C6 alkynyl)Z 8 , -N(C3~C6 cycloalkyl)Z 8 ,-N(C3~C6 cycloalkenyl)Z 8 -N(C1~C6 haloalkyl)Z 8 , and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) -C(=O)Z 7 , (v) C2-C6 alkynyl, (vi) C3-C6 cycloalkyl, (vii) C3-C6 cycloalkenyls, and (viii) C1-C6 haloalkyl; and each Z 7 It is independently selected from the following group: (i) Hydrogen, (ii) Hydroxyl, (iii) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C1-C6 alkyl groups, c. -S(=O)2Z 9 , d. C3-C8 cycloalkyl, e. -C(=O)OH, f. -NHZ 8 , g. -N(unsubstituted or substituted C1-C6 alkyl)Z 8 , h. -N (unsubstituted or substituted C2-C6 alkenyl) Z 8 , i. -N(-C(=O) unsubstituted or substituted C3-C6 cycloalkyl)Z 8 , j. -N(-C(=O) unsubstituted or substituted C3~C6 cycloalkenyl)Z 8 , k. -N(-C(=O) unsubstituted or substituted C1-C6 haloalkyl)Z 8 , l. -N(C2~C6 alkynyl)Z 8 , m. -N(C3~C6 cycloalkyl)Z 8 , n. -N(C3~C6 cycloalkenyl)Z 8 , o. -N(C1~C6 haloalkyl)Z 8 , p. Halogen, q. An unsubstituted or substituted 3- to 8-membered heteroring, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more of the heteroring carbons can be oxidized to form C=O. r. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more heteroaryl carbons can be oxidized to form C=O, and s. Non-substitutive or substituted C6~C 10An aryl, where zero or more aryl carbons can be oxidized to form a C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 haloalkyls, and cyanos. (iv) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. -S(=O)2Z 9 , c. Halogens, and (v) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. -S(=O)2Z 9 , c. C3-C8 cycloalkyl, d. -C(=O)OH, (vi) -NHZ 8 , (vii) -N(unsubstituted or substituted C1-C6 alkyl)Z 8 , (viii) -N(unsubstituted or substituted C2-C6 alkenyl)Z 8 , (ix) -N(unsubstituted or substituted C2-C6 alkynyl)Z 8 , (x) -N(unsubstituted or substituted C3-C6 cycloalkyl)Z 8 , (xi) -N(unsubstituted or substituted C3-C6 cycloalkenyl)Z 8 , (xii) -N(C1~C6 Haloalkyl)Z 8 , (xiii) Halogen, (xiv) Unsubstituted or substituted 3- to 8-membered heterorings, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 acetyls and C2-C6 alkenyls, and zero or more of the heteroring carbons can be oxidized to form C=O. (xv) Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more heteroaryl carbons can be oxidized to form C=O, and (xvi) C6~C of non-substitution or substitution 10 Aryl, where one or more substituents are halogen, C1-C6 haloalkyl, cyano, -S(=O)2Z 9 , -NZ 6 Z 8 , and an unsubstituted or substituted 3- to 8-membered heterocycle (where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls), wherein zero or more aryl carbons can be oxidized to form C=O, (xvii) C2~C6 Alkinyl, (xviii) C3-C6 cycloalkyl, (xix) C3~C6 cycloalkenyl, (xx) C1~C6 haloalkyl, (xxi) -OZ 10 , (xxii) -C(=O)Z 10 , (xxiii) -NHZ 10 , (xxiv) Unsubstituted or substituted C3-C8 cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 9 , -NZ 6 Z 8 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xxv) C6~C non-substituted or substituted 10Aryl, where zero or more aryl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 9 , -NZ 6 Z 8 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xxvi) Unsubstituted or substituted 3-8 membered heteroaryls, where zero or more heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls. (xxvii) Unsubstituted or substituted 3- to 8-membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls; each Z 8 It is independently selected from the following group: (i) Hydrogen, (ii) C1-C6 alkyl, and (iii) C3-C6 cycloalkyl; each Z 9 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are independently selected from the group consisting of halogens, cyanos, and C1-C6 alkyls. (iii) Unsubstituted or substituted C2-C6 alkenyl, where one or more substituents are halogens, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are -NZ 6 Z 8 And independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) Halogens, and (v) hydroxy; and each Z 10 It is independently selected from the following group: (i) C1-C6 alkyl groups, (ii) -NH2, (iii) -NH(C1~C6 alkyl), (iv) -N(C1~C6 alkyl)2, (v) Unsubstituted or substituted C2-C6 alkenyl, where one or more substituents are cyano, -S(=O)2Z 9 , halogens, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 9 , -NZ 6 Z 8 (and independently selected from the group consisting of 4- to 8-membered heterocycles), (vi) C2~C6 alkinyl, (vii) C3-C6 cycloalkyl, (viii) C3-C6 cycloalkenyl, (ix) C1-C6 haloalkyls, and (x) Hydrogen.

[0162] In one embodiment, the disclosure provides a compound of formula VIII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z is selected from -O- or -N-, including, if Z is -O-, R 3 This is accompanied by the condition that it does not exist.

[0163] In one embodiment, the present disclosure provides a compound of formula VIII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z is selected from -O, -N-, or -S(O)2-, including, if Z is -O- or -S(O)2-, R 3 This is accompanied by the condition that it does not exist.

[0164] In one embodiment, the present disclosure provides a compound of formula VIII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z is selected from -S(O)2-, including, if Z is -S(O)2-, R 3 This is accompanied by the condition that it does not exist.

[0165] In another embodiment, the present disclosure provides a compound of formula VIII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Q 1 Q 2 Q 3 , and Q 4 It is =CH-.

[0166] In another embodiment, the present disclosure provides a compound of formula VIII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Q 1 Q 2 , and Q 4 is =CH- and Q 3 This is equal to N-.

[0167] In another embodiment, the present disclosure provides a compound of formula VIII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Q 1 Q 2 , and Q 3 is =CH- and Q 4 This is equal to N-.

[0168] In another embodiment, the present disclosure provides a compound of formula VIII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z is -O-.

[0169] In another embodiment, the present disclosure provides a compound of formula VIII, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where Z is -N-.

[0170] In another embodiment, the present disclosure relates to a compound of formula IX: [ka] Or provide stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates thereof, in the formula, Q 1 Q 2 Q 3 , and Q 4 Each of them is independently =N- or =CH-; Q 5 Q 6 Q 7 , and Q 8 Each of these is independently =N- or =CR-, where each R is independently H or C1-C6 alkyl (e.g., Me); L is either -O- or -NR 2 And here, R 2 is H or C1-C6 alkyl (e.g., Me); R a , R b , R c , R d , R e , R f , R g and R h Each of them is independently H or C1-C6 alkyl (e.g., Me), or R a and R b , R c and R d , R e and R f , and / or R g and R h One or more of these, together with the carbon atoms to which they are bonded, form a carbonyl (-C(=O)) group; and R 1 This is H or a C1-C6 alkyl group (for example, Me).

[0171] In another embodiment, the present disclosure provides a compound of formula IX, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, where L is -O-, -NH-, or -NMe-.

[0172] In another embodiment, the present disclosure provides a compound of formula IX, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Q 1 Q 2 Q 3 , and Q 4 Each of these is =CH-.

[0173] In another embodiment, the present disclosure provides a compound of formula IX, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Q 5 Q 6 Q 7 , and Q 8 Each of these is =CH-.

[0174] In another embodiment, the present disclosure provides a compound of formula IX, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Q 5 is =N- and Q 6 Q 7 , and Q 8 Each of them is =CR- (for example, Q 6 is = C(Me)- and Q 7 and Q 8 (is =CH-).

[0175] In another embodiment, the present disclosure provides a compound of formula IX, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein R 1 H is H.

[0176] In another embodiment, the present disclosure provides a compound of formula IX, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein R a , R b , R e , R f , R g , and R h Each of them is independently H and R c and R d These, together with the carbon atoms to which they are bonded, form a carbonyl (-C(=O)) group.

[0177] In another embodiment, the present disclosure provides a compound, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, selected from the group consisting of: N-((1-(2-hydroxyethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(2-hydroxyethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; N-((1-(cyanomethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(cyanomethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; N-((1-(3-hydroxypropyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(3-hydroxypropyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; 3-(2-(acrylamidomethyl)-4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)propanoic acid; 3-(2-(acetamidomethyl)-4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)propanoic acid; N-((1-(3-(methylamino)-3-oxopropyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; 6-(4-(trifluoromethyl)phenyl)-4,4a,5,6-tetrahydro-1H-pyrazino[1,2-a]quinoxaline-2(3H)-one; N-((1-(2-amino-2-oxoethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(2-(methylamino)-2-oxoethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(3-amino-3-oxopropyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; 1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; (R)-or (S)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; 1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; (R)-or (S)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; 3-(methylsulfonyl)-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline; N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (R)-or (S)-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-acetyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; Methyl 6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-carboxylate; 1-(8-(4-(trifluoromethyl)phenyl)octahydro-2H-pyrazino[1,2-a]pyrazine-2-yl)propa-2-en-1-one; N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (R)-or (S)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(methylsulfonyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; 2-methyl-5-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)-1,3,4-oxadiazole; 2-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)oxazole; 3-Methyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxaline; N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-or (S)-N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-or (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propa-2-en-1-one; (R)-or (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; 2-Hydroxy-4-((6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-Hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)methyl)benzaldehyde; 2-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)acetic acid; N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; (R)-or (S)-N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; 8-Acryloyl-2-(4-(trifluoromethyl)phenyl)hexahydro-2H-pyrazino[1,2-a]pyrazine-3(4H)-one; N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; (R)-or (S)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; (R)-or (S)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; (R)-or (S)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; 8-Acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (R)-or (S)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (S)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; (R)-or (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; (R)-or (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one (diastereomer 1); 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one (diastereomer 2); 1-(1,1-dichloro-2-(4-(trifluoromethyl)phenyl)octahydrocyclopropa[e]pyrazino[1,2-a]pyrazine-5(1H)-yl)propa-2-en-1-one; 8-Acetyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; (R)-or (S)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; Cyclopropyl(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)methanone; 2-Methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; (R)-or (S)-2-methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 1-((4H-1,2,4-triazol-3-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-((1H-imidazole-5-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; 1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; 1-(5-(6-(trifluoromethyl)pyridine-3-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-ylmethylcarbamate; 1-(3-(4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)azetidine-1-yl)ethane-1-one; and N-(2-(4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)ethyl)acetamide.

[0178] In another embodiment, the present disclosure provides a compound, or a tautomer, pharmaceutically acceptable salt, or solvate thereof, selected from the group consisting of: 1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; (R)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; (S)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; 1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; (R)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; (S)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (R)-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (S)-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (R)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (S)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (S)-N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propa-2-en-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propa-2-en-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propa-2-en-1-one; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; (R)-N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; (S)-N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; (R)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; (S)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; (R)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; (S)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; (R)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; (S)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; 8-Acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (R)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (S)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one; 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one (diastereomer 1); 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one (diastereomer 2); N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; (R)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; (S)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; 2-Methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; (R)-2-methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; (S)-2-methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; and (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-ylmethylcarbamate.

[0179] In another embodiment, the present disclosure provides a compound, or a tautomer, pharmaceutically acceptable salt, or solvate thereof, selected from the group consisting of: (R)-or (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; (R)-or (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; (R)-or (S)-1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; N-((4,4-dioxide-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]thiadin-3-yl)methyl)acetamide; 8-Acetyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8-tetrahydroimidazo[1,5-a]pyrido[3,2-e]pyrazine-9(5H)-one; 1-((1-methyl-1H-imidazole-5-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-((2-methyl-1H-imidazole-5-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-((1H-imidazole-2-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-((1H-pyrazole-4-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-(pyridine-3-ylmethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; (cis)-or (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; 1-((4-methyl-1H-imidazole-5-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 5-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)methyl)oxazole; 5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydropyrido[3',2':5,6]pyrazino[2,1-c][1,4]thiazine 8,8-dioxide; 5-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)methyl)isoxazole; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; N-((6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; 8-(methylsulfonyl)-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; N-methyl-6-oxo-8-(4-(trifluoromethyl)phenyl)octahydro-2H-pyrazino[1,2-a]pyrazine-2-sulfonamide; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-((6-Methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (1H-pyrazole-4-yl)(4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)methanone; N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-(trifluoromethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-((6-Methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((1-(5-(trifluoromethyl)pyridine-2-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-Acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; 1-((1H-pyrazole-4-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-2(1H)-one; (R)-or (S)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-ethyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; Methyl((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)carbamate; 1-Methyl-3-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-Hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)urea; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)methanesulfonamide; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl),N'-methylsulfate diamide; N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (cis)-or (trans)-3-acryloyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (cis)-or (trans)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-ylmethylcarbamate; N-((6aR,8R)-3-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; (R)-or (S)-N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-Oxo-3-(((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-Hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)amino)propanoic acid; 2-Hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-Hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; (cis)-or (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; 2-Amino-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-Hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; N-((6aR,8R)-3-chloro-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; (R)-or (S)-N-((6-cyano-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-3-(acetamidomethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-6-carboxamide; (cis)-or (trans)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-carbonitrile; (cis)-or (trans)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-or (trans)-1-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-or (trans)-2-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-((6aR,8R)-2-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; N-((6-(difluoromethoxy)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-2-hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)propanamide; (S)-2-hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)propanamide; 2-Hydroxy-2-methyl-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-Hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)propanamide; N-((6-(difluoromethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-carboxylic acid; (cis)-or (trans)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-or (trans)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (cis)-or (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; (R)-or (S)-N-((6-bromo-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-8-fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; and (cis)-or (trans)-8-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid.

[0180] In another embodiment, the present disclosure provides a compound, or a tautomer, pharmaceutically acceptable salt, or solvate thereof, selected from the group consisting of: N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; (R)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; (S)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; 1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (R)-1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (S)-1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; 5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; N-((6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; N-((6-Methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-Methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-Methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-(S)-N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-Acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; (R)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; (S)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-Acryloyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (cis)-3-acryloyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (trans)-3-acryloyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; 3-Acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (cis)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (trans)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; 5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (cis)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; N-((6-cyano-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-cyano-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-cyano-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-(acetamidomethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-6-carboxamide; (R)-3-(acetamidomethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-6-carboxamide; (S)-3-(acetamidomethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-6-carboxamide; 3-Chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (cis)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (trans)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; 2-Methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8S)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8S)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8R)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8R)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; 3-Chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-Hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (trans)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; 1-Chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-1-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (trans)-1-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; 2-Chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-2-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (trans)-2-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; 2-Hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-Hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)propanamide; (R)-2-hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)propanamide; (S)-2-hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)propanamide; 8-Methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-Hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (trans)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; 8-Methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-Hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8S)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8R)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8R)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (cis)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (trans)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; 5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (cis)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; 8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; (6aS,8S)-8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; (6aR,8S)-8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; (6aR,8R)-8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; (6aS,8R)-8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; N-((6-bromo-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-bromo-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-bromo-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 8-Fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-Hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)-8-fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8S)-8-fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8R)-8-fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8R)-8-fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8S)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aR,8S)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aR,8R)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8R)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; 5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; 8-Hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-Hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-8-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; and (trans)-8-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid.

[0181] In another embodiment, the present disclosure provides a compound, or a tautomer, pharmaceutically acceptable salt, or solvate thereof, selected from the group consisting of: 1-(2-((4-(trifluoromethyl)phenyl)amino)phenyl)piperidine-4-carboxylic acid; 1-(2-(methyl(4-(trifluoromethyl)phenyl)amino)phenyl)piperidine-4-carboxylic acid; 2-Oxo-1-(2-((4-(trifluoromethyl)phenyl)amino)phenyl)piperidine-4-carboxylic acid; 1-(2-(4-(trifluoromethyl)phenoxy)phenyl)piperidine-4-carboxylic acid; 1-(3-((4-(trifluoromethyl)phenyl)amino)pyridine-2-yl)piperidine-4-carboxylic acid; and 1-(6-methyl-3-((4-(trifluoromethyl)phenyl)amino)pyridine-2-yl)piperidine-4-carboxylic acid.

[0182] In another embodiment, the present disclosure provides a compound, or a tautomer, pharmaceutically acceptable salt, or solvate thereof, selected from the group consisting of: 8-Acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (R)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (S)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; and (6aR,8S)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid.

[0183] Preferred or specific descriptions (features) and embodiments of the compounds of this disclosure are described below. Each of the descriptions, aspects, and embodiments of this disclosure defined herein may be combined with any other descriptions, aspects, and / or embodiments unless expressly indicated otherwise. In particular, any feature indicated as preferred, specific, or advantageous may be combined with any other feature or description indicated as preferred, specific, or advantageous. In this specification, this disclosure is expressed in particular by any one or more of the numbered descriptions and embodiments below, or in any combination with any other descriptions, aspects, and / or embodiments (unnumbered).

[0184] Embodiment 1. Compound of Formula I: [ka] or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Z is selected from -O-, -N-, -S-, -S(O)-, or -S(O)2-. However, if Z is -O-, -S-, -S(O)-, or -S(O)2-, R 3 It does not exist; X 1 and X 2 Is it independently selected from the following group: (i) Hydrogen, (ii) Halogen, (iii) Hydroxyl, (iv) Cyano, (v) C1-C6 alkyl groups, (vi) C1-C6 haloalkyl, (vii) C2-C6 alkenyls, and (viii) Carbonyl, or X 1 and X 2 Together with the carbon atoms to which they are bonded, they form the following: (i) Unsubstituted or substituted C3-C6 cycloalkyls, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), (ii) an unsubstituted or substituted 3-6 membered heteroring, wherein zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1)2 (for example, -C(O)NH2), (iii) C6~C non-substituted or substituted 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), or (iv) Unsubstituted or substituted 5- to 9-membered heteroaryl compounds, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), However, these are subject to the following conditions: (i) X 1 and X 2 When these come together to form an aryl or heteroaryl, [ka] represents a double bond, and (ii) X 1 and X2 If that is not the case (i.e., X 1 and X 2 (If they do not form an aryl or heteroaryl group together), [ka] represents a single bond; R 1 The group is selected from the following: (i) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: (a) Non-substituted or substituted C6~C 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) C1-C6 alkyl, (4) C3-C6 cycloalkyl, (5) C1-C6 haloalkyl, (6) -OZ 1 , (7) C2-C6 alkenyls, and (8) C2-C6 alkynyl, (b) Unsubstituted or substituted C3-C6 cycloalkyl, wherein zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) C1-C6 alkyl, (4) C3-C6 cycloalkyl, (5) C1-C6 haloalkyls, (6) -OZ 1 , (c) C2-C6 alkinyls, and (d) an unsubstituted or substituted 3-6 membered heteroring, wherein zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, cyanos, C2-C8 alkenyls, and C1-C6 alkyls. (ii) Non-substitutive or substituted C6~C 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) C1-C6 alkyl groups, (d) C3-C6 cycloalkyl, (e) C1-C6 haloalkyl, (f) -OZ 1 , and (g) Unsubstituted or substituted C6~C 10 Aryl, where one or more substituents are halogens, C1-C6 alkyls, C1-C6 haloalkyls, and -OZ 1 Independently selected from the group consisting of, (iii) Unsubstituted or substituted 5- to 9-membered heteroaryl compounds, wherein zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) C1-C6 alkyl groups, (d) C3-C6 cycloalkyl, (e) C1-C6 haloalkyl, (f) -OZ 1 , and (g) Unsubstituted or substituted C6~C 10 Aryl, where one or more substituents are halogens, C1-C6 alkyls, C1-C6 haloalkyls, and -OZ 1 Independently selected from the group consisting of, (iv) Unsubstituted or substituted C3-C6 cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) C1-C6 alkyl groups, (d) C3-C6 cycloalkyl, (e) C1-C6 haloalkyls, and (f) -OZ 1 , (v) an unsubstituted or substituted 3-6 membered heteroring, wherein zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) C1-C6 alkyl groups, (d) C3-C6 cycloalkyl, (e) C1-C6 haloalkyls, and (f) -OZ 1 , (vi) -S(=O)2Z 2、 and (vii) -C(=O)Z 2 ; R 2 and R 3 Is it independently selected from the following group: (i) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C1-C6 alkyl groups, c. -S(=O)2Z 5 , d. C3-C8 cycloalkyl, e. -C(=O)OH, f. -C(=O)Z 1 , g. -NZ 3 Z 4 , h. Halogen, i. Hydroxyl, j. An unsubstituted or substituted 3- to 8-membered heteroring, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more carbon atoms of the heteroring can be oxidized to form C=O. k. Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more of the heteroaryl carbons can be oxidized to form C=O, and l. Non-substitutive or substituted C6~C 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 haloalkyls, and cyanos. (ii) Unsubstituted or substituted 3-6 membered heteroaryl compounds, wherein zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. C1-C6 alkyl groups, d. C3-C6 cycloalkyl, e. C1-C6 haloalkyl, f. -OZ 1 , and g. -C(=O)Z 1 , (iii) an unsubstituted or substituted 3-6 membered heteroring, wherein zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. C1-C6 alkyl groups, d. C3-C6 cycloalkyl, e. C1-C6 haloalkyl, f. -OZ 1 , and g. -C(=O)Z 1 , (iv) Hydrogen, (v) -C(=O)Z 1 , and (vi) -S(=O)2Z 5 ,or, R 2 and R 3 They are bonded together with the carbon and nitrogen atoms, respectively, to form the following: (i) an unsubstituted or substituted 3-6 membered heteroring, wherein zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are independently selected from the group consisting of: (1) Cyano, (2) C3-C8 cycloalkyl, (3) -C(=O)OH, (4) -S(=O)2Z 1 , (5) -NZ 3 Z 4 , (6) Halogens, and (7) Unsubstituted or substituted C3-C6 aryls, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. Hydroxy, d. C1-C6 alkyl groups, e. C3-C6 cycloalkyl, f. C1-C6 haloalkyl, g. -OZ 1 , h. -C(=O)Z 1 , and i. S(=O)2Z 5 , (d) C3-C6 cycloalkyl, (e) C1-C6 haloalkyl, (f) -OZ 1 , (g) -C(=O)Z 1 , (h) -S(=O)2Z 1 , (i) Unsubstituted or substituted C3-C6 aryls, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) Hydroxy, (4) C1-C6 alkyl, (5) C3-C6 cycloalkyl, (6) C1-C6 haloalkyl, (7) -OZ 1 , (8) -C(=O)Z 1 , and (9) S(=O)2Z 5 , and (j) Unsubstituted or substituted 3-6 membered heteroaryl compounds, wherein zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) C1-C6 alkyl, (4) C3-C6 cycloalkyl, (5) C1-C6 haloalkyl, (6) -OZ 1 , (7) -C(=O)Z 1 , and (8) S(=O)2Z 5 ; each Z 1 It is independently selected from the following group: (i) Hydrogen, (ii) Hydroxyl, (iii) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C1-C6 alkyl groups, c. -S(=O)2Z 5 , d. C3-C8 cycloalkyl, e. -C(=O)OH, f. -NZ 3 Z 4 , g. Halogen, h. An unsubstituted or substituted 3-8 membered heteroring, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more carbon atoms of the heteroring can be oxidized to form C=O. i. Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more of the heteroaryl carbons can be oxidized to form C=O, and j. Non-substitutive or substituted C6~C 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 haloalkyls, and cyanos. (iv) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. -S(=O)2Z 5 , c. Halogens, and d. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: i. Cyano, ii. -S(=O)2Z 5 , iii. C3-C8 cycloalkyl, iv. -C(=O)OH, v. -NZ 3 Z 4 , vi. Halogen, vii. An unsubstituted or substituted 3- to 8-membered heteroring, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more carbon atoms of the heteroring can be oxidized to form C=O. viii. Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more of the heteroaryl carbons can be oxidized to form C=O, and ix. Non-substitutive or substituted C6~C 10 Aryl, where one or more substituents are halogen, C1-C6 haloalkyl, cyano, -S(=O)2Z 5 , -NZ 3 Z 4 and an unsubstituted or substituted 3- to 8-membered heterocycle (where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls), wherein zero or more of the aryl carbons can be oxidized to form C=O. (v) C2-C6 alkynyl, (vi) C3-C6 cycloalkyl, (vii) C3-C6 cycloalkenyl, (viii) C1-C6 haloalkyl, (ix) -OZ 2 , (x) -C(=O)Z 2 , (xi) -NHZ 2 , (xii) Unsubstituted or substituted C3-C8 cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 5 , -NZ 3 Z 4and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiii) C6~C of non-substitutive or substituted types 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 5 , -NZ 3 Z 4 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiv) Unsubstituted or substituted 3-8 membered heteroaryls, wherein zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and (xv) an unsubstituted or substituted 3- to 8-membered heteroring, wherein zero or more carbon atoms of the heteroring can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls; each Z 2 It is independently selected from the following group: (i) C1-C6 alkyl groups, (ii) -NHZ 3 , (iii) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are cyano, -S(=O)2Z 5 , halogens, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 5 , -NZ 3 Z 4 (and independently selected from the group consisting of 4- to 8-membered heterocycles), (iv) C2-C6 alkinyl, (v) C3-C6 cycloalkyl, (vi) C3-C6 cycloalkenyl, (vii) C1-C6 haloalkyls, and (viii) Hydrogen; each Z 3 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are C2-C6 alkenyl, cyano, -C(=O)OH, or -S(=O)2Z. 5 Halogen, -NZ 6 Z 4 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iii) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are cyano, -S(=O)2Z 5 , halogens, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 5 , -NZ 6 Z 4 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) -C(=O)Z 7 , (v) C2-C6 alkynyl, (vi) C3-C6 cycloalkyl, (vii) C3-C6 cycloalkenyls, and (viii) C1-C6 haloalkyl; each Z 4 It is independently selected from the following group: (i) Hydrogen, (ii) C1-C6 alkyl, and (iii) C3-C6 cycloalkyl; each Z 5 It is independently selected from the following group: (iv) Hydrogen, (v) unsubstituted or substituted C1-C6 alkyl, wherein one or more substituents are independently selected from the group consisting of halogen, cyano, and C1-C6 alkyl, (vi) unsubstituted or substituted C2-C6 alkenyl, wherein one or more substituents are halogen, and unsubstituted or substituted C1-C6 alkyl (wherein one or more substituents are -NZ 6 Z 4 and independently selected from the group consisting of 4- to 8-membered heterocycles (wherein zero or more of the heterocyclic carbons may be oxidized to form C=O)), (vii) halogen, and (viii) hydroxy; each Z 6 is independently selected from the group consisting of: a. hydrogen, b. unsubstituted or substituted C1-C6 alkyl, wherein one or more substituents are C2-C6 alkenyl, cyano, -C(=O)OH, -S(=O)2H, -S(=O)2(unsubstituted or substituted C1-C6 alkyl), -S(=O)2(unsubstituted or substituted C2-C6 alkenyl), -S(=O)2(halogen), -S(=O)2OH, -NHZ 8 , -N(unsubstituted or substituted C1-C6 alkyl)Z 8 , -N(unsubstituted or substituted C2-C6 alkenyl)Z 8 , -N(-C(=O)Z 7 )Z 8 , -N(C2-C6 alkynyl)Z 8 , -N(C3-C6 cycloalkyl)Z 4 , -N(C3-C6 cycloalkenyl)Z 8 , -N(C1-C6 haloalkyl)Z 8 , and independently selected from the group consisting of 4- to 8-membered heterocycles (wherein zero or more of the heterocyclic carbons may be oxidized to form C=O)), c. Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are cyano, -S(=O)2H, -S(=O)2 (unsubstituted or substituted C1-C6 alkyl), -S(=O)2 (unsubstituted or substituted C2-C6 alkenyl), -S(=O)2 (halogen), -S(=O)2OH, halogen, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 9 , -NHZ 8 -N (unsubstituted or substituted C1-C6 alkyl)Z 8 , -N (unsubstituted or substituted C2-C6 alkenyl) Z 8 , -N(-C(=O)Z 7 )Z 8 -N(C2~C6 alkynyl)Z 8 , -N(C3~C6 cycloalkyl)Z 8 ,-N(C3~C6 cycloalkenyl)Z 8 -N(C1~C6 haloalkyl)Z 8 and independently selected from the group consisting of a 4-8 membered heteroring (where zero or more carbon atoms of the heteroring can be oxidized to form C=O), d. -C(=O)Z 7 , e. C2-C6 alkynyl, f. C3-C6 cycloalkyl groups, g. C3-C6 cycloalkenyls, h. C1-C6 haloalkyl; and each Z 7 It is independently selected from the following group: (i) Hydrogen, (ii) Hydroxyl, (iii) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C1-C6 alkyl groups, c. -S(=O)2Z 9 , d. C3-C8 cycloalkyl, e. -C(=O)OH, f. -NHZ8 , g. -N(unsubstituted or substituted C1-C6 alkyl)Z 8 , h. -N (unsubstituted or substituted C2-C6 alkenyl) Z 8 , i. -N(-C(=O) unsubstituted or substituted C3-C6 cycloalkyl)Z 8 , j. -N(-C(=O) unsubstituted or substituted C3~C6 cycloalkenyl)Z 8 , k. -N(-C(=O) unsubstituted or substituted C1-C6 haloalkyl)Z 8 , l. -N(C2~C6 alkynyl)Z 8 , m. -N(C3~C6 cycloalkyl)Z 8 , n. -N(C3~C6 cycloalkenyl)Z 8 , o. -N(C1~C6 haloalkyl)Z 8 , p. Halogen, q. An unsubstituted or substituted 3- to 8-membered heteroring, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more carbon atoms of the heteroring can be oxidized to form C=O. r. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more of the heteroaryl carbons can be oxidized to form C=O, and s. Non-substitutive or substituted C6~C 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 haloalkyls, and cyanos. (iv) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are independently selected from the group consisting of: t. Cyano, u. -S(=O)2Z 9 , v. Halogens, and w. Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are independently selected from the group consisting of: e. Cyano, f. -S(=O)2Z 9 , g. C3-C8 cycloalkyl, h. -C(=O)OH, x. -NHZ 8 , y. -N(unsubstituted or substituted C1-C6 alkyl)Z 8 , z. -N (unsubstituted or substituted C2-C6 alkenyl) Z 8 , aa. -N(unsubstituted or substituted C2-C6 alkynyl)Z 8 , bb. -N (unsubstituted or substituted C3-C6 cycloalkyl)Z 8 , cc. -N (unsubstituted or substituted C3-C6 cycloalkenyl) Z 8 , dd. -N(C1~C6 haloalkyl)Z8 4 ,halogen, ee. An unsubstituted or substituted 3- to 8-membered heteroring, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more carbon atoms of the heteroring can be oxidized to form C=O. ff. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more of the heteroaryl carbons can be oxidized to form C=O, and gg. C6~C (non-substitutive or substituted) 10 Aryl, where one or more substituents are halogen, C1-C6 haloalkyl, cyano, -S(=O)2Z 9 , -NZ 6 Z 8and an unsubstituted or substituted 3- to 8-membered heterocycle (where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls), wherein zero or more of the aryl carbons can be oxidized to form C=O. (v) C2-C6 alkynyl, (vi) C3-C6 cycloalkyl, (vii) C3-C6 cycloalkenyl, (viii) C1-C6 haloalkyl, (ix) -OZ 10 , (x) -C(=O)Z 10 , (xi) -NHZ 10 , (xii) Unsubstituted or substituted C3-C8 cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 9 , -NZ 6 Z 8 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiii) C6~C of non-substitutive or substituted types 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 9 , -NZ 6 Z 8 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiv) Unsubstituted or substituted 3-8 membered heteroaryls, wherein zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and (i) (xv) Unsubstituted or substituted 3- to 8-membered heterorings, where zero or more carbon atoms of the heteroring can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls; each Z 8 It is independently selected from the following group: (i) Hydrogen, (ii) C1-C6 alkyl, and (iii) C3-C6 cycloalkyl; each Z 9 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are independently selected from the group consisting of halogens, cyanos, and C1-C6 alkyls. (iii) Unsubstituted or substituted C2-C6 alkenyl, where one or more substituents are halogens, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are -NZ 6 Z 8 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) Halogens, and (v) hydroxy; and each Z 10 It is independently selected from the following group: (i) C1-C6 alkyl groups, (ii) -NH2, (iii) -NH(C1~C6 alkyl), (iv) -N(C1~C6 alkyl)2, (v) Unsubstituted or substituted C2-C6 alkenyl, where one or more substituents are cyano, -S(=O)2Z 9 , halogens, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 9 , -NZ 6 Z 8 (and independently selected from the group consisting of 4- to 8-membered heterocycles), (vi) C2~C6 alkinyl, (vii) C3-C6 cycloalkyl, (viii) C3-C6 cycloalkenyl, (ix) C1-C6 haloalkyls, and (x) Hydrogen, The aforementioned compound, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0185] Embodiment 2. Compound of Formula II: [ka] or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Z' and Z'' are the compound described in Embodiment 1, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, independently selected from -CH= or -N=.

[0186] Embodiment 3. The compound described in Embodiment 2, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein Z' and Z'' are -CH=.

[0187] Embodiment 4. The compound according to Embodiment 2, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z' is -N= and Z'' is -CH=.

[0188] Embodiment 5. The compound described in Embodiment 2, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein Z' and Z'' are -N=.

[0189] Embodiment 6.Z is -O-, the compound described in Embodiment 2, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.

[0190] Embodiment 7.Z is the compound described in Embodiment 2, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z is -N-.

[0191] Embodiment 8. Compound of Formula III: [ka] or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, R' is selected from the following group: i. Hydrogen, ii. Halogen, iii. Cyano, iv. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a) Cyano, b) C3-C8 cycloalkyl, c) -C(=O)OH, d) -S(=O)2Z 1 , e) -NZ 3 Z 4 , f) Halogens, and g) Unsubstituted or substituted C3-C6 aryls, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: 1. Halogen, 2. Cyano, 3. Hydroxyl, 4. C1-C6 alkyl groups, 5. C3-C6 cycloalkyl, 6. C1-C6 haloalkyl, 7. -OZ 1 , 8. -C(=O)Z 1 and 9. S(=O)2Z 5 、 v. C3-C6 cycloalkyl vi. C1-C6 haloalkyl vii. -OZ 1 、 viii. -C(=O)Z 1 、 ix. -S(=O)2Z 1 、 x. unsubstituted or substituted C3-C6 aryl, where zero or more of the aryl carbons may be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) halogen b) cyano c) hydroxy d) C1-C6 alkyl e) C3-C6 cycloalkyl f) C1-C6 haloalkyl g) -OZ 1 、 h) -C(=O)Z 1 and i) S(=O)2Z 5 and xi. unsubstituted or substituted 3-6 member heteroaryl, where zero or more of the heteroaryl carbons may be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) halogen b) cyano c) C1-C6 alkyl d) C3-C6 cycloalkyl e) C1-C6 haloalkyl f) -OZ 1 、 g) -C(=O)Z 1 and h) S(=O)2Z 5 、 The compound described in Embodiment 1, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0192] Embodiment 9. R' is -C(=O)Z 1 The compound described in Embodiment 8, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0193] Embodiment 10.R' is -S(=O)2Z 1 The compound described in Embodiment 8, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0194] Embodiment 11. R' is an unsubstituted or substituted 3-6 membered heteroaryl, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 , The compound described in Embodiment 8, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0195] Embodiment 12. Compound of Formula IV: [ka] or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Z' and Z'' are selected independently of -CH= or -N=; R' is selected from the following group: i. Hydrogen, ii. Halogen, iii. Cyano, iv. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a) Cyano, b) C3-C8 cycloalkyl, c) -C(=O)OH, d) -S(=O)2Z 1 , e) -NZ 3 Z 4 , f) Halogens, and g) Unsubstituted or substituted C3-C6 aryls, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: 1. Halogen, 2. Cyano, 3. Hydroxyl, 4. C1-C6 alkyl groups, 5. C3-C6 cycloalkyl, 6. C1-C6 haloalkyl, 7. -OZ 1 , 8. -C(=O)Z 1 , and 9. S(=O)2Z 5 , v. C3-C6 cycloalkyl, vi. C1-C6 haloalkyl groups, vii. -OZ 1 , viii. -C(=O)Z 1 , ix. -S(=O)2Z 1 , x. Unsubstituted or substituted C3-C6 aryl atoms, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) Hydroxy, d) C1-C6 alkyl groups, e) C3-C6 cycloalkyl, f) C1-C6 haloalkyl, g) -OZ 1 , h) -C(=O)Z 1 , and i) S(=O)2Z 5 , and xi. Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 , The compound described in Embodiment 1, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0196] Embodiment 13. The compound described in Embodiment 12, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein Z' and Z'' are -CH=.

[0197] Embodiment 14. The compound described in Embodiment 12, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z' is -N= and Z'' is -CH=.

[0198] Embodiment 15. The compound described in Embodiment 12, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein Z' and Z'' are -N=.

[0199] Embodiment 16.R' is -C(=O)Z 1The compound described in Embodiment 12, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0200] Embodiment 17.R' is -S(=O)2Z 1 The compound described in Embodiment 12, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0201] Embodiment 18.R' is an unsubstituted or substituted 3-6 membered heteroaryl, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 , The compound described in Embodiment 12, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0202] Embodiment 19. Compound of formula V: [ka] or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Z' and Z'' are selected independently of -CH= or -N=; Q 1 Q 2 Q 3 , and Q 4 Each of these is independently =N- or =CH-, the compound described in Embodiment 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.

[0203] Embodiment 20. The compound described in Embodiment 19, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein Z' and Z'' are -CH=.

[0204] Embodiment 21. The compound according to Embodiment 19, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z' is -N= and Z'' is -CH=.

[0205] Embodiment 22. The compound described in Embodiment 19, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein Z' and Z'' are -N=.

[0206] Embodiment 23.Z is the compound described in Embodiment 19, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z is -O-.

[0207] Embodiment 24.Z is -N-, the compound described in Embodiment 19, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.

[0208] Embodiment 25.Q 1 Q 2 Q 3 , and Q 4 The compound described in Embodiment 19, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein the compound is =CH-.

[0209] Embodiment 26.Q 1 Q 2 , and Q 4 is =CH- and Q 3 The compound described in Embodiment 19, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, is =N-.

[0210] Embodiment 27.Q 1 Q 2 , and Q 3 is =CH- and Q 4The compound described in Embodiment 19, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, is =N-.

[0211] Embodiment 28. Compound of Formula VI: [ka] or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, R' is selected from the following group: i. Hydrogen, ii. Halogen, iii. Cyano, iv. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a) Cyano, b) C3-C8 cycloalkyl, c) -C(=O)OH, d) -S(=O)2Z 1 , e) -NZ 3 Z 4 , f) Halogens, and g) Unsubstituted or substituted C3-C6 aryls, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: 1. Halogen, 2. Cyano, 3. Hydroxyl, 4. C1-C6 alkyl groups, 5. C3-C6 cycloalkyl, 6. C1-C6 haloalkyl, 7. -OZ 1 , 8. -C(=O)Z 1 , and 9. S(=O)2Z 5 , v. C3-C6 cycloalkyl, vi. C1-C6 haloalkyl groups, vii. -OZ1 , viii. -C(=O)Z 1 , ix. -S(=O)2Z 1 , x. Unsubstituted or substituted C3-C6 aryl atoms, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) Hydroxy, d) C1-C6 alkyl groups, e) C3-C6 cycloalkyl, f) C1-C6 haloalkyl, g) -OZ 1 , h) -C(=O)Z 1 , and i) S(=O)2Z 5 , and xi. Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 ; Q 1 Q 2 Q 3 , and Q 4 Each of these is independently =N- or =CH-, the compound described in Embodiment 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.

[0212] Embodiment 29.R' is -C(=O)Z 1The compound described in Embodiment 28, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0213] Embodiment 30.R' is -S(=O)2Z 1 The compound described in Embodiment 28, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0214] Embodiment 31. R' is an unsubstituted or substituted 3-6 membered heteroaryl, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 , The compound described in Embodiment 28, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0215] Embodiment 32.Q 1 Q 2 Q 3 , and Q 4 The compound described in Embodiment 28, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein the compound is =CH-.

[0216] Embodiment 33.Q 1 Q 2 , and Q 4 is =CH- and Q 3 The compound described in Embodiment 28, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, is =N-.

[0217] Embodiment 34.Q 1 Q 2 , and Q 3 is =CH- and Q 4 The compound described in Embodiment 28, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, is =N-.

[0218] Embodiment 35. Embodiment of Formula VII: [ka] or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Z' and Z'' are selected independently of -CH= or -N=; R' is selected from the following group: i. Hydrogen, ii. Halogen, iii. Cyano, iv. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a) Cyano, b) C3-C8 cycloalkyl, c) -C(=O)OH, d) -S(=O)2Z 1 , e) -NZ 3 Z 4 , f) Halogens, and g) Unsubstituted or substituted C3-C6 aryls, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: 1. Halogen, 2. Cyano, 3. Hydroxyl, 4. C1-C6 alkyl groups, 5. C3-C6 cycloalkyl, 6. C1-C6 haloalkyl, 7. -OZ 1 , 8. -C(=O)Z1 , and 9. S(=O)2Z 5 , v. C3-C6 cycloalkyl, vi. C1-C6 haloalkyl groups, vii. -OZ 1 , viii. -C(=O)Z 1 , ix. -S(=O)2Z 1 , x. Unsubstituted or substituted C3-C6 aryl atoms, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) Hydroxy, d) C1-C6 alkyl groups, e) C3-C6 cycloalkyl, f) C1-C6 haloalkyl, g) -OZ 1 , h) -C(=O)Z 1 , and i) S(=O)2Z 5 , and xi. Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1 , and h) S(=O)2Z 5 ; Q 1 Q 2 Q 3 , and Q 4Each of these is independently =N- or =CH-, the compound described in Embodiment 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.

[0219] Embodiment 36. The compound described in Embodiment 35, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein Z' and Z'' are -CH=.

[0220] Embodiment 37. The compound according to Embodiment 35, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z' is -N= and Z'' is -CH=.

[0221] Embodiment 38. The compound described in Embodiment 35, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein Z' and Z'' are -N=.

[0222] Embodiment 39.R' is -C(=O)Z 1 The compound described in Embodiment 35, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0223] Embodiment 40.R' is -S(=O)2Z 1 The compound described in Embodiment 35, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0224] Embodiment 41.R' is an unsubstituted or substituted 3-6 membered heteroaryl, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C1-C6 alkyl groups, d) C3-C6 cycloalkyl, e) C1-C6 haloalkyl, f) -OZ 1 , g) -C(=O)Z 1, and h) S(=O)2Z 5 , The compound described in Embodiment 35, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0225] Embodiment 42.Q 1 Q 2 Q 3 , and Q 4 The compound described in Embodiment 35, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, is =CH-.

[0226] Embodiment 43.Q 1 Q 2 , and Q 4 is =CH- and Q 3 The compound described in Embodiment 35, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, is =N-.

[0227] Embodiment 44.Q 1 Q 2 , and Q 3 is =CH- and Q 4 The compound described in Embodiment 35, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, is =N-.

[0228] Embodiment 45, compound of formula VIII: [ka] or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Q 1 Q 2 Q 3 , and Q 4 Each of them is independently =N- or =CH-; Z is selected from -O-, -N-, -S-, -S(O)-, or -S(O)2-. However, if Z is -O-, -S-, -S(O)-, or -S(O)2-, R 3It does not exist; X 1 and X 2 Is it independently selected from the following group: (i) Hydrogen, (ii) Halogen, (iii) Hydroxyl, (iv) Cyano, (v) C1-C6 alkyl groups, (vi) C1-C6 haloalkyl, (vii) C2-C6 alkenyls, and (viii) Carbonyl, or X 1 and X 2 Together with the carbon atoms to which they are bonded, they form the following: (i) Unsubstituted or substituted C3-C6 cycloalkyls, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), (ii) an unsubstituted or substituted 3-6 membered heteroring, wherein zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), (iii) C6~C non-substituted or substituted 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), or (iv) Unsubstituted or substituted 5- to 9-membered heteroaryl compounds, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C1-C6 alkyl groups, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyls, and vi. -OZ 1 , vii. -N(Z 1 )2 (for example, NMe2), and viii. -C(O)N(Z 1 )2 (for example, -C(O)NH2), However, these are subject to the following conditions: (i) X 1 and X 2 When these come together to form an aryl or heteroaryl, [ka] represents a double bond, and (ii) X 1 and X 2 If that is not the case, [ka] represents a single bond; R 2 and R 3 Is it independently selected from the following group: (i) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C1-C6 alkyl groups, c. -S(=O)2Z 5 , d. C3-C8 cycloalkyl, e. -C(=O)OH, f. -C(=O)Z 1 , g. -NZ 3 Z 4 , h. Halogen, i. Hydroxyl, j. An unsubstituted or substituted 3- to 8-membered heteroring, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more carbon atoms of the heteroring can be oxidized to form C=O. k. Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more of the heteroaryl carbons can be oxidized to form C=O, and l. Non-substitutive or substituted C6~C 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 haloalkyls, and cyanos. (ii) Unsubstituted or substituted 3-6 membered heteroaryl compounds, wherein zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. C1-C6 alkyl groups, d. C3-C6 cycloalkyl, e. C1-C6 haloalkyl, f. -OZ 1 , and g. -C(=O)Z 1 , (iii) an unsubstituted or substituted 3-6 membered heteroring, wherein zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. C1-C6 alkyl groups, d. C3-C6 cycloalkyl, e. C1-C6 haloalkyl, f. -OZ 1 , and g. -C(=O)Z 1 , (iv) Hydrogen, (v) -C(=O)Z 1 , and (vi) -S(=O)2Z 5 ,or, R 2 and R 3 They are bonded together with the carbon and nitrogen atoms, respectively, to form the following: (ix) an unsubstituted or substituted 3-6 membered heteroring, wherein zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: 1. Cyano, 2. C3-C8 cycloalkyl, 3. -C(=O)OH, 4. -S(=O)2Z 1 , 5. -NZ 3 Z 4 , and 6. Halogen, iv. C3-C6 cycloalkyl groups, v. C1-C6 haloalkyl, vi. -OZ 1 , vii. -C(=O)Z 1 , viii. -S(=O)2Z 1 , ix. Unsubstituted or substituted C3-C6 aryls, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: 1. Halogen, 2. Cyano, 3. Hydroxyl, 4. C1-C6 alkyl groups, 5. C3-C6 cycloalkyl, 6. C1-C6 haloalkyl, 7. -OZ 1 , 8. -C(=O)Z 1 , and 9. S(=O)2Z 5 , and x. Unsubstituted or substituted 3-6 membered heteroaryls, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: 1. Halogen, 2. Cyano, 3. C1-C6 alkyl groups, 4. C3-C6 cycloalkyl, 5. C1-C6 haloalkyl, 6. -OZ 1 , 7. -C(=O)Z 1 , and 8. S(=O)2Z 5 ; each Z 1 It is independently selected from the following group: (i) Hydrogen, (ii) Hydroxyl, (iii) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C1-C6 alkyl groups, c. -S(=O)2Z 5 , d. C3-C8 cycloalkyl, e. -C(=O)OH, f. -NZ 3 Z 4 , g. Halogen, h. An unsubstituted or substituted 3-8 membered heteroring, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more carbon atoms of the heteroring can be oxidized to form C=O. i. Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more of the heteroaryl carbons can be oxidized to form C=O, and j. Non-substitutive or substituted C6~C 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 haloalkyls, and cyanos. (iv) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. -S(=O)2Z 5 , c. Halogens, and d. Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: i. Cyano, ii. -S(=O)2Z 5 , iii. C3-C8 cycloalkyl, iv. -C(=O)OH, v. -NZ 3 Z 4 , vi. Halogen, vii. An unsubstituted or substituted 3- to 8-membered heteroring, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more carbon atoms of the heteroring can be oxidized to form C=O. viii. Unsubstituted or substituted 3- to 9-membered heteroaryls, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more of the heteroaryl carbons can be oxidized to form C=O, and ix. Non-substitutive or substituted C6~C 10 Aryl, where one or more substituents are halogen, C1-C6 haloalkyl, cyano, -S(=O)2Z 5 , -NZ 3 Z 4 and an unsubstituted or substituted 3- to 8-membered heterocycle (where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls), wherein zero or more of the aryl carbons can be oxidized to form C=O. (v) C2-C6 alkynyl, (vi) C3-C6 cycloalkyl, (vii) C3-C6 cycloalkenyl, (viii) C1-C6 haloalkyl, (ix) -OZ 2 , (x) -C(=O)Z 2 , (xi) -NHZ 2 , (xii) Unsubstituted or substituted C3-C8 cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 5 , -NZ 3 Z 4 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiii) C6~C of non-substitutive or substituted types 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 5 , -NZ 3 Z 4 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiv) Unsubstituted or substituted 3-8 membered heteroaryls, wherein zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and (xv) an unsubstituted or substituted 3- to 8-membered heteroring, wherein zero or more carbon atoms of the heteroring can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls; each Z 2 It is independently selected from the following group: (i) C1-C6 alkyl groups, (ii) -NHZ 3 , (iii) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are cyano, -S(=O)2Z 5, halogens, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 5 , -NZ 3 Z 4 (and independently selected from the group consisting of 4- to 8-membered heterocycles), (iv) C2-C6 alkinyl, (v) C3-C6 cycloalkyl, (vi) C3-C6 cycloalkenyl, (vii) C1-C6 haloalkyls, and (viii) Hydrogen; each Z 3 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are C2-C6 alkenyl, cyano, -C(=O)OH, or -S(=O)2Z. 5 Halogen, -NZ 6 Z 4 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iii) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are cyano, -S(=O)2Z 5 , halogens, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 5 , -NZ 6 Z 4 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) -C(=O)Z 7 , (v) C2-C6 alkynyl, (vi) C3-C6 cycloalkyl, (vii) C3-C6 cycloalkenyls, and (viii) C1-C6 haloalkyl; each Z 4It is independently selected from the following group: (i) Hydrogen, (ii) C1-C6 alkyl, and (iii) C3-C6 cycloalkyl; each Z 5 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are independently selected from the group consisting of halogens, cyanos, and C1-C6 alkyls. (iii) Unsubstituted or substituted C2-C6 alkenyl, where one or more substituents are halogens, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are -NZ 6 Z 4 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) Halogens, and (v) hydroxy; each Z 6 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are C2-C6 alkenyl, cyano, -C(=O)OH, -S(=O)2H, -S(=O)2 (unsubstituted or substituted C1-C6 alkyl), -S(=O)2 (unsubstituted or substituted C2-C6 alkenyl), -S(=O)2 (halogen), -S(=O)2OH, -NHZ 8 -N (unsubstituted or substituted C1-C6 alkyl)Z 8 , -N (unsubstituted or substituted C2-C6 alkenyl) Z 8 , -N(-C(=O)Z 7 )Z 8 -N(C2~C6 alkynyl)Z 8 , -N(C3~C6 cycloalkyl)Z 8 ,-N(C3~C6 cycloalkenyl)Z 8 -N(C1~C6 haloalkyl)Z 8and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iii) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are cyano, -S(=O)2H, -S(=O)2 (unsubstituted or substituted C1-C6 alkyl), -S(=O)2 (unsubstituted or substituted C2-C6 alkenyl), -S(=O)2 (halogen), -S(=O)2OH, halogen, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 9 , -NHZ 8 -N (unsubstituted or substituted C1-C6 alkyl)Z 8 , -N (unsubstituted or substituted C2-C6 alkenyl) Z 8 , -N(-C(=O)Z 7 )Z 8 -N(C2~C6 alkynyl)Z 8 , -N(C3~C6 cycloalkyl)Z 8 ,-N(C3~C6 cycloalkenyl)Z 8 -N(C1~C6 haloalkyl)Z 8 and independently selected from the group consisting of a 4-8 membered heteroring (where zero or more carbon atoms of the heteroring can be oxidized to form C=O), (iv) -C(=O)Z 7 , (v) C2-C6 alkynyl, (vi) C3-C6 cycloalkyl, (vii) C3-C6 cycloalkenyls, and (viii) C1-C6 haloalkyl; each Z 7 It is independently selected from the following group: (i) Hydrogen, (ii) Hydroxyl, (iii) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C1-C6 alkyl groups, c. -S(=O)2Z 9 , d. C3-C8 cycloalkyl, e. -C(=O)OH, f. -NHZ 8 , g. -N(unsubstituted or substituted C1-C6 alkyl)Z 8 , h. -N (unsubstituted or substituted C2-C6 alkenyl) Z 8 , i. -N(-C(=O) unsubstituted or substituted C3-C6 cycloalkyl)Z 8 , j. -N(-C(=O) unsubstituted or substituted C3~C6 cycloalkenyl)Z 8 , k. -N(-C(=O) unsubstituted or substituted C1-C6 haloalkyl)Z 8 , l. -N(C2~C6 alkynyl)Z 8 , m. -N(C3~C6 cycloalkyl)Z 8 , n. -N(C3~C6 cycloalkenyl)Z 8 , o. -N(C1~C6 haloalkyl)Z 8 , p. Halogen, q. An unsubstituted or substituted 3- to 8-membered heteroring, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more carbon atoms of the heteroring can be oxidized to form C=O. r. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls, and zero or more of the heteroaryl carbons can be oxidized to form C=O, and s. Non-substitutive or substituted C6~C 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 haloalkyls, and cyanos. (iv) Unsubstituted or substituted C2-C6 alkenyls, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. -S(=O)2Z 9 , c. Halogens, and (v) Unsubstituted or substituted C1-C6 alkyl groups, where one or more substituents are independently selected from the group consisting of: i. Cyano, j. -S(=O)2Z 9 , k. C3-C8 cycloalkyl, l. -C(=O)OH, (vi) -NHZ 8 , (vii) -N(unsubstituted or substituted C1-C6 alkyl)Z 8 , (viii) -N(unsubstituted or substituted C2-C6 alkenyl)Z 8 , (ix) -N(unsubstituted or substituted C2-C6 alkynyl)Z 8 , (x) -N(unsubstituted or substituted C3-C6 cycloalkyl)Z 8 , (xi) -N(unsubstituted or substituted C3-C6 cycloalkenyl)Z 8 , (xii) -N(C1~C6 Haloalkyl)Z 8 , (xiii) Halogen, (xiv) an unsubstituted or substituted 3- to 8-membered heteroring, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 acetyls and C2-C6 alkenyls, and zero or more carbon atoms of the heteroring can be oxidized to form C=O. (xv) Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls, and zero or more of the heteroaryl carbons can be oxidized to form C=O, and (xvi) C6~C of non-substitution or substitution 10 Aryl, where one or more substituents are halogen, C1-C6 haloalkyl, cyano, -S(=O)2Z 9 , -NZ 6 Z 8 and an unsubstituted or substituted 3- to 8-membered heterocycle (where one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls and C2-C6 alkenyls), wherein zero or more of the aryl carbons can be oxidized to form C=O. (xvii) C2~C6 Alkinyl, (xviii) C3-C6 cycloalkyl, (xix) C3~C6 cycloalkenyl, (xx) C1~C6 haloalkyl, (xxi) -OZ 10 , (xxii) -C(=O)Z 10 , (xxiii) -NHZ 10 , (xxiv) Unsubstituted or substituted C3-C8 cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 5 , -NZ 3 Z 4 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xxv) C6~C non-substituted or substituted 10 Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are halogen, cyano, -S(=O)2Z 5 , -NZ 3 Z 4and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (xxvi) Unsubstituted or substituted 3-8 membered heteroaryls, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls. (xxvii) an unsubstituted or substituted 3- to 8-membered heteroring, wherein zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of halogens, C1-C6 alkyls, and C2-C6 alkenyls; and each Z 8 It is independently selected from the following group: (i) Hydrogen, (ii) C1-C6 alkyl, and (iii) C3-C6 cycloalkyl; each Z 9 It is independently selected from the following group: (i) Hydrogen, (ii) Unsubstituted or substituted C1-C6 alkyl, where one or more substituents are independently selected from the group consisting of halogens, cyanos, and C1-C6 alkyls. (iii) Unsubstituted or substituted C2-C6 alkenyl, where one or more substituents are halogens, and unsubstituted or substituted C1-C6 alkyl (where one or more substituents are -NZ 6 Z 4 and independently selected from the group consisting of 4-8 membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) Halogens, and (v) hydroxy; and each Z 10 It is independently selected from the following group: (i) C1-C6 alkyl groups, (ii) -NH2, (iii) -NH(C1~C6 alkyl), (iv) -N(C1~C6 alkyl)2, (v) Unsubstituted or substituted C2-C6 alkenyl, where one or more substituents are cyano, -S(=O)2Z 9 , halogens, and unsubstituted or substituted C1-C6 alkyls (where one or more substituents are cyano, -S(=O)2Z 9 , -NZ 6 Z 8 (and independently selected from the group consisting of 4- to 8-membered heterocycles), (vi) C2~C6 alkinyl, (vii) C3-C6 cycloalkyl, (viii) C3-C6 cycloalkenyl, (ix) C1-C6 haloalkyls, and (x) Hydrogen, The aforementioned compound, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0229] Embodiment 46.Q 1 Q 2 Q 3 , and Q 4 The compound described in Embodiment 45, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein the compound is =CH-.

[0230] Embodiment 47.Q 1 Q 2 , and Q 4 is =CH- and Q 3 The compound described in Embodiment 45, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, is =N-.

[0231] Embodiment 48.Q 1 Q 2 , and Q 3 is =CH- and Q 4 The compound described in Embodiment 45, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, is =N-.

[0232] Embodiment 49.Z is a compound described in Embodiment 45, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z is -O-.

[0233] Embodiment 50.Z is the compound described in Embodiment 45, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z is -N-.

[0234] Embodiment 51: Compound of formula IX: [ka] or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Q 1 Q 2 Q 3 , and Q 4 Each of them is independently =N- or =CH-; Q 5 Q 6 Q 7 , and Q 8 Each of these is independently =N- or =CR-, where each R is individually H or C1-C6 alkyl (e.g., Me); L is either -O- or -NR 2 And here, R 2 is H or C1-C6 alkyl (e.g., Me); R a , R b , R c , R d , R e , R f , R g and R h Each of them is independently H or C1-C6 alkyl (e.g., Me), or R a and R b , R c and R d , R e and R f , and / or R g and R hOne or more of these, together with the carbon atoms to which they are bonded, form a carbonyl (-C(=O)) group; and R 1 The compound, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein the compound is H or a C1-C6 alkyl group (e.g., Me).

[0235] Embodiment 52.L is the compound described in Embodiment 51, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein L is -O-, -NH-, or -NMe-.

[0236] Embodiment 53.Q 1 Q 2 Q 3 , and Q 4 Each of the compounds is =CH-, as described in Embodiment 51, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.

[0237] Embodiment 54.Q 5 Q 6 Q 7 , and Q 8 Each of the compounds is =CH-, as described in Embodiment 51, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.

[0238] Embodiment 55.Q 5 is =N- and Q 6 Q 7 , and Q 8 Each of them is =CR- (for example, Q 5 is =N- and Q 6 is = C(Me)- and Q 7 and Q 8 Is it =CH- or Q 5 is =N- and Q 6 Q 7 , and Q 8 Each of these is =CH-), the compound described in Embodiment 51, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

[0239] Embodiment 56.R 1 The compound described in Embodiment 51, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein H is present.

[0240] Embodiment 57.R a , R b , R e , R f , R g , and R h Each of them is H and R c and R d The compound described in Embodiment 51, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, which together with the carbon atoms to which they are bonded, form a carbonyl (-C(=O)) group.

[0241] Embodiment 58. N-((1-(2-hydroxyethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(2-hydroxyethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; N-((1-(cyanomethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(cyanomethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; N-((1-(3-hydroxypropyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(3-hydroxypropyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; 3-(2-(acrylamidomethyl)-4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)propanoic acid; 3-(2-(acetamidomethyl)-4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)propanoic acid; N-((1-(3-(methylamino)-3-oxopropyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; 6-(4-(trifluoromethyl)phenyl)-4,4a,5,6-tetrahydro-1H-pyrazino[1,2-a]quinoxaline-2(3H)-one; N-((1-(2-amino-2-oxoethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(2-(methylamino)-2-oxoethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(3-amino-3-oxopropyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; 1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; (R)-or (S)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; 1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; (R)-or (S)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; 3-(methylsulfonyl)-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline; N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (R)-or (S)-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-acetyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; Methyl 6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-carboxylate; 1-(8-(4-(trifluoromethyl)phenyl)octahydro-2H-pyrazino[1,2-a]pyrazine-2-yl)propa-2-en-1-one; N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (R)-or (S)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(methylsulfonyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; 2-methyl-5-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)-1,3,4-oxadiazole; 2-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)oxazole; 3-Methyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxaline; N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-or (S)-N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-or (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propa-2-en-1-one; (R)-or (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; 2-Hydroxy-4-((6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-Hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)methyl)benzaldehyde; 2-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)acetic acid; N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; (R)-or (S)-N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; 8-Acryloyl-2-(4-(trifluoromethyl)phenyl)hexahydro-2H-pyrazino[1,2-a]pyrazine-3(4H)-one; N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; (R)-or (S)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; (R)-or (S)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; (R)-or (S)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; 8-Acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (R)-or (S)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (S)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; (R)-or (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; (R)-or (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one (diastereomer 1); 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one (diastereomer 2); 1-(1,1-dichloro-2-(4-(trifluoromethyl)phenyl)octahydrocyclopropa[e]pyrazino[1,2-a]pyrazine-5(1H)-yl)propa-2-en-1-one; 8-Acetyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; (R)-or (S)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; Cyclopropyl(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)methanone; 2-Methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; (R)-or (S)-2-methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 1-((4H-1,2,4-triazol-3-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-((1H-imidazole-5-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; 1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; 1-(5-(6-(trifluoromethyl)pyridine-3-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-ylmethylcarbamate; 1-(3-(4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)azetidine-1-yl)ethane-1-one; and N-(2-(4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)ethyl)acetamide, A compound, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, selected from the group consisting of the above.

[0242] Embodiment 59. 1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; (R)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; (S)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; 1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; (R)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; (S)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (R)-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (S)-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (R)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (S)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (S)-N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propa-2-en-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propa-2-en-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propa-2-en-1-one; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; (R)-N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; (S)-N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; (R)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; (S)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; (R)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; (S)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; (R)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; (S)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; 8-Acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (R)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (S)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one; 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one (diastereomer 1); 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one (diastereomer 2); N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; (R)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; (S)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; 2-Methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; (R)-2-methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; (S)-2-methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; and (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-ylmethylcarbamate, A compound, or a tautomer thereof, a pharmaceutically acceptable salt, or a solvate thereof, selected from the group consisting of the above.

[0243] Embodiment 60. (R)-or (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; (R)-or (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; (R)-or (S)-1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; N-((4,4-dioxide-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]thiadin-3-yl)methyl)acetamide; 8-Acetyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8-tetrahydroimidazo[1,5-a]pyrido[3,2-e]pyrazine-9(5H)-one; 1-((1-methyl-1H-imidazole-5-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-((2-methyl-1H-imidazole-5-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-((1H-imidazole-2-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-((1H-pyrazole-4-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-(pyridine-3-ylmethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; (cis)-or (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; 1-((4-methyl-1H-imidazole-5-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 5-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)methyl)oxazole; 5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydropyrido[3',2':5,6]pyrazino[2,1-c][1,4]thiazine 8,8-dioxide; 5-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)methyl)isoxazole; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; N-((6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; 8-(methylsulfonyl)-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; N-methyl-6-oxo-8-(4-(trifluoromethyl)phenyl)octahydro-2H-pyrazino[1,2-a]pyrazine-2-sulfonamide; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-((6-Methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (1H-pyrazole-4-yl)(4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)methanone; N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-(trifluoromethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-((6-Methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((1-(5-(trifluoromethyl)pyridine-2-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-Acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; 1-((1H-pyrazole-4-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-2(1H)-one; (R)-or (S)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-ethyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; Methyl((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)carbamate; 1-Methyl-3-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-Hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)urea; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)methanesulfonamide; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl),N'-methylsulfate diamide; N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (cis)-or (trans)-3-acryloyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (cis)-or (trans)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-ylmethylcarbamate; N-((6aR,8R)-3-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; (R)-or (S)-N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-Oxo-3-(((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-Hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)amino)propanoic acid; 2-Hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-Hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; (cis)-or (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; 2-Amino-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-Hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; N-((6aR,8R)-3-chloro-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; (R)-or (S)-N-((6-cyano-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-3-(acetamidomethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-6-carboxamide; (cis)-or (trans)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-carbonitrile; (cis)-or (trans)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-or (trans)-1-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-or (trans)-2-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-((6aR,8R)-2-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; N-((6-(difluoromethoxy)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-2-hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)propanamide; (S)-2-hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)propanamide; 2-Hydroxy-2-methyl-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-Hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)propanamide; N-((6-(difluoromethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-carboxylic acid; (cis)-or (trans)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-or (trans)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (cis)-or (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; (R)-or (S)-N-((6-bromo-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-8-fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; and (cis)-or (trans)-8-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid, A compound, or a tautomer thereof, a pharmaceutically acceptable salt, or a solvate thereof, selected from the group consisting of the above.

[0244] Embodiment 61. N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; (R)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; (S)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; 1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (R)-1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (S)-1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; 5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; N-((6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)acetamide; N-((6-Methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-Methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-Methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-(S)-N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-Acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; (R)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; (S)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-Acryloyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (cis)-3-acryloyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (trans)-3-acryloyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; 3-Acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (cis)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (trans)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; 5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (cis)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; N-((6-cyano-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-cyano-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-cyano-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-(acetamidomethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-6-carboxamide; (R)-3-(acetamidomethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-6-carboxamide; (S)-3-(acetamidomethyl)-1-(4-(trifluo...

Claims

1. Compound of formula I: 【Chemistry 1】 or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Z is -O-, -N-, -S-, -S(O)-, or -S(O) ２ - Selected from, However, Z is -O-, -S-, -S(O)-, or -S(O) ２ - If R ３ It does not exist; X １ and X ２ Is it independently selected from the following group: (i) Hydrogen, (ii) Halogen, (iii) Hydroxyl, (iv) Cyano, (v) C １ ~C ６ Alkyl, (vi) C １ ~C ６ haloalkyl, (vii) C ２ ~C ６ Alkenyl, and (viiii) Carbonyl, or X １ and X ２ Together with the carbon atoms to which they are bonded, they form the following: (i) C of non-substitutive or substituted ３ ~C ６ Cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C １ ~C ６ Alkyl, iv. C ３ ~C ６ Cycloalkyl, v. C １ ~C ６ Haloalkyl, and vi.-OZ １ 、 vii. -N(Z １ ) ２ , and v)) _())() １ ) ２ 、 (ii) Unsubstituted or substituted 3-6 membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C １ ~C ６ Alkyl, iv. C ３ ~C ６ Cycloalkyl, v. C １ ~C ６ Haloalkyl, and vi.-OZ １ 、 vii. -N(Z １ ) ２ , and v)) _())() １ ) ２ 、 (iii) C of non-substitutive or substituted ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C １ ~C ６ Alkyl, iv. C ３ ~C ６ Cycloalkyl, v. C １ ~C ６ Haloalkyl, and vi.-OZ １ 、 vii. -N(Z １ ) ２ , and viii. -C(O)N(Z １ ) ２ ,or (iv) Unsubstituted or substituted 5- to 9-membered heteroaryl compounds, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C １ ~C ６ Alkyl, iv. C ３ ~C ６ Cycloalkyl, v. C １ ~C ６ Haloalkyl, and vi.-OZ １ 、 vii. -N(Z １ ) ２ , and v)) _())() １ ) ２ 、 However, these are subject to the following conditions: (i) X １ and X ２ When these come together to form an aryl or heteroaryl, 【Chemistry 2】 represents a double bond, and (ii) X １ and X ２ If that is not the case, 【Transformation 3】 represents a single bond; R １ The group is selected from the following: (i) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: (a) Non-substitutive or substituted C ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) C １ ~C ６ Alkyl, (4) C ３ ~C ６ Cycloalkyl, (5) C １ ~C ６ Haloalkyl, (6) -OZ １ 、 (7) C ２ ~C ６ Alkenyl, and (8) C ２ ~C ６ Alkinil, (b) Non-substitutive or substituted C ３ ~C ６ Cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) C １ ~C ６ Alkyl, (4) C ３ ~C ６ Cycloalkyl, (5) C １ ~C ６ Haloalkyl, and (6) -OZ １ 、 (c) C ２ ~C ６ Alkinyl, and (d) Unsubstituted or substituted 3-6 membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, or C ２ ~C ８ Alkenyl and C １ ~C ６ Independently selected from the group consisting of alkyl groups, (ii) unsubstituted or substituted C ６ -C １０ aryl, where zero or more of said aryl carbons may be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) C １ ~C ６ Alkyl, (d) C ３ ~C ６ Cycloalkyl, (e) C １ ~C ６ Haloalkyl, (f) - OZ １ , and (g) Unsubstituted or substituted C ６ ~C １０ Aryl, where one or more substituents are halogens, C １ ~C ６ Alkyl and C １ ~C ６ Haloalkyl and -OZ １ Independently selected from the group consisting of, (iii) Unsubstituted or substituted 5- to 9-membered heteroaryl compounds, wherein zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) C １ ~C ６ Alkyl, (d) C ３ ~C ６ Cycloalkyl, (e) C １ ~C ６ Haloalkyl, (f) - OZ １ , and (g) Unsubstituted or substituted C ６ ~C １０ Aryl, where one or more substituents are halogens, C １ ~C ６ Alkyl and C １ ~C ６ Haloalkyl and -OZ １ Independently selected from the group consisting of, (iv) C of non-substitutive or substituted ３ ~C ６ Cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) C １ ~C ６ Alkyl, (d) C ３ ~C ６ Cycloalkyl, (e) C １ ~C ６ Haloalkyl, and (f) -OZ １ 、 (v) an unsubstituted or substituted 3- to 6-membered heteroring, wherein zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) C １ ~C ６ Alkyl, (d) C ３ ~C ６ Cycloalkyl, (e) C １ ~C ６ Haloalkyl, and (f) -OZ １ 、 (vi) -S (=O) ２ Z ２、 and (vii) -C(=O)Z ２ ; R ２ and R ３ Is it independently selected from the following group: (i) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C １ ~C ６ Alkyl, c. -S(=O) ２ Z ５ 、 d. C ３ ~C ８ Cycloalkyl, e. -C(=O)OH, f. -C(=O)Z １ 、 '.-NZ ３ Z ４ 、 h. Halogen, i. Hydroxy, j. Unsubstituted or substituted 3- to 8-membered heterorings, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ A molecule independently selected from the group consisting of alkenyls, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O. k. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenyls, and capable of oxidizing zero or more of the heteroaryl carbons to form C=O, l. Non-substitutive or substituted C ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ A group independently selected from the group consisting of haloalkyl and cyano, (ii) Unsubstituted or substituted 3-6 membered heteroaryl compounds, wherein zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. C １ ~C ６ Alkyl, d. C ３ ~C ６ Cycloalkyl, e. C １ ~C ６ Haloalkyl, f. -OZ １ , and g. -C(=O)Z １ 、 (iii) Unsubstituted or substituted 3-6 membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. C １ ~C ６ Alkyl, d. C ３ ~C ６ Cycloalkyl, e. C １ ~C ６ Haloalkyl, f. -OZ １ , and g. -C(=O)Z １ 、 (iv) Hydrogen, (v)-C(=O)Z １ and (vi) -S (=O) ２ Z ５ ,or, R ２ and R ３ They are bonded together with the carbon and nitrogen atoms, respectively, to form the following: (i) an unsubstituted or substituted 3- to 6-membered heteroring, wherein zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) Non-substitutive or substituted C １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: (1) Cyano, (2) C ３ ~C ８ Cycloalkyl, (3) -C(=O)OH, (4) -S (=O) ２ Z １ 、 (5) -NZ ３ Z ４ 、 (6) Halogens, and (7) Non-substitutive or substituted C ３ ~C ６ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. Hydroxy, d. C １ ~C ６ Alkyl, e. C ３ ~C ６ Cycloalkyl, f. C １ ~C ６ Haloalkyl, g. -OZ １ 、 h. -C(=O)Z １ and i. S(=O) ２ Z ５ 、 (d) C ３ ~C ６ Cycloalkyl, (e) C １ ~C ６ Haloalkyl, (f) -OZ １ 、 (g) -C(=O)Z １ 、 (h) -S(=O) ２ Z １ 、 (i) C of non-substitutive or substituted ３ ~C ６ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) Hydroxy, (4) C １ ~C ６ Alkyl, (5) C ３ ~C ６ Cycloalkyl, (6) C １ ~C ６ Haloalkyl, (7) -OZ １ 、 (8) -C(=O)Z １ , and (9) S (= O) ２ Z ５ , and (j) Unsubstituted or substituted 3-6 membered heteroaryl compounds, wherein zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) C １ ~C ６ Alkyl, (4) C ３ ~C ６ Cycloalkyl, (5) C １ ~C ６ Haloalkyl, (6) -OZ １ 、 (7) -C(=O)Z １ , and (8) S (=O) ２ Z ５ ; Each Z １ It is independently selected from the following group: (i) Hydrogen, (ii) Hydroxyl, (iii) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C １ ~C ６ Alkyl, c. -S(=O) ２ Z ５ 、 d. C ３ ~C ８ Cycloalkyl, e. -C(=O)OH, f.-NZ ３ Z ４ 、 g. Halogen, h. Unsubstituted or substituted 3- to 8-membered heterorings, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ A molecule independently selected from the group consisting of alkenyls, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O. i. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenyls, and capable of oxidizing zero or more of the heteroaryl carbons to form C=O, j. Non-substitutive or substituted C ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ A group independently selected from the group consisting of haloalkyl and cyano, (iv) C of non-substitutive or substituted ２ ~C ６ An alkenyl, where one or more substituents are independently selected from the following group: a. Cyano, b. -S(=O) ２ Z ５ 、 c. Halogens, and d. Non-substitutive or substituted C １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: i. Cyano, ii. -S(=O) ２ Z ５ 、 iii. C ３ ~C ８ Cycloalkyl, iv. -C(=O)OH, v.-NZ ３ Z ４ 、 vi. Halogen, vii. Unsubstituted or substituted 3- to 8-membered heterorings, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ A molecule independently selected from the group consisting of alkenyls, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O. viiii. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenyls, and capable of oxidizing zero or more of the heteroaryl carbons to form C=O, ix. Non-substitutive or substituted C ６ ~C １０ Aryl, where one or more substituents are halogens, C １ ~C ６ Haloalkyl, cyano, -S (=O) ２ Z ５ , -NZ ３ Z ４ , and unsubstituted or substituted 3- to 8-membered heterorings (where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ A group independently selected from the group consisting of alkenyls, wherein zero or more of the aryl carbons can be oxidized to form C=O. (v) C ２ ~C ６ Alkinil, (vi) C ３ ~C ６ Cycloalkyl, (vii) C ３ ~C ６ Cycloalkenyl, (viiii) C １ ~C ６ Haloalkyl, (ix) -OZ ２ 、 (x) -C(=O)Z ２ 、 (xi) -NHZ ２ 、 (xi) C of non-substitution or substitution ３ ~C ８ Cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are halogen, cyano, -S (=O)) ２ Z ５ , -NZ ３ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiiii) C of non-substitution or substitution ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are halogen, cyano, -S (=O)) ２ Z ５ , -NZ ３ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiv) Unsubstituted or substituted 3- to 8-membered heteroaryl, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenyls, and (xv) Unsubstituted or substituted 3- to 8-membered heteroring, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenils; Each Z ２ It is independently selected from the following group: (i) C １ ~C ６ Alkyl, (fi) -EZ ３ 、 (iii) C of non-substitutive or substituted ２ ~C ６ Alkenyl, where one or more substituents are cyano, -S (=O) ２ Z ５ , halogens, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are cyano, -S (=O)) ２ Z ５ , -NZ ３ Z ４ (and independently selected from the group consisting of 4- to 8-membered heterocycles), (iv) C ２ ~C ６ Alkinil, (v) C ３ ~C ６ Cycloalkyl, (vi) C ３ ~C ６ Cycloalkenyl, (vii) C １ ~C ６ Haloalkyl, and (viiii) Hydrogen; Each Z ３ It is independently selected from the following group: (i) Hydrogen, (ii) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are C ２ ~C ６ Alkenyl, cyano, -C(=O)OH, -S(=O) ２ Z ５ , halogen, -NZ ３ Z ４ and independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iii) C of non-substitutive or substituted ２ ~C ６ Alkenyl, where one or more substituents are cyano, -S (=O) ２ Z ５ , halogens, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are cyano, -S (=O)) ２ Z ５ , -NZ ６ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (vv)-C(=O)Z ７ 、 (v) C ２ ~C ６ Alkinil, (vi) C ３ ~C ６ Cycloalkyl, (vii) C ３ ~C ６ Cycloalkenyl, and (viiii) C １ ~C ６ Haloalkyl; Each Z ４ It is independently selected from the following group: (i) Hydrogen, (ii) C １ ~C ６ Alkyl, and (iii) C ３ ~C ６ Cycloalkyl; Each Z ５ It is independently selected from the following group: (i) Hydrogen, (ii) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are halogens, cyanos, and C １ ~C ６ Independently selected from the group consisting of alkyl groups, (iii) C of non-substitutive or substituted ２ ~C ６ Alkenyl, where one or more substituents are halogens and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are -NZ ６ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) Halogens, and (v) Hydroxy; Each Z ６ It is independently selected from the following group: (i) Hydrogen, (ii) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are C ２ ~C ６ Alkenyl, cyano, -C(=O)OH, -S(=O) ２ H, -S (=O) ２ (C of non-substitutive or substituted type) １ ~C ６ Alkyl), -S (=O) ２ (C of non-substitutive or substituted type) ２ ~C ６ Alkenyl), -S (=O) ２ (Halogen), -S (=O) ２ OH, -NHZ ４ , -N (C of non-substitutive or substituted) １ ~C ６ Alkyl) Z ４ , -N (C of non-substitutive or substituted) ２ ~C ６ Alkenil) Z ４ , -N(-C(=O)Z ７ ) Z ４ , -N(C ２ ~C ６ Alkinyl) Z ４ , -N(C ３ ~C ６ Cycloalkyl) Z ４ , -N(C ３ ~C ６ Cycloalkenyl) Z ４ , -N(C １ ~C ６ Haloalkyl) Z ４ and independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iii) C of non-substitutive or substituted ２ ~C ６ Alkenyl, where one or more substituents are cyano, -S (=O) ２ H, -S (=O) ２ (C of non-substitutive or substituted type) １ ~C ６ Alkyl), -S (=O) ２ (C of non-substitutive or substituted type) ２ ~C ６ Alkenyl), -S (=O) ２ (Halogen), -S (=O) ２ OH, halogens, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are cyano, -S (=O)) ２ Z ５ , -NHZ ４ , -N (C of non-substitutive or substituted) １ ~C ６ Alkyl) Z ４ , -N (C of non-substitutive or substituted) ２ ~C ６ Alkenil) Z ４ , -N(-C(=O)Z ７ ) Z ４ , -N(C ２ ~C ６ Alkinyl) Z ４ , -N(C ３ ~C ６ Cycloalkyl) Z ４ , -N(C ３ ~C ６ Cycloalkenyl) Z ４ , -N(C １ ~C ６ Haloalkyl) Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (vv)-C(=O)Z ７ 、 (v) C ２ ~C ６ Alkinil, (vi) C ３ ~C ６ Cycloalkyl, (vii) C ３ ~C ６ Cycloalkenyl, and (viiii) C １ ~C ６ Haloalkyl; and Each Z ７ It is independently selected from the following group: (i) Hydrogen, (ii) Hydroxyl, (iii) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C １ ~C ６ Alkyl, c. -S(=O) ２ Z ９ 、 d. C ３ ~C ８ Cycloalkyl, e. -C(=O)OH, f. -NHZ ８ 、 g. -N (C of non-substituted or substituted C) １ ~C ６ Alkyl) Z ８ , h. -N (C of non-substitutive or substituted C) ２ ~C ６ Alkenil) Z ８ , i. -N(-C(=O) non-substitutive or substituted C) ３ ~C ６ Cycloalkyl) Z ８ , j. -N(-C(=O) non-substitutive or substituted C) ３ ~C ６ Cycloalkenyl) Z ８ , k. -N(-C(=O) non-substitutive or substituted C) １ ~C ６ Haloalkyl) Z ８ , l. -N(C) ２ ~C ６ Alkinyl) Z ８ , m. -N(C) ３ ~C ６ Cycloalkyl) Z ８ , n. -N(C) ３ ~C ６ Cycloalkenyl) Z ８ , o. -N(C) １ ~C ６ Haloalkyl) Z ８ , p. Halogen, q. Unsubstituted or substituted 3- to 8-membered heterorings, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ A molecule independently selected from the group consisting of alkenyls, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O. r. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenyls, and capable of oxidizing zero or more of the heteroaryl carbons to form C=O, s. Non-substitutive or substituted C ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ A group independently selected from the group consisting of haloalkyl and cyano, (iv) C of non-substitutive or substituted ２ ~C ６ An alkenyl, where one or more substituents are independently selected from the following group: a. Cyano, b. -S(=O) ２ Z ９ 、 c. Halogens, and (v) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. -S(=O) ２ Z ９ 、 c. C ３ ~C ８ Cycloalkyl, d. -C(=O)OH, (vi) -NHZ ８ 、 (vii) -N (C of non-substitutive or substituted) １ ~C ６ Alkyl) Z ８ , (viiii) -N (C of non-substitutive or substituted) ２ ~C ６ Alkenil) Z ８ , (ix) -N (C of non-substitutive or substituted) ２ ~C ６ Alkinyl) Z ８ , (x) - N (C of non-substitutive or substituted) ３ ~C ６ Cycloalkyl) Z ８ , (xi) - N (C of non-substitutive or substituted) ３ ~C ６ Cycloalkenyl) Z ８ , (xii) -N(C １ ~C ６ Haloalkyl) Z ８ , (xiiii) Halogen, (xiv) Unsubstituted or substituted 3- to 8-membered heteroring, where one or more substituents are halogens, C １ ~C ６ Akil and C ２ ~C ６ A molecule independently selected from the group consisting of alkenyls, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O. (xv) Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenyls, and capable of oxidizing zero or more of the heteroaryl carbons to form C=O, (xvi) C of non-substitution or substitution ６ ~C １０ Aryl, where one or more substituents are halogens, C １ ~C ６ Haloalkyl, cyano, -S (=O) ２ Z ９ , -NZ ６ Z ８ , and unsubstituted or substituted 3- to 8-membered heterorings (where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ A group independently selected from the group consisting of alkenyls, wherein zero or more of the aryl carbons can be oxidized to form C=O. (xvii) C ２ ~C ６ Alkinil, (xviiii) C ３ ~C ６ Cycloalkyl, (xix) C ３ ~C ６ Cycloalkenyl, (xx) C １ ~C ６ Haloalkyl, (xxi) -OZ １０ 、 (xxii) -C(=O)Z １０ 、 (xxxii) -NHZ １０ 、 (xxiv) C of non-substitutive or substituted ３ ~C ８ Cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are halogen, cyano, -S (=O)) ２ Z ５ , -NZ ３ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (xxv) C of non-substitutive or substituted ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are halogen, cyano, -S (=O)) ２ Z ５ , -NZ ３ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (xxvi) Unsubstituted or substituted 3- to 8-membered heteroaryl, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenils, (xxvii) Unsubstituted or substituted 3- to 8-membered heteroring, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenils; and Each Z ８ It is independently selected from the following group: (i) Hydrogen, (ii) C １ ~C ６ Alkyl, and (iii) C ３ ~C ６ Cycloalkyl; Each Z ９ It is independently selected from the following group: (i) Hydrogen, (ii) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are halogens, cyanos, and C １ ~C ６ Independently selected from the group consisting of alkyl groups, (iii) C of non-substitutive or substituted ２ ~C ６ Alkenyl, where one or more substituents are halogens and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are -NZ ６ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) Halogens, and (v) Hydroxy; and Each Z １０ It is independently selected from the following group: (i) C １ ~C ６ Alkyl, (ii) -NH ２ 、 (iii) -NH(C １ ~C ６ Alkyl), (iv) -N(C １ ~C ６ Alkyl) ２ , (v) C of non-substitutive or substituted ２ ~C ６ Alkenyl, where one or more substituents are cyano, -S (=O) ２ Z ５ , halogens, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are cyano, -S (=O)) ２ Z ５ , -NZ ３ Z ４ (and independently selected from the group consisting of 4- to 8-membered heterocycles), (vi) C ２ ~C ６ Alkinil, (vii) C ３ ~C ６ Cycloalkyl, (viiii) C ３ ~C ６ Cycloalkenyl, (ix) C １ ~C ６ Haloalkyl, and (x) Hydrogen, The aforementioned compound, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

2. Compounds of formula II: 【Chemistry 4】 or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Z' and Z'' are independently selected from -CH= or -N=, and the compound according to claim 1, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

3. The compound according to claim 2, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

4. The compound according to claim 2, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z' is -N= and Z'' is -CH=.

5. The compound according to claim 2, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

6. The compound according to claim 2, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z is -O-.

7. The compound according to claim 2, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z is -N-.

8. Compounds of formula III: 【Transformation 5】 or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, R' is selected from the following group: i. Hydrogen, ii. Halogen, iii. Cyano, iv. Non-substitutive or substituted C １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: a) Cyano, b) C ３ ~C ８ Cycloalkyl, c) -C(=O)OH, d) -S(=O) ２ Z １ 、 e)-NZ ３ Z ４ 、 f) Halogens, and g) Unsubstituted or substituted C ３ ~C ６ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of:

1. Halogen, 2. Cyano, 3. Hydroxy, 4. C １ ~C ６ Alkyl, 5. C ３ ~C ６ Cycloalkyl, 6. C １ ~C ６ Haloalkyl, 7. -OZ １ 、 8. -C(=O)Z １ , and 9. S (=O) ２ Z ５ 、 v. C ３ ~C ６ Cycloalkyl, vi. C １ ~C ６ Haloalkyl, vii.-OZ １ 、 v)) ____] １ 、 ix. (#) ２ : １ 、 x. Non-substitutive or substituted C ３ ~C ６ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) Hydroxy, d) C １ ~C ６ Alkyl, e) C ３ ~C ６ Cycloalkyl, f) C １ ~C ６ Haloalkyl, g) -OZ １ 、 h) -C(=O)Z １ and i) S (= O) ２ Z ５ , and xi. Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C １ ~C ６ Alkyl, d) C ３ ~C ６ Cycloalkyl, e) C １ ~C ６ Haloalkyl, f) -OZ １ 、 g) -C(=O)Z １ , and h) S(=O) ２ Z ５ 、 The compound described in claim 1, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

9. R' is -C(=O)Z １ The compound according to claim 8, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

10. R' is -S (=O) ２ Z １ The compound according to claim 8, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

11. R' is an unsubstituted or substituted 3- to 6-membered heteroaryl compound, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the following group: a) Halogen, b) Cyano, c) C １ ~C ６ Alkyl, d) C ３ ~C ６ Cycloalkyl, e) C １ ~C ６ Haloalkyl, f) -OZ １ 、 g) -C(=O)Z １ , and h) S(=O) ２ Z ５ 、 The compound according to claim 8, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

12. Compounds of formula IV: 【Transformation 6】 or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Z' and Z'' are selected independently of -CH= or -N=; R' is selected from the following group: i. Hydrogen, ii. Halogen, iii. Cyano, iv. Non-substitutive or substituted C １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: a) Cyano, b) C ３ ~C ８ Cycloalkyl, c) -C(=O)OH, d) -S(=O) ２ Z １ 、 e)-NZ ３ Z ４ 、 f) Halogens, and g) Unsubstituted or substituted C ３ ~C ６ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of:

1. Halogen, 2. Cyano, 3. Hydroxy, 4. C １ ~C ６ Alkyl, 5. C ３ ~C ６ Cycloalkyl, 6. C １ ~C ６ Haloalkyl, 7. -OZ １ 、 8. -C(=O)Z １ , and 9. S (=O) ２ Z ５ 、 v. C ３ ~C ６ Cycloalkyl, vi. C １ ~C ６ Haloalkyl, vii.-OZ １ 、 v)) ____] １ 、 ix. (#) ２ : １ 、 x. Non-substitutive or substituted C ３ ~C ６ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) Hydroxy, d) C １ ~C ６ Alkyl, e) C ３ ~C ６ Cycloalkyl, f) C １ ~C ６ Haloalkyl, g) -OZ １ 、 h) -C(=O)Z １ and i) S (= O) ２ Z ５ , and xi. Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C １ ~C ６ Alkyl, d) C ３ ~C ６ Cycloalkyl, e) C １ ~C ６ Haloalkyl, f) -OZ １ 、 g) -C(=O)Z １ , and h) S(=O) ２ Z ５ 、 The compound described in claim 1, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

13. The compound according to claim 12, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

14. The compound according to claim 12, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z' is -N= and Z'' is -CH=.

15. The compound according to claim 12, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

16. R' is -C(=O)Z １ The compound according to claim 12, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

17. R' is -S (=O) ２ Z １ The compound according to claim 12, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

18. R' is an unsubstituted or substituted 3- to 6-membered heteroaryl compound, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the following group: a) Halogen, b) Cyano, c) C １ ~C ６ Alkyl, d) C ３ ~C ６ Cycloalkyl, e) C １ ~C ６ Haloalkyl, f) -OZ １ 、 g) -C(=O)Z １ , and h) S(=O) ２ Z ５ 、 The compound according to claim 12, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

19. Compound of formula V: 【Transformation 7】 or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Z' and Z'' are selected independently of -CH= or -N=; Q １ Q ２ Q ３ , and Q ４ Each of them is independently =N- or =CH-. The compound described in claim 1, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

20. The compound according to claim 19, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z' and Z'' are -CH=.

21. The compound according to claim 19, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z' is -N= and Z'' is -CH=.

22. The compound according to claim 19, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z' and Z'' are -N =.

23. The compound according to claim 19, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z is -O-.

24. The compound according to claim 19, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z is -N-.

25. Q １ Q ２ Q ３ , and Q ４ The compound according to claim 19, or its stereoisomer tautomer, pharmaceutically acceptable salt, or solvate, wherein is =CH-.

26. Q １ Q ２ , and Q ４ is = CH- and Q ３ The compound according to claim 19, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein is = N-.

27. Q １ Q ２ , and Q ３ is = CH- and Q ４ The compound according to claim 19, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein is = N-.

28. Compounds of formula VI: 【Transformation 8】 or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, R' is selected from the following group: i. Hydrogen, ii. Halogen, iii. Cyano, iv. Non-substitutive or substituted C １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: a) Cyano, b) C ３ ~C ８ Cycloalkyl, c) -C(=O)OH, d) -S(=O) ２ Z １ 、 e)-NZ ３ Z ４ 、 f) Halogens, and g) Unsubstituted or substituted C ３ ~C ６ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of:

1. Halogen, 2. Cyano, 3. Hydroxy, 4. C １ ~C ６ Alkyl, 5. C ３ ~C ６ Cycloalkyl, 6. C １ ~C ６ Haloalkyl, 7. -OZ １ 、 8. -C(=O)Z １ , and 9. S (=O) ２ Z ５ 、 v. C ３ ~C ６ Cycloalkyl, vi. C １ ~C ６ Haloalkyl, vii.-OZ １ 、 v)) ____] １ 、 ix. (#) ２ : １ 、 x. Non-substitutive or substituted C ３ ~C ６ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) Hydroxy, d) C １ ~C ６ Alkyl, e) C ３ ~C ６ Cycloalkyl, f) C １ ~C ６ Haloalkyl, g) -OZ １ 、 h) -C(=O)Z １ and i) S (= O) ２ Z ５ , and xi. Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C １ ~C ６ Alkyl, d) C ３ ~C ６ Cycloalkyl, e) C １ ~C ６ Haloalkyl, f) -OZ １ 、 g) -C(=O)Z １ , and h) S(=O) ２ Z ５ ; Q １ Q ２ Q ３ , and Q ４ Each of the compounds is independently =N- or =CH-, according to claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.

29. R' is -C(=O)Z １ The compound according to claim 28, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

30. R' is -S (=O) ２ Z １ The compound according to claim 28, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

31. R' is an unsubstituted or substituted 3- to 6-membered heteroaryl compound, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the following group: a) Halogen, b) Cyano, c) C １ ~C ６ Alkyl, d) C ３ ~C ６ Cycloalkyl, e) C １ ~C ６ Haloalkyl, f) -OZ １ 、 g) -C(=O)Z １ , and h) S(=O) ２ Z ５ 、 The compound according to claim 28, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

32. Q １ Q ２ Q ３ , and Q ４ The compound according to claim 28, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein is =CH-.

33. Q １ Q ２ , and Q ４ is = CH- and Q ３ The compound according to claim 28, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein is =N-.

34. Q １ Q ２ , and Q ３ is = CH- and Q ４ The compound according to claim 28, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein is =N-.

35. Compounds of formula VII: 【Chemistry 9】 or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Z' and Z'' are selected independently of -CH= or -N=; R' is selected from the following group: i. Hydrogen, ii. Halogen, iii. Cyano, iv. Non-substitutive or substituted C １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: a) Cyano, b) C ３ ~C ８ Cycloalkyl, c) -C(=O)OH, d) -S(=O) ２ Z １ 、 e)-NZ ３ Z ４ 、 f) Halogens, and g) Unsubstituted or substituted C ３ ~C ６ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of:

1. Halogen, 2. Cyano, 3. Hydroxy, 4. C １ ~C ６ Alkyl, 5. C ３ ~C ６ Cycloalkyl, 6. C １ ~C ６ Haloalkyl, 7. -OZ １ 、 8. -C(=O)Z １ , and 9. S (=O) ２ Z ５ 、 v. C ３ ~C ６ Cycloalkyl, vi. C １ ~C ６ Haloalkyl, vii.-OZ １ 、 v)) ____] １ 、 ix. (#) ２ : １ 、 x. Non-substitutive or substituted C ３ ~C ６ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) Hydroxy, d) C １ ~C ６ Alkyl, e) C ３ ~C ６ cycloalkyl, f) C １ ~C ６ Haloalkyl, g) -OZ １ 、 h) -C(=O)Z １ and i) S (= O) ２ Z ５ , and xi. Unsubstituted or substituted 3-6 membered heteroaryl compounds, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a) Halogen, b) Cyano, c) C １ ~C ６ Alkyl, d) C ３ ~C ６ Cycloalkyl, e) C １ ~C ６ Haloalkyl, f) -OZ １ 、 g) -C(=O)Z １ , and h) S(=O) ２ Z ５ ; Q １ Q ２ Q ３ , and Q ４ Each of the compounds is independently =N- or =CH-, according to claim 1, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.

36. The compound according to claim 35, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z' and Z'' are -CH=.

37. The compound according to claim 35, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z' is -N= and Z'' is -CH=.

38. The compound according to claim 35, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein Z' and Z'' are -N =.

39. R' is -C(=O)Z １ The compound according to claim 35, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

40. R' is -S (=O) ２ Z １ The compound according to claim 35, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

41. R' is an unsubstituted or substituted 3- to 6-membered heteroaryl compound, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the following group: a) Halogen, b) Cyano, c) C １ ~C ６ Alkyl, d) C ３ ~C ６ Cycloalkyl, e) C １ ~C ６ Haloalkyl, f) -OZ １ 、 g) -C(=O)Z １ , and h) S(=O) ２ Z ５ 、 The compound according to claim 35, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

42. Q １ Q ２ Q ３ , and Q ４ The compound according to claim 35, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein is =CH-.

43. Q １ Q ２ , and Q ４ is = CH- and Q ３ The compound according to claim 35, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein is =N-.

44. Q １ Q ２ , and Q ３ is = CH- and Q ４ The compound according to claim 35, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, wherein is =N-.

45. Compounds of formula VIII: 【Chemistry 10】 or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Q １ Q ２ Q ３ , and Q ４ Each of them is independently =N- or =CH-; Z is -O-, -N-, -S-, -S(O)-, or -S(O) ２ - Selected from, However, Z is -O-, -S-, -S(O)-, or -S(O) ２ - If R ３ It does not exist; X １ and X ２ Is it independently selected from the following group: (i) Hydrogen, (ii) Halogen, (iii) Hydroxyl, (iv) Cyano, (v) C １ ~C ６ Alkyl, (vi) C １ ~C ６ Haloalkyl, (vii) C ２ ~C ６ Alkenyl, and (viiii) Carbonyl, or X １ and X ２ together with the carbon atoms to which they are attached form the following: (i) C of non-substitutive or substituted ３ ~C ６ Cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C １ ~C ６ Alkyl, iv. C ３ ~C ６ Cycloalkyl, v. C １ ~C ６ Haloalkyl, and vi.-OZ １ 、 vii. -N(Z １ ) ２ , and v)) _())() １ ) ２ 、 (ii) Unsubstituted or substituted 3-6 membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C １ ~C ６ Alkyl, iv. C ３ ~C ６ Cycloalkyl, v. C １ ~C ６ Haloalkyl, and vi.-OZ １ 、 vii. -N(Z １ ) ２ , and v)) _())() １ ) ２ 、 (iii) C of non-substitutive or substituted ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C １ ~C ６ Alkyl, iv. C ３ ~C ６ Cycloalkyl, v. C １ ~C ６ Haloalkyl, and vi.-OZ １ 、 vii. -N(Z １ ) ２ , and viii. -C(O)N(Z １ ) ２ ,or, (iv) Unsubstituted or substituted 5- to 9-membered heteroaryl compounds, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: i. Halogen, ii. Cyano, iii. C １ ~C ６ Alkyl, iv. C ３ ~C ６ Cycloalkyl, v. C １ ~C ６ Haloalkyl, and vi.-OZ １ 、 vii. -N(Z １ ) ２ , and v)) _())() １ ) ２ 、 However, these are subject to the following conditions: (i) X １ and X ２ When these come together to form an aryl or heteroaryl, 【Chemistry 11】 represents a double bond, and (ii) X １ and X ２ If that is not the case, 【Chemistry 12】 represents a single bond; R ２ and R ３ Is it independently selected from the following group: (i) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C １ ~C ６ Alkyl, c. -S(=O) ２ Z ５ 、 d. C ３ ~C ８ Cycloalkyl, e. -C(=O)OH, f. -C(=O)Z １ 、 '.-NZ ３ Z ４ 、 h. Halogen, i. Hydroxy, j. Unsubstituted or substituted 3- to 8-membered heterorings, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ A molecule independently selected from the group consisting of alkenyls, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O. k. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenyls, and capable of oxidizing zero or more of the heteroaryl carbons to form C=O, l. Non-substitutive or substituted C ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ A group independently selected from the group consisting of haloalkyl and cyano, (ii) Unsubstituted or substituted 3-6 membered heteroaryl compounds, wherein zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. C １ ~C ６ Alkyl, d. C ３ ~C ６ Cycloalkyl, e. C １ ~C ６ Haloalkyl, f. -OZ １ , and g. -C(=O)Z １ 、 (iii) Unsubstituted or substituted 3-6 membered heterorings, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: a. Halogen, b. Cyano, c. C １ ~C ６ Alkyl, d. C ３ ~C ６ Cycloalkyl, e. C １ ~C ６ Haloalkyl, f. -OZ １ , and g. -C(=O)Z １ 、 (iv) Hydrogen, (v)-C(=O)Z １ and (vi) -S (=O) ２ Z ５ ,or, R ２ and R ３ They are bonded together with the carbon and nitrogen atoms, respectively, to form the following: (i) an unsubstituted or substituted 3- to 6-membered heteroring, wherein zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (a) Halogen, (b) Cyano, (c) Non-substitutive or substituted C １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: (1) Cyano, (2) C ３ ~C ８ Cycloalkyl, (3) -C(=O)OH, (4) -S (=O) ２ Z １ 、 (5) - NZ ３ Z ４ , and (6) Halogen, (d) C ３ ~C ６ Cycloalkyl, (e) C １ ~C ６ Haloalkyl, (f) -OZ １ 、 (g) -C(=O)Z １ 、 (h) -S(=O) ２ Z １ 、 (i) C of non-substitutive or substituted ３ ~C ６ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) Hydroxy, (4) C １ ~C ６ Alkyl, (5) C ３ ~C ６ Cycloalkyl, (6) C １ ~C ６ Haloalkyl, (7) -OZ １ 、 (8) -C(=O)Z １ , and (9) S (= O) ２ Z ５ , and (j) Unsubstituted or substituted 3-6 membered heteroaryl compounds, wherein zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are independently selected from the group consisting of: (1) Halogen, (2) Cyano, (3) C １ ~C ６ Alkyl, (4) C ３ ~C ６ Cycloalkyl, (5) C １ ~C ６ Haloalkyl, (6) -OZ １ 、 (7) -C(=O)Z １ , and (8) S (=O) ２ Z ５ ; Each Z １ It is independently selected from the following group: (i) Hydrogen, (ii) Hydroxyl, (iii) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C １ ~C ６ Alkyl, c. -S(=O) ２ Z ５ 、 d. C ３ ~C ８ Cycloalkyl, e. -C(=O)OH, f.-NZ ３ Z ４ 、 g. Halogen, h. Unsubstituted or substituted 3- to 8-membered heterorings, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ A molecule independently selected from the group consisting of alkenyls, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O. i. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenyls, and capable of oxidizing zero or more of the heteroaryl carbons to form C=O, j. Non-substitutive or substituted C ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ A group independently selected from the group consisting of haloalkyl and cyano, (iv) C of non-substitutive or substituted ２ ~C ６ An alkenyl, where one or more substituents are independently selected from the following group: a. Cyano, b. -S(=O) ２ Z ５ 、 c. Halogens, and d. Non-substitutive or substituted C １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: i. Cyano, ii. -S(=O) ２ Z ５ 、 iii. C ３ ~C ８ Cycloalkyl, iv. -C(=O)OH, v.-NZ ３ Z ４ 、 vi. Halogen, vii. Unsubstituted or substituted 3- to 8-membered heterorings, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ A molecule independently selected from the group consisting of alkenyls, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O. viiii. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenyls, and capable of oxidizing zero or more of the heteroaryl carbons to form C=O, ix. Non-substitutive or substituted C ６ ~C １０ Aryl, where one or more substituents are halogens, C １ ~C ６ Haloalkyl, cyano, -S (=O) ２ Z ５ , -NZ ３ Z ４ , and unsubstituted or substituted 3- to 8-membered heterorings (where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ A group independently selected from the group consisting of alkenyls, wherein zero or more of the aryl carbons can be oxidized to form C=O. (v) C ２ ~C ６ Alkinil, (vi) C ３ ~C ６ Cycloalkyl, (vii) C ３ ~C ６ Cycloalkenyl, (viiii) C １ ~C ６ Haloalkyl, (ix) -OZ ２ 、 (x) -C(=O)Z ２ 、 (xi) -NHZ ２ 、 (xi) C of non-substitution or substitution ３ ~C ８ Cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are halogen, cyano, -S (=O)) ２ Z ５ , -NZ ３ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiiii) C of non-substitution or substitution ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are halogen, cyano, -S (=O)) ２ Z ５ , -NZ ３ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (xiv) Unsubstituted or substituted 3- to 8-membered heteroaryl, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenyls, and (xv) Unsubstituted or substituted 3- to 8-membered heteroring, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenils; Each Z ２ It is independently selected from the following group: (i) C １ ~C ６ Alkyl, (fi) -EZ ３ 、 (iii) C of non-substitutive or substituted ２ ~C ６ Alkenyl, where one or more substituents are cyano, -S (=O) ２ Z ５ , halogens, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are cyano, -S (=O)) ２ Z ５ , -NZ ３ Z ４ (and independently selected from the group consisting of 4- to 8-membered heterocycles), (iv) C ２ ~C ６ Alkinil, (v) C ３ ~C ６ Cycloalkyl, (vi) C ３ ~C ６ Cycloalkenyl, (vii) C １ ~C ６ Haloalkyl, and (viiii) Hydrogen; Each Z ３ It is independently selected from the following group: (i) Hydrogen, (ii) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are C ２ ~C ６ Alkenyl, cyano, -C(=O)OH, -S(=O) ２ Z ５ , halogen, -NZ ３ Z ４ and independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iii) C of non-substitutive or substituted ２ ~C ６ Alkenyl, where one or more substituents are cyano, -S (=O) ２ Z ５ , halogens, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are cyano, -S (=O)) ２ Z ５ , -NZ ６ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (vv)-C(=O)Z ７ 、 (v) C ２ ~C ６ Alkinil, (vi) C ３ ~C ６ Cycloalkyl, (vii) C ３ ~C ６ Cycloalkenyl, and (viiii) C １ ~C ６ Haloalkyl; Each Z ４ It is independently selected from the following group: (i) Hydrogen, (ii) C １ ~C ６ Alkyl, and (iii) C ３ ~C ６ Cycloalkyl; Each Z ５ It is independently selected from the following group: (i) Hydrogen, (ii) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are halogens, cyanos, and C １ ~C ６ Independently selected from the group consisting of alkyl groups, (iii) C of non-substitutive or substituted ２ ~C ６ Alkenyl, where one or more substituents are halogens and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are -NZ ６ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) Halogens, and (v) Hydroxy; Each Z ６ It is independently selected from the following group: (i) Hydrogen, (ii) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are C ２ ~C ６ Alkenyl, cyano, -C(=O)OH, -S(=O) ２ H, -S (=O) ２ (C of non-substitutive or substituted type) １ ~C ６ Alkyl), -S (=O) ２ (C of non-substitutive or substituted type) ２ ~C ６ Alkenyl), -S (=O) ２ (Halogen), -S (=O) ２ OH, -NHZ ４ , -N (C of non-substitutive or substituted) １ ~C ６ Alkyl) Z ４ , -N (C of non-substitutive or substituted) ２ ~C ６ Alkenil) Z ４ , -N(-C(=O)Z ７ ) Z ４ , -N(C ２ ~C ６ Alkinyl) Z ４ , -N(C ３ ~C ６ Cycloalkyl) Z ４ , -N(C ３ ~C ６ Cycloalkenyl) Z ４ , -N(C １ ~C ６ Haloalkyl) Z ４ and independently selected from the group consisting of 4- to 8-membered heterorings (where zero or more of the heteroring carbons can be oxidized to form C=O), (iii) C of non-substitutive or substituted ２ ~C ６ Alkenyl, where one or more substituents are cyano, -S (=O) ２ H, -S (=O) ２ (C of non-substitutive or substituted type) １ ~C ６ Alkyl), -S (=O) ２ (C of non-substitutive or substituted type) ２ ~C ６ Alkenyl), -S (=O) ２ (Halogen), -S (=O) ２ OH, halogens, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are cyano, -S (=O)) ２ Z ５ , -NHZ ４ , -N (C of non-substitutive or substituted) １ ~C ６ Alkyl) Z ４ , -N (C of non-substitutive or substituted) ２ ~C ６ Alkenil) Z ４ , -N(-C(=O)Z ７ ) Z ４ , -N(C ２ ~C ６ Alkinyl) Z ４ , -N(C ３ ~C ６ Cycloalkyl) Z ４ , -N(C ３ ~C ６ Cycloalkenyl) Z ４ , -N(C １ ~C ６ Haloalkyl) Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (vv)-C(=O)Z ７ 、 (v) C ２ ~C ６ Alkinil, (vi) C ３ ~C ６ Cycloalkyl, (vii) C ３ ~C ６ Cycloalkenyl, and (viiii) C １ ~C ６ Haloalkyl; Each Z ７ It is independently selected from the following group: (i) Hydrogen, (ii) Hydroxyl, (iii) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: a. Cyano, b. C １ ~C ６ Alkyl, c. -S(=O) ２ Z ９ 、 d. C ３ ~C ８ Cycloalkyl, e. -C(=O)OH, f. -NHZ ８ 、 g. -N (C of non-substituted or substituted C) １ ~C ６ Alkyl) Z ８ , h. -N (C of non-substitutive or substituted C) ２ ~C ６ Alkenil) Z ８ , i. -N(-C(=O) non-substitutive or substituted C) ３ ~C ６ Cycloalkyl) Z ８ , j. -N(-C(=O) non-substitutive or substituted C) ３ ~C ６ Cycloalkenyl) Z ８ , k. -N(-C(=O) non-substitutive or substituted C) １ ~C ６ Haloalkyl) Z ８ , l. -N(C) ２ ~C ６ Alkinyl) Z ８ , m. -N(C) ３ ~C ６ Cycloalkyl) Z ８ , n. -N(C) ３ ~C ６ Cycloalkenyl) Z ８ , o. -N(C) １ ~C ６ Haloalkyl) Z ８ , p. Halogen, q. Unsubstituted or substituted 3- to 8-membered heterorings, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ A molecule independently selected from the group consisting of alkenyls, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O. r. Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenyls, and capable of oxidizing zero or more of the heteroaryl carbons to form C=O, s. Non-substitutive or substituted C ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ A group independently selected from the group consisting of haloalkyl and cyano, (iv) C of non-substitutive or substituted ２ ~C ６ An alkenyl, where one or more substituents are independently selected from the following group: a. Cyano, b. -S(=O) ２ Z ９ 、 c. Halogens, and (v) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are independently selected from the group consisting of: Q. Cyano, r. -S(=O) ２ Z ９ 、 s. C ３ ~C ８ Cycloalkyl, t. -C(=O)OH, (vi) -NHZ ８ 、 (vii) -N (C of non-substitutive or substituted) １ ~C ６ Alkyl) Z ８ , (viiii) -N (C of non-substitutive or substituted) ２ ~C ６ Alkenil) Z ８ , (ix) -N (C of non-substitutive or substituted) ２ ~C ６ Alkinyl) Z ８ , (x) - N (C of non-substitutive or substituted) ３ ~C ６ Cycloalkyl) Z ８ , (xi) - N (C of non-substitutive or substituted) ３ ~C ６ Cycloalkenyl) Z ８ , (xii) -N(C １ ~C ６ Haloalkyl) Z ８ , (xiiii) Halogen, (xiv) Unsubstituted or substituted 3- to 8-membered heteroring, where one or more substituents are halogens, C １ ~C ６ Akil and C ２ ~C ６ A molecule independently selected from the group consisting of alkenyls, wherein zero or more of the heterocyclic carbons can be oxidized to form C=O. (xv) Unsubstituted or substituted 3- to 9-membered heteroaryl compounds, where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenyls, and capable of oxidizing zero or more of the heteroaryl carbons to form C=O, (xvi) C of non-substitution or substitution ６ ~C １０ Aryl, where one or more substituents are halogens, C １ ~C ６ Haloalkyl, cyano, -S (=O) ２ Z ９ , -NZ ６ Z ８ , and unsubstituted or substituted 3- to 8-membered heterorings (where one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ A group independently selected from the group consisting of alkenyls, wherein zero or more of the aryl carbons can be oxidized to form C=O. (xvii) C ２ ~C ６ Alkinil, (xviiii) C ３ ~C ６ Cycloalkyl, (xix) C ３ ~C ６ Cycloalkenyl, (xx) C １ ~C ６ Haloalkyl, (xxi) -OZ １０ 、 (xxii) -C(=O)Z １０ 、 (xxxii) -NHZ １０ 、 (xxiv) C of non-substitutive or substituted ３ ~C ８ Cycloalkyl, where zero or more of the cycloalkyl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are halogen, cyano, -S (=O)) ２ Z ５ , -NZ ３ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (xxv) C of non-substitutive or substituted ６ ~C １０ Aryl, where zero or more of the aryl carbons can be oxidized to form C=O, and one or more substituents are halogen, cyano, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are halogen, cyano, -S (=O)) ２ Z ５ , -NZ ３ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (xxvi) Unsubstituted or substituted 3- to 8-membered heteroaryl, where zero or more of the heteroaryl carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenils, (xxvii) Unsubstituted or substituted 3- to 8-membered heteroring, where zero or more of the heteroring carbons can be oxidized to form C=O, and one or more substituents are halogens, C １ ~C ６ Alkyl and C ２ ~C ６ Independently selected from the group consisting of alkenils; and Each Z ８ It is independently selected from the following group: (i) Hydrogen, (ii) C １ ~C ６ Alkyl, and (iii) C ３ ~C ６ Cycloalkyl; Each Z ９ It is independently selected from the following group: (i) Hydrogen, (ii) C of non-substitutive or substituted １ ~C ６ Alkyl, where one or more substituents are halogens, cyanos, and C １ ~C ６ Independently selected from the group consisting of alkyl groups, (iii) C of non-substitutive or substituted ２ ~C ６ Alkenyl, where one or more substituents are halogens and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are -NZ ６ Z ４ and independently selected from the group consisting of a 4- to 8-membered heteroring (where zero or more of the heteroring carbons can be oxidized to form C=O), (iv) Halogens, and (v) Hydroxy; and Each Z １０ It is independently selected from the following group: (i) C １ ~C ６ Alkyl, (ii) -NH ２ 、 (iii) -NH(C １ ~C ６ Alkyl), (iv) -N(C １ ~C ６ Alkyl) ２ , (v) C of non-substitutive or substituted ２ ~C ６ Alkenyl, where one or more substituents are cyano, -S (=O) ２ Z ５ , halogens, and unsubstituted or substituted C １ ~C ６ Alkyl (where one or more substituents are cyano, -S (=O)) ２ Z ５ , -NZ ３ Z ４ (and independently selected from the group consisting of 4- to 8-membered heterocycles), (vi) C ２ ~C ６ Alkinil, (vii) C ３ ~C ６ Cycloalkyl, (viiii) C ３ ~C ６ Cycloalkenyl, (ix) C １ ~C ６ Haloalkyl, and (x) Hydrogen, The aforementioned compound, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

46. Q １ Q ２ Q ３ , and Q ４ The compound according to claim 45, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein is =CH-.

47. Q １ Q ２ , and Q ４ is = CH- and Q ３ The compound according to claim 45, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein is = N-.

48. Q １ Q ２ , and Q ３ is = CH- and Q ４ The compound according to claim 45, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein is = N-.

49. The compound according to claim 19, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z is -O-.

50. The compound according to claim 19, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein Z is -N-.

51. Compounds of formula IX: 【Chemistry 13】 or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates, wherein in the formula, Q １ Q ２ Q ３ , and Q ４ Each of them is independently =N- or =CH-; Q ５ Q ６ Q ７ , and Q ８ Each of these is independently =N- or =CR-, where each R is independently H or C １ ~C ６ It is alkyl; L is -O- or -NR ２ And here, R ２ is H or C １ ~C ６ It is alkyl (for example, Me); R ａ , R ｂ , R ｃ , R ｄ , R ｅ , R ｆ , R ｇ and R ｈ Each of these is independently H or C １ ~C ６ It is alkyl (e.g., Me) or R ａ and R ｂ , R ｃ and R ｄ , R ｅ and R ｆ , and / or R ｇ and R ｈ One or more of them, together with the carbon atoms to which they are bonded, form a carbonyl (-C(=O)) group; and R １ is H or C １ ~C ６ The aforementioned compound, or its stereoisomers, tautomers, pharmaceutically acceptable salts, or solvates.

52. The compound according to claim 51, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein L is -O-, -NH-, or -NMe-.

53. Q １ Q ２ Q ３ , and Q ４ Each of the compounds is =CH- according to claim 51, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.

54. Q ５ Q ６ Q ７ , and Q ８ Each of the compounds is =CH- according to claim 51, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.

55. Q ５ is = N- and Q ６ Q ７ , and Q ８ Each of the compounds is =CR-, according to claim 51, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof.

56. R １ The compound according to claim 51, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein is H.

57. R ａ , R ｂ , R ｅ , R ｆ , R ｇ , and R ｈ Each of them is H and R ｃ and R ｄ The compound according to claim 51, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate thereof, wherein these atoms, together with the carbon atoms to which they are bonded, form a carbonyl (-C(=O)) group.

58. N-((1-(2-hydroxyethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(2-hydroxyethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; N-((1-(cyanomethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(cyanomethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; N-((1-(3-hydroxypropyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(3-hydroxypropyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; 3-(2-(acrylamidemethyl)-4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)propanoic acid; 3-(2-(acetamidomethyl)-4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)propanoic acid; N-((1-(3-(methylamino)-3-oxopropyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; 6-(4-(trifluoromethyl)phenyl)-4,4a,5,6-tetrahydro-1H-pyrazino[1,2-a]quinoxaline-2(3H)-one; N-((1-(2-amino-2-oxoethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(2-(methylamino)-2-oxoethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(3-amino-3-oxopropyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; 1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; (R)-or (S)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; 1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; (R)-or (S)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; 3-(methylsulfonyl)-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline; N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (R)-or (S)-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-acetyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; Methyl 6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-carboxylate; 1-(8-(4-(trifluoromethyl)phenyl)octahydro-2H-pyrazino[1,2-a]pyrazine-2-yl)propa-2-en-1-one; N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (R)-or (S)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((1-(methylsulfonyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; 2-methyl-5-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)-1,3,4-oxadiazole; 2-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)oxazole; 3-methyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline; N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-or (S)-N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-or (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propa-2-en-1-one; (R)-or (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; 2-Hydroxy-4-((6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)methyl)benzaldehyde; 2-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)acetic acid; N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; (R)-or (S)-N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; 8-Acryloyl-2-(4-(trifluoromethyl)phenyl)hexahydro-2H-pyrazino[1,2-a]pyrazine-3(4H)-one; N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; (R)-or (S)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; (R)-or (S)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; (R)-or (S)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; 8-Acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (R)-or (S)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (S)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; (R)-or (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; (R)-or (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one (diastereomer 1); 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one (diastereomer 2); 1-(1,1-dichloro-2-(4-(trifluoromethyl)phenyl)octahydrocyclopropa[e]pyrazino[1,2-a]pyrazine-5(1H)-yl)propa-2-en-1-one; 8-Acetyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; (R)-or (S)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; Cyclopropyl(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)methanone; 2-methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; (R)-or (S)-2-methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 1-((4H-1,2,4-triazole-3-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-((1H-imidazole-5-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; 1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; 1-(5-(6-(trifluoromethyl)pyridine-3-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-ylmethylcarbamate; 1-(3-(4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)azetidine-1-yl)ethane-1-one; and N-(2-(4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)ethyl)acetamide, A compound, or its stereoisomer, tautomer, pharmaceutically acceptable salt, or solvate, selected from the group consisting of the above.

59. 1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; (R)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; (S)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)propa-2-en-1-one; 1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; (R)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; (S)-1-(6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-yl)ethane-1-one; N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (R)-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (S)-N-((1-methyl-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (R)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; (S)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acrylamide; N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (S)-N-((4-methyl-1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propa-2-en-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propa-2-en-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propa-2-en-1-one; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; (R)-N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; (S)-N-methyl-6-(4-(trifluoromethyl)phenyl)-1,2,4,4a,5,6-hexahydro-3H-pyrazino[1,2-a]quinoxaline-3-sulfonamide; N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; (R)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; (S)-N-((4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline-2-yl)methyl)acetamide; N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; (R)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; (S)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acrylamide; N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; (R)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; (S)-N-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydro-2H-benzo[b][1,4]oxazin-2-yl)methyl)acetamide; 8-Acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (R)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (S)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acrylamide; N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrido[2,3-b]pyrazine-3-yl)methyl)acetamide; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)ethane-1-one; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-dipyrazino[1,2-a:2',3'-e]pyrazine-8-yl)propa-2-en-1-one; 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one; 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one (diastereomer 1); 1-(3-(4-(trifluoromethyl)phenyl)decahydro-6H-cyclobuta[e]pyrazino[1,2-a]pyrazine-6-yl)propa-2-en-1-one (diastereomer 2); N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; (R)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; (S)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-sulfonamide; 2-methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; (R)-2-methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; (S)-2-methyl-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)propan-1-one; and (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-ylmethylcarbamate, A compound, or a tautomer thereof, a pharmaceutically acceptable salt, or a solvate thereof, selected from the group consisting of the above.

60. (R)-or (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; (R)-or (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; (R)-or (S)-1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; N-((4,4-dioxide-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]thiadin-3-yl)methyl)acetamide; 8-acetyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8-tetrahydroimidazo[1,5-a]pyrido[3,2-e]pyrazine-9(5H)-one; 1-((1-methyl-1H-imidazole-5-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-((2-methyl-1H-imidazole-5-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-((1H-imidazole-2-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-((1H-pyrazole-4-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 1-Pyridine-3-ylmethyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; (cis)-or (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; 1-((4-methyl-1H-imidazole-5-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydroquinoxaline; 5-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)methyl)oxazole; 5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydropyrido[3',2':5,6]pyrazino[2,1-c][1,4]thiazine 8,8-dioxide; 5-((4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)methyl)isoxazole; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)acetamide; N-((6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)acetamide; 8-(methylsulfonyl)-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; N-methyl-6-oxo-8-(4-(trifluoromethyl)phenyl)octahydro-2H-pyrazino[1,2-a]pyrazine-2-sulfonamide; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-((6-methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (1H-pyrazole-4-yl)(4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-1(2H)-yl)methanone; N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-(trifluoromethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-((6-methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((1-(5-(trifluoromethyl)pyridine-2-yl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-Acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; 1-((1H-pyrazole-4-yl)methyl)-4-(4-(trifluoromethyl)phenyl)-3,4-dihydroquinoxaline-2(1H)-one; (R)-or (S)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-ethyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; Methyl((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)carbamate; 1-Methyl-3-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)urea; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)methanesulfonamide; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl),N'-methylsulfate diamide; N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (cis)-or (trans)-3-acryloyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (cis)-or (trans)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-ylmethylcarbamate; N-((6aR,8R)-3-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)acetamide; (R)-or (S)-N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-oxo-3-(((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2a]pyrazine-8-yl)amino)propanoic acid; 2-Hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)acetamide; (cis)-or (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; 2-amino-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)acetamide; N-((6aR,8R)-3-chloro-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)acetamide; (R)-or (S)-N-((6-cyano-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-or (S)-3-(acetamidomethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-6-carboxamide; (cis)-or (trans)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8S)-or (6aR,8S)-or (6aR,8R)-or (6aS,8R)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-carbonitrile; (cis)-or (trans)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-or (trans)-1-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-or (trans)-2-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-((6aR,8R)-2-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)acetamide; N-((6-(difluoromethoxy)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-2-hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)propanamide; (S)-2-hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)propanamide; 2-Hydroxy-2-methyl-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)propanamide; N-((6-(difluoromethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-carboxylic acid; (cis)-or (trans)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)-or (6aR,8S)-or (6aR,8R)-or (6aS,8R)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-or (trans)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (cis)-or (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8S)-or (6aR,8S)-or (6aR,8R)-or (6aS,8R)-8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; (R)-or (S)-N-((6-bromo-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (6aS,8S)-or (6aR,8S)-or (6aR,8R)-or (6aS,8R)-8-fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)-or (6aR,8S)-or (6aR,8R)-or (6aS,8R)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8S)- or (6aR,8S)- or (6aR,8R)- or (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; and (cis)-or (trans)-8-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid, A compound, or a tautomer thereof, a pharmaceutically acceptable salt, or a solvate thereof, selected from the group consisting of the above.

61. N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acrylamide; N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; (R)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; (S)-N-methyl-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-carboxamide; 1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (R)-1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (S)-1-(5-(5-(trifluoromethyl)pyridine-2-yl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; 5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)acetamide; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)acetamide; N-((6aR,8S)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)acetamide; N-((6-methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-methoxy-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-(S)-N-((7-chloro-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-methyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-Acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; (R)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; (S)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-1-one; N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-cyclopropyl-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-(dimethylamino)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-Acryloyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-Hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (cis)-3-acryloyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (trans)-3-acryloyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; 3-Acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (cis)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; (trans)-3-acetyl-6-(4-(trifluoromethyl)phenyl)-2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a]quinoxaline-2-carboxylic acid; 5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (cis)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; N-((6-cyano-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-cyano-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-cyano-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 3-(acetamidomethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-6-carboxamide; (R)-3-(acetamidomethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-6-carboxamide; (S)-3-(acetamidomethyl)-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazine-6-carboxamide; 3-Chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (cis)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (trans)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; 2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8S)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8S)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aR,8R)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; (6aS,8R)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; 3-Chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (trans)-3-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; 1-Chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-1-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (trans)-1-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; 2-Chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-2-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (trans)-2-chloro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; 2-Hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)propanamide; (R)-2-hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)propanamide; (S)-2-hydroxy-N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)propanamide; 8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (trans)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; 8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8S)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8R)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8R)-8-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (cis)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (trans)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; 5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (cis)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (trans)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; 8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; (6aS,8S)-8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; (6aR,8S)-8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; (6aR,8R)-8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; (6aS,8R)-8-(1H-tetrazole-5-yl)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline; N-((6-bromo-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((6-bromo-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((6-bromo-1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 8-Fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8S)-8-fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8S)-8-fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8R)-8-fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aS,8R)-8-fluoro-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8S)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aR,8S)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aR,8R)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8R)-N-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; 5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aR,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; (6aS,8R)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxamide; 8-Hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-Hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (cis)-8-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; and (trans)-8-hydroxy-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid, A compound, or a tautomer thereof, a pharmaceutically acceptable salt, or a solvate thereof, selected from the group consisting of the above.

62. 1-(2-((4-(trifluoromethyl)phenyl)amino)phenyl)piperidine-4-carboxylic acid; 1-(2-(methyl(4-(trifluoromethyl)phenyl)amino)phenyl)piperidine-4-carboxylic acid; 2-oxo-1-(2-((4-(trifluoromethyl)phenyl)amino)phenyl)piperidine-4-carboxylic acid; 1-(2-(4-(trifluoromethyl)phenoxy)phenyl)piperidine-4-carboxylic acid; 1-(3-((4-(trifluoromethyl)phenyl)amino)pyridine-2-yl)piperidine-4-carboxylic acid; and 1-(6-methyl-3-((4-(trifluoromethyl)phenyl)amino)pyridine-2-yl)piperidine-4-carboxylic acid, A compound, or a tautomer thereof, a pharmaceutically acceptable salt, or a solvate thereof, selected from the group consisting of the above.

63. 8-Acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (R)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; (S)-8-acryloyl-2-(4-(trifluoromethyl)phenyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one; N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (R)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; (S)-N-((1-(4-(trifluoromethyl)phenyl)-2,3-dihydro-1H-pyrido[2,3-b][1,4]oxazin-3-yl)methyl)acetamide; 1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (R)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; (S)-1-(5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,9,10-hexahydro-8H-pyrazino[1,2-a]pyrido[3,2-e]pyrazine-8-yl)ethane-1-one; N-((6aR,8R)-5-(4-(trifluoromethyl)phenyl)-5,6,6a,7,8,9-hexahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine-8-yl)acetamide; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-pyrido[1,2-a]quinoxaline-8-carboxylic acid; (6aR,8S)-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid; and (6aR,8S)-2-methyl-5-(4-(trifluoromethyl)phenyl)-6,6a,7,8,9,10-hexahydro-5H-dipyrido[1,2-a:3',2'-e]pyrazine-8-carboxylic acid, A compound, or a tautomer thereof, a pharmaceutically acceptable salt, or a solvate thereof, selected from the group consisting of the above.

64. A pharmaceutical composition comprising a compound according to any one of claims 1 to 63, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

65. A compound according to any one of claims 1 to 63, or a pharmaceutical composition according to claim 64, for use as a pharmaceutical.

66. A compound according to any one of claims 1 to 63, or a pharmaceutical composition according to claim 64, for use in the prevention or treatment of YAP / TAZ-TEAD activation-mediated disorders in animals, mammals, or humans.

67. The compound according to claim 66, or the pharmaceutical composition according to claim 66, wherein the YAP / TAZ-TEAD activation-mediated disorder is selected from the group including cancer, fibrosis, and YAP / TAZ-TEAD activation-mediated congenital disorders.

68. The YAP / TAZ-TEAD activation-mediated disorder is selected from lung cancer, breast cancer, head and neck cancer, esophageal cancer, kidney cancer, bladder cancer, colon cancer, ovarian cancer, cervical cancer, endometrial cancer, liver cancer (including but not limited to bile duct cancer), skin cancer, pancreatic cancer, gastric cancer, brain cancer, and prostate cancer, mesothelioma, and / or sarcoma, and is the compound according to claim 66, or the pharmaceutical composition according to claim 66.

69. The aforementioned YAP / TAZ-TEAD activation-mediated disorders include acoustic neuroma, acute leukemia, acute lymphoblastic leukemia, acute myeloid leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, basal cell carcinoma, cholangiocarcinoma, bronchogenic carcinoma, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myeloid (granulocytic) leukemia, chronic myeloid leukemia, colorectal cancer, craniopharyngioma, cystadenocarcinoma, Diffuse large B-cell lymphoma, abnormal proliferation (dysplasia and degeneration), embryonal carcinoma, endometrial cancer, endometrial sarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen receptor-positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, gliablastoma, gliosarcoma, heavy chain disease, hemangioblastoma, liver cancer, hepatocellular carcinoma, hormone-insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, re-lymphatic Endoplasma sarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma), malignant tumors and hyperproliferative disorders of the bladder, breast, colon, lung, ovary, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myeloid leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, A compound according to claim 66, selected from oral cancer, osteosarcoma of osteogenic origin, papillary adenocarcinoma, papillary carcinoma, pineal gland tumor, polycythemia vera, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous carcinoma, seminomas, small cell lung cancer, solid tumors (carcinomas and sarcomas), small cell lung cancer, gastric cancer, squamous cell carcinoma, synoviomas, sweat gland carcinoma, thyroid cancer, Waldenström macroglobulinemia, testicular tumor, uterine cancer, and Wilms' tumor, or a pharmaceutical composition according to claim 66.

70. A method for the prevention or treatment of YAP / TAZ-TEAD activation-mediated disorder in an animal, mammal, or human, comprising administering an effective amount of a compound according to any one of claims 1 to 63 to the animal, mammal, or human in need of such prevention or treatment.

71. A method for treating or preventing YAP / TAZ-TEAD activation-mediated disorder according to claim 70, further comprising administering one or more additional pharmaceuticals selected from the group consisting of EGFR inhibitors, MEK inhibitors, AXL inhibitors, B-RAF inhibitors, and RAS inhibitors.

Images